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ABSTRACT 
Mycoplasmas are responsible for many important diseases of animals, 
including contagious bovine pleuropneumonia (CBPP) caused by Mycoplasma 
mycoides subsp. mycoides SC and calf pneumonia, arthritis and mastitis caused by 
Mycoplasma bovis. However, diagnostic techniques currently available are 
laborious and imprecise. The work described in this thesis concentrates on the 
critical evaluation of existing techniques and the development of improved 
procedures. The role of aneimicrobial resistance in limiting the options for disease 
control was also considered. 
Diagnostic methods for the detection of M. mycoides subsp. mycoides 
SC in clinical material were critically evaluated during a CBPP outbreak in Portugal. 
Immunoblotting was more sensitive and specific than CFT or ELISA. The 
polymerase chain reaction (PCR) was more rapid and sensitive than culture. 
However immunocytohistochernistry (ICC) was far the best test for detecting M. 
mycoides subsp. mycoides SC antigen in lungs. 
A rapid latex agglutination test (LAT) to detect CBPP using a 
carbohydrate extract of M. mycoides subsp. mycoides SC was developed. Analysis 
of the carbohydrate extract composition demonstrated that fucose, glucosamine and 
galactose are present in the ratio of 1: 2: 16 respectively. N-acetyl neuraminic acid 
was also detected. Evaluation of the LAT with sera from negative, naturally 
infected and experimentally infected cattle demonstrates that the test clearly 
differentiates positive and negative CBPP sera. The LAT compared favourably with 
the CFT but was not as specific as the immunoblotting; however the LAT had the 
advantage of being more rapid and robust and could be used in the field. 
Molecular methods including the polymerase chain reaction (PCR) and 
16S rRNA gene sequencing were assessed for their potential use in the diagnostic 
laboratory. A PCR method for identifying M. bovis was adapted, evaluated and 
introduced as a routine laboratory test. Using a set of universal 16S rRNA gene 
primers, amplicons of two serologically untypable isolates, one from a peregrine 
falcon, and the other from an ostrich were obtained. Results imply that the isolates 
may be new mycoplasma species. 
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The development of antimicrobial resistance has been seen in many 
microorganisms but little evidence exists for resistance in mycoplasmas. 
Consequently, the in vitro effect of five antimicrobials; danofloxacin, 
oxytetracycline, spectinomycin, florfenicol and tilmicosin on 62 isolates of M. bovis 
and 20 of M. mycoides subsp. mycoides SC was investigated. Nfinimum inhibitory 
concentrations (MICs) and mycoplasmacidal (MMC) values were determined. 
Evidence of antimicrobial resistance by M. bovis is shown. The potential for M. 
mycoides subsp. mycoides SC to develop antimicrobial resistance against 
spectinomycin in vitro is also demonstrated. 
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SDSPAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
subsp. Subspecies 
Taq Thennus aquaticus 
TCA Tricarboxylic acid 
Th I T helper cells 
TLC Thin Layer Chromatography 
TMIB 3,3', 5,5'-tetramethylbenzidene 
Am Nficrometres 
VLA Veterinary Laboratories Agency 
vsp Variable surface protein 
W Watt 





Within the Kingdom Procaryotae, there are four divisions (Razin and 
Freundt, 1984): Finnicules, the gram positive bacteria; Gracilicutes, the gram 
negative bacteria; Mendosicutes, the archaebacteria; and, Tenericutes, the cell wall- 
less bacteria. Mollicutes is the sole class in this division and contains the genera, 
Ureaplasma, Spiroplasma, Acholeplasma, Anaeroplasma, Asteroleplasma, 
Entomoplasma, Mesoplasma and Mycoplasma. The genera Mycoplasma and 
Ureaplasma form the family Mycoplasmataceae (Razin et A, 1998). 
1.2. MAJOR CHARACTERISTICS OF MOLLICUTES 
Mollicutes are prokaryotic organisms that are generally smaller than 
other bacteria and lack a cell wall, which increases their susceptibility to osmotic 
stress. The absence of specific cell wall associated polymers also renders mollicutes 
resistant to the action of antimicrobials (such as penicillin and cycloserine) which 
act against cell wall synthesis (Rosenbusch, 1994). Cell size ranges from 0.15 Jim to 
over 1 Itin. in diameter and the small size and plasticity of cells enables them to pass 
through 0.45 itm bacteriological filters. Generally, Mollicutes can be cultivated on 
cell-free nutrient media enriched with serum that provides sterols and fatty acids. 
On agar media they give a characteristic 'fried egg' colonial morphology caused by 
the cells in the central zone of the colony growing into the medium (Razin and 
Freundt, 1984). 
The genera Asteroleplasma, Acholeplasma, Anaeroplasma, Mycoplasma 
and Ureaplasma are mostly found in man or animals, but one species, A. laidlawii, 
has also been isolated from soil and sewage, although it does not grow in these 
environments. Spiroplasma and Mesoplasma occur in plants and insects with 
Entomoplasma having only been isolated from insects. Both Mesoplasma and 
Entomoplasma have been classified as belonging to the mycoides phylogenetic 
cluster within the spiroplasma phylogenetic group (Dybvig and Voelker, 1996; see 
Figure 1.1. ). The first mollicute to be isolated, which became the type species of 
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Mycoplasma, was isolated from cattle affected by contagious bovine 
pleuropneumonia (Nocard and Roux, 1898); it was later named Mycoplasma 
mycoides (Edward and Freundt, 1956). Mycoplasmas subsequently isolated were 
called pleuropneumonia like organisms (PPLO's). 
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FIGURE 1.1. PHYLOGENY OF MYCOPLASMAS BASED ON THE 16S rRNA 
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The major characteristics of mollicutes are described in Table 1.1. The 
mollicutes, are characterised by the low guanine plus cytosine (GQ content of their 
DNA (2340 %). They possess a circular double-stranded DNA chromosome of 
-600 kb, to -1,800 kb and include the organisms with the smallest known genome 
size. The genome sizes of some mollicutes are compared with other bacteria in 
Table 1.2. 
Because of their small genome size and simple ultrastructure, mollicutes, 
in particular mycoplasmas, have attracted significant attention in the search to 
deterniine the key components required for life and for the 'minimal cell' (Wells, 
1997). Proposals were first made in 1984 to carry out the complete physical and 
functional mapping of a mycoplasma genome. This was to include detennination 
of. the entire DNA sequence; the open reading frames (ORFs) present; and the 
amino acid sequences encoded so defining all the genes of the mycoplasma and their 
products. In this way, a complete molecular description of the machinery of a cell 
would be achieved (Morowitz, 1984). Since 1984 many genomes have been 
sequenced, including those of M. genitalium, M. pneumoniae, M. pulmonis 
(Chambaud et al., 2000) and Ureaplasma urealyticum (Glass et al., 2000) and the 
cell-walled bacteria Haemophilus influenzae and Escherichia coli (Razin et al., 
1998). Complete genome sequences for 30 microbial species have been determined 
and a further 100 are expected in the next four years (Fraser et al., 2000). A 
comparison of the properties of selected bacterial genomes is given in Table 1.3. 
The availability of complete genome sequences has enhanced comparative studies of 
the functional contents of genomes and their evolution. One finding demonstrates 
that the absence of a cell wall in Mycoplasma leads to a significant saving in the 
genetic information required by cells. The synthesis of cytoplasmic membrane 
proteins in M. genitalium and M. pneumoniae requires only 30 and 54 genes 
respectively. In contrast, 105 genes have been identified which are involved in cell 
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TABLE 1.2. COMPARISON OF GENOME SIZES IN MOLLICUTES AND OTHER 
BACTERIAL SPECIES 
Species Size kb 
Mycoplasma genitalium 580 
Mycoplasma hominis 684 
Ureaplasma urealyticum serovar 3 752 
Mycoplasma mobile 780 
Mycoplasma pneumoniae 816 
Mycoplasma synoviae WVU 1853 900 
Mycoplasma gallisepticum PG31 1,050 
Mycoplasma hyopneumoniae strain J 1,140 
Mycoplasmajermentans 1,160 
Mycoplasma mycoides subsp. mycoides Y 1,240 
Mycoplasma iowae 1,280 
Mycoplasma mycoides subsp. mycoides GC 1176-2 1,330 
Acholeplasma laidlawii 1,580 
Helicobacterpylori 1,660 
Haemophilus influenzae 1,830 
Vibrio, cholerae El Tor N 1696 4,030 
Escherichia coli K-12 4,639 
Bacillus cereus 5,700 
Pseudomonas aeruginosa 5,900 
Data obtained from: Krawiec and Riley (1990); Barlev and Borchsenius (1991); 
Fraser et al. (1995; 2000); Glass et al. (2000); I-Emmelreich et al. (1996); Razin et 
al. (1998). 
25 
TABLE 1.3. GROSS PROPERTIES OF SOME BACTERIAL GENOMES 
Property M. M. ii. E. coli 
genitalium pneumoniae infuenzae 
No. of bp 580,070 816,394 1,830,137 4,639,221 
G+C content (mol%) 32 40 38 50 
No. of putative coding 479 677 1,703 4,288 
sequences (ORFs) 
No. of ORFs tentatively 468 603 1,408 2,659 
identified 
No. of ORFs with no 11 74 295 1,629 
functional prediction or 
database match 
Table adapted from Razin et al. (1998). 
1.1.3. PHYLOGENY 
Mycoplasma genitalium has the smallest genome of any known 
organism capable of independent replication with just 580,070 base pairs (Fraser et 
aL, 1995). This may be close to the minimal genome size necessary for cellular 
survival. Two theories have been proposed as to how mollicutes with such small 
genomes have evolved. Wallace and Morowitz (1973) considered mollicutes as 
extremely primitive living relics that preceded present day bacteria, whereas others 
saw them as degenerate forms of what might be called "normal" bacteria (Razin, 
1978). If the latter theory is correct, the genorne size of mollicutes must have been 
severely reduced during their evolution, with only the essential functions being 
retained, leading to a reliance on their hosts for nutrients. 
The study of evolution using DNA composition and immunological 
relationships provides little phylogenetic information, although it is useful for 
taxonomy. However, the examination of highly conserved ribosomal RNA (rRNA) 
has provided much information on evolution. The longer 16S rRNA gene is more 
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useful than the smaller 5S rRNA gene, allowing accurate determination of 
phylogenetic distance (Woese, 1987). 
On the basis of sequence information it is now accepted that the class 
Mollicutes constitutes a phylogenetically distinct group of highly unusual bacteria 
that are only distantly related to other eubacteria (Gibbons and Murray, 1978; Razin, 
1978, Kamla et al., 1996). They appear to have evolved from clostridia, with cell 
wall and other genes being lost during evolution. Using a hypothetical model for 
mollicute phylogeny, Maniloff (1996) concluded that the ancestral mollicute arose 
from the Streptococcus phylogenetic branch about 600 million years ago, probably 
from an organism with a genome of 2,000 kb. Degenerate evolution continued, 
giving the different genera within the class Mollicutes that currently exist. 
Although mutation rates have not been widely measured, mollicute 
rRNA sequences appear to change more rapidly than those of other eubacteria. 
Thus, there are significant variations amongst the mollicutes sequences (Woese et 
al., 1985), even within well-defined species. In M. gallisepticum for example, bases 
at generally conserved positions are known to vary (Woese, 1987). However, it has 
been shown that mycoplasmas lack DNA polymerase Y-5' exonuclease activity. 
This may limit their ability to repair genetic errors, so leading to high mutation rates 
(Woese, 1987). 
The phylogenetic relationships amongst mollicutes, based on 16S rRNA 
homology are given in Figure 1.1. Five major groups are recognised: 
asteroleplasma, spiroplasma, pneumoniae, hominis and anaeroplasma. Within these 
groups organisms that are very closely related, based on the 16S rRNA sequences, 
are grouped in clusters. 
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1.2. STRUCTURE, METABOLISM AND PATHOGENICITY 
1.2.1. THE CELL ENVELOPE AND CYTOSKELETON 
The most notable differences between mollicutes and other prokaryotes 
are the inability of mollicutes to synthesise a cell wall and their lack of intracellular 
membrane structures. Direct proof for the absence of cell walls was obtained by 
electron microscopy of thin sections of mycoplasma cells (van Iterson and Ruys, 
1960; Domermuth et al., 1964). Osmium-fixed sections showed that cells were 
bounded by a single trilaminar membrane, about 8-10nm thick. Proteins constituted 
over two-thirds of mollicute membrane mass, with the rest being membrane lipids 
(Razin et al., 1998). Studies on the molecular organization and function of the lipids 
in mollicute membranes have been aided by the dependence of Mollicute species on 
external supplies of fatty acids and sterol. By varying the nature and concentration 
of fatty acids and sterol in the growth medium, alterations in membrane lipid 
composition may be achieved (Razin et al., 1998). The bulk of the membrane lipids 
form a bilayer (Steim et al., 1969), in which the distribution of phospholipids and 
glycolipids shows a definite transbilayer asymmetry (Razin, 1993). Mollicutes alter 
the polar head group structure of membrane and phospho- and glycolipids, and 
change the acyl chain structure, in response to changes in environmental and 
physiological conditions (Andersson et al., 1996); the most likely membrane 
structure for Mycoplasnia species is shown in Figures 1.2 and 1.3 (Razin, 1993). 
Mycoplasmas typically have a number of distinct lipoproteins anchored on the outer 
face of the plasma membrane (Figure 1.3; Chambaud et al., 1999). These surface 
antigens are preferential targets for the host immune response. However, variation 
of their size and expression provides mycoplasmas with an effective means of 
evading the host immune defence system. The plasma membranes of some 
Mycoplasma species also contain lipoglycans, which although clearly distinct from 
the lipopolysaccharides of the outer-membrane of Gram -ve bacteria, similarly 
possess a lipid membrane anchor and a repetitive oligosaccharide structure (Fig. 1.3; 
Chambaud et al., 1999). 
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FIGURE 1.2. THE ORGANISATION OF PROTEINS AND LIPIDS IN MOLLICUTE 
MEMBRANES 
Lipid 1 Polar Head -0' 
ýNonPolar Tal l --)0 
Protein 
Model showing the most likely arrangement of proteins and lipids in the molecular 
organisation of mollicute membranes. 
Figure adapted from Razin (1993). 
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Peripheral Membrane Protein 
Figure 1.3. The mycoplasma cell envelope lacks a cell wall and an outer membrane. 
In mycoplasmas, lipoproteins are anchored onto the outer surface of the plasina 
membrane. 
Figure adapted from Chambaud et al. (1999). 
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Capsules are bound to the outside of the cell membrane in some 
Mycoplasma and Ureaplasma species, including M. mycoides subsp. mycoides small 
colony (SC), M. dispar, M. gallisepticum, M. hominis, M. hyopneumoniae, M. 
meleagridis, M. pneumoniae, M. pulmonis, M. synoviae and M. capricolum subsp. 
capricolum (Robertson and Smook, 1976; Rurangirwa et al., 1987a). Indirect 
evidence for their carbohydrate nature has been derived from electron microscopic 
studies on preparations stained with ruthenium red which binds to polysaccharides 
(Minion and Rosenbusch, 1993). In M. mycoides subsp. mycoides SC, the capsule 
comprises 10% of the dry weight of the cell and is typically 20-40 nm in thickness 
(Howard and Gourlay, 1974). The M. mycoides subsp. mycoides SC capsule is 
composed of approximately 90% galactose and 10% glucose (Plackett and Buttery, 
1958). In contrast, the capsule of M. mycoides subsp. capri is composed largely of 
glucose with a small amount of galactose (Jones et al., 1965), whilst that of M. 
capricolum subsp. capripneumoniae (formerly known as M. F38) is reported to 
contain glucose, galactose, mannose, fructose, galactosamine and glucosamine in 
approximately equal amounts (Rurangirwa et al., 1987a). In some studies lectins 
have been used to identify cell-surface carbohydrate groups. Lectins are useful 
because they are highly specific in the groups they bind. For example, concanavalin 
A binds to internal and nonreducing terminal (x-mannosyl residues, whereas wheat- 
germ agglutinin binds to terminal N-acetylglucosamine residues (Stryer, 1995). 
Studies based on lectin binding to cells have concluded that mycoplasma capsules 
are generally composed of acidic carbohydrates or lipids (Minion and Rosenbusch, 
1993). Capsules have not been described amongst acholeplasmas, spiroplasmas, 
anaeroplasmas or asteroplasmas. Mycoplasma capsule function generally remains 
obscure (Minion and Rosenbusch, 1993). However, in cell-walled bacteria capsules 
are thought to play a role in pathogenicity by promoting adherence to host tissues 
and particularly to negatively charged receptor surfaces (Robb, 1984), by their 
toxicity, or by promoting resistance to phagocytosis (Rosenbusch and Minion, 1992; 
Marshall et al., 1995). 
The anti-phagocytic properties of polysaccharide capsules are associated 
with their electronegative charge, the prevention of the nonspecific deposition of 
immunoglobulin G (Absolom, 1988), and the capacity to bind non-specific factor H, 
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an inhibitor of the alternative pathway of complement activation (Kasper, 1986). 
Additional protection is also provided where cell aggregates are surrounded by a 
common capsule (glycocalyx) of exopolysaccharide material. This increases 
resistance to degradative enzymes (Isenberg, 1998), but it is not clear whether such 
aggregates are commonly formed by mollicute cells. In mollicutes, the importance 
of the capsule in resisting phagocytosis was demonstrated by Marshall et al., (1995). 
They showed that mutant strains of M. mycoides subsp mycoides which produced 
reduced quantities of capsular polysaccharide, had an increased susceptibility to 
phagocytosis in an in vitro assay. 
Association of the mycoplasma capsule with attachment was first 
suggested by Wilson and Collier (1976). Attachment of M. dispar to erythrocytes 
appeared to be mediated by ruthenium red-stainable capsular material. However, 
other possible methods of attachment in the form of fine extracellular threads or 
fibrils were previously observed between the mycoplasma membranes and 
erythrocytes by Howard and Gourlay, (1974). However, strains of M. 
hyopneumoniae that were extensively passaged in vitro did not exhibit fibrillar 
structures and were less pathogenic to pigs (Tajima and Yagihashi, f 982), indicating 
attachment mechanisms have an effect on the pathogenicity of mycoplasmas. 
In addition to their roles in attachment and avoiding phagocytosis, 
mycoplasma capsules may have a direct toxic effect on host cells. Calves inoculated 
intravenously with the purified galactan capsule of M. mycoides subsp. mycoides 
SC, showed increased mycoplasmaernia and polyarthritis when subsequently 
challenged with viable organisms (Lloyd et al., 1971). Another effect ascribed to 
the galactan of M. mycoides subsp. mycoides was that it promoted deposition of 
fibrin around chronic lung lesions in cattle (Buttery et al., 1980); it also increased 
their sensitivity to subsequent challenge with live organisms (Buttery et al., 1976). 
The galactan capsule has a close biochemical relationship with that of the host lung 
tissue pneurnogalactan and might therefore trigger an auto-immune reaction 
(Ferronha et al., 1988). 
Recently, capsular carbohydrates have received increasing attention and 
have been investigated for use in vaccines (Abusugra and Morein, 2000); and in 
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ELISA and rapid latex-agglutination tests for antibodies in serum (see chapters 5 
and 6) (Ayling et al., 1999; March et al., 1999) 
Mollicute cells are generally described as pleomorphic; they vary in 
shape from spherical or pear-shaped structures to branched or helical filaments. 
Genome replication precedes, but is not necessarily synchronised with cell division 
(Razin, 1995). Thus, budding forms and filaments are frequently seen, especially in 
species such as M. mycoides. Although mollicutes have no flagella and are mostly 
non-motile, some mycoplasmas exhibit gliding motility on liquid-covered surfaces. 
These gliding mycoplasmas generally grow as pear-shaped cells with a specialised 
tip structure. Studies on the M. pneumoniae tip structure show that it plays an 
important role in colonisation of host cell surfaces by providing orientation and 
polarity of attachment (Baseman, 2000). A protein identified as PI is localised in 
the tip region and is probably the major component responsible for attachment 
(Carson et al., 1992) although there is evidence of other mechanisms of adherence 
and colonization (Baseman, 2000). The tip structure consists of a striated rod with 
associated microfilaments, possibly representing a primitive cytoskeleton (Razin, 
1995). Proteins related to P1 have been identified in M. genitalium (Tully et al., 
1983), M. gallisepticum (Athamna et al., 1997) and a range of other human and 
animal mycoplasmas. 
1.2.2. METABOLISM 
The small genome size of mollicutes limits the range of their metabolic 
activities and they are largely dependent on extracellular sources of amino acids, 
nucleic acid precursors and lipids. In typical mycoplasma media, these are 
contained within such components as serum, yeast and animal tissue extracts and 
protein digests (see Chapter 2, Section 2). As the precursors for synthetic pathways 
need to be provided in the environment, the role of catabolic pathways is mainly. 
concerned with energy generation (NEles, 1992). In the majority of mollicutes, 
glucose and other metabolizable polysaccharides are the sole or major energy 
sources. In addition, certain Mycoplasma and Spiroplasma species are able to 
generate ATP from the hydrolysis of arginine (Pollack, 1979) and in Ureaplasma, 
energy generation is dependent on urea hydrolysis (Masover et al., 1977; Glass et 
al., 2000). 
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In M. mycoides glucose uptake is by a phosphoenol 
pyruvate: phosphotransferase system (PEP: PTS) (Cirillo, 1979) and metabolism 
proceeds by the Embden-Meyerhof pathway (Cocks et al., 1985). Anaerobically, 
lactate is the end product of glucose metabolism and there is a net yield of 2 mol 
ATP/mol glucose. However, under aerobic conditions, there is a partial oxidation 
and pyruvate is converted via phosphate-acetyl transferase and acetate kinase 
activities to acetate plus C02, giving a total of 4 mol ATP/mol glucose. Mollicutes 
lack the tricarboxylic acid cycle (TCA) and acetate is not further metabolised. 
Where pyruvate is oxidised to acetate, there is a net production of 
NADH, which is reoxidised to NAD+ by molecular oxygen through the action of 
NADH oxidase. Cocks et al. (1985) assumed the product of NADH oxidation to be 
H202. However, Wes et al. (1991) and Taylor et al. (1996) reported that water was 
the major product of NADH oxidation in the Mycoplasma species they studied. 
Subsequently, Rice et al. (2001) showed that in M. mycoides subsp. mycoides 
strains, the quantity of H202 produced varied. This is potentially significant in 
pathogenicity since H202 may cause host cell damage. 
In fermentative mycoplasmas, sugars other than glucose may sometimes 
be utilised and patterns of substrate utilization are potentially useful in the 
characterisation of species (Miles et al., 1991; Abu-Groun, et al., 1994; Taylor et al., 
1996). For example, maltose and trehalose were metabolised by strains of M. 
mycoides subsp. capri (Wadher and Miles, 1988) and certain other members of the 
"M. mycoides cluster" (Abu-Groun et al., 1994), but not by M. mycoides subsp. 
mycoides SC strains (Miles & Lee, 1983; Abu-Groun et al., 1994). 
Mycoplasma mycoides may be considered typical of those species that 
produce acid from glucose; however in a number of other glucose fermenting 
Mycoplasma species, including M. fermentans and A canis, pyruvate is not 
oxidised to acetate and lactate appears to be the end product of glucose metabolism 
under aerobic and anaerobic conditions (Miles et al., 1991). In contrast, some non- 
fermentative mycoplasmas are able to oxidise pyruvate and in some of these species, 
organic acid oxidation appears to be the sole source of ATP generation. Examples 
of these species include M. agalactiae and A bovis (Miles et al., 1994; 1996). 
34 
1.2.3. PATHOGENICITY 
Most mollicutes exist as commensals, apparently living in harmony with 
their host (Razin et al., 1998). However, many Mycoplasma species are pathogenic 
(see Section 1.3). In many cases it appears that the major symptoms of disease result 
from damage due to host immune and inflammatory responses rather than to direct 
effects of the mycoplasmas themselves (Razin et al., 1998). Host immune responses 
are generally brought about by the induction of cytokine synthesis and are outside 
the scope of this thesis. Other factors which are important or potentially important 
in pathogenicity include: adhesion to host cell surfaces; the ability to avoid host 
defences by an intracellular location (Baseman, 2000) or the ability to penetrate cell 
crypts; the production of a capsule (see Section 1.2.1); the production of toxins; the 
depletion of host cell substrates, particularly of arginine by arginine-hydrolysing 
mycoplasmas; the production of mitogens which cause non-specific stimulation and 
proliferation of lymphocytes (Naot, 1995); surface antigenic variation; and the 
secretion of degradative enzymes. Those factors of particular importance to 
pathogenicity in M. mycoides and/or M. bovis are considered below. 
The adhesion of mollicutes to host cells is a prerequisite for colonisation 
and for infection. Amongst mycoplasmas, the most detailed knowledge of adhesion 
mechanisms has been obtained for M. pneumoniae. In this organism, binding to 
solid surfaces and animal cells requires the PI adhesin together with a number of 
accessory proteins which are concentrated within the cell membrane of a tip 
organelle (see Section 1.2.1.; Krause, 1996,1998); the correct formation of the P1 
structure is a prerequisite for a successful infection (Krause, 1998). The adhesion 
mechanism of M. gallisepticum also involves a specialised tip-like organelle and 
appears similarly complex (Athamna et al., 1997). Adhesion is dependent upon a 
PvpA surface protein, which has a high homology to other mycoplasmal adhesins 
and shares an epitope with M. bovis (Yogev et al., 2000). Sachse et al. (1996) 
studied cytadhesion of M. bovis to embryonic bovine lung cells and concluded that 
adherence rates were strongly dependent on temperature and involved variable 
surface proteins (vsps). Following adhesion to host cells most mycoplasmas appear 
to remain surface-attached; however, evidence of tissue invasion and an intracellular 
location in certain species is accumulating, notably for M. bovis, M. fermentans, M. 
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penetrans and M. gallisepticum (Howard et al., 1987; Pfutzner, 1990; Lo, S-C, 
1992, Winner et al., 2000). 
The toxic by-products of mycoplasma metabolism, such as hydrogen 
peroxide and superoxide radicals have been incriminated in causing oxidative 
damage to host cell membranes (Razin, 1991; Houshaymi et al., 1997). Hydrogen 
peroxide may be formed during the oxidation of NADH (see Section 1.5.3. ); 
however, it is also formed in large quantities during the oxidation of a- 
glycerophosphate, an intermediate in the metabolism of glycerol (Taylor et al., 
1996). All M. mycoides strains (except European M. mycoides subsp. mycoides SC 
strains) oxidise glycerol at high rates (Rice et al., 2001). There is also evidence that 
some mycoplasmas produce high molecular weight toxins. M. neurolyticum 
produces a membrane-associated toxin and some variants of M. gallisepticum 
produce a neurotoxin (Kumars et al., 1963; Thomas, 1967). An inflammatory toxin 
has been extracted from M. bovis and toxic components have been described for 
other mycoplasmas including M. arthritidis and M. hyopneumoniae. The galactan 
capsule produced by M. mycoides may also have a pathogenic role, though the 
mechanism is poorly understood (Egwu et al., 1996). 
One means by which pathogens may evade detection by the host 
immune system is to vary their surface antigens. Surface antigenic variation in 
mycoplasmas was first discovered in M. bovis (Behrens et al., 1994). In the M. bovis 
system, lipoproteins designated as vsps, undergo frequent and spontaneous changes 
in expression state and in size (Behrens et al., 1994). More recently, surface 
antigenic variation has been demonstrated in M. gallisepticum, M. agalactiae, M. 
pulmonis, M. hominis, M. fennentans and M. hyorhinis (Razin et al., 1998). In M. 
bovis variation is thought to be caused by the random transposition of an insertion 
element in the regulatory region of the vspA gene (Lysnyansky et al., 1998). 
There is little evidence to suggest that the secretions of degradative 
enzymes play a significant role in mycoplasma pathogenicity. However, proteolytic 
activity, as detected by casein hydrolysis or the liquefaction of inspissated animal 
serum or gelatin, is present in a numbertspecies. In addition, M. mycoides subsp. 
mycoides SC strain Y appears to be able to obtain some amino acids for growth by 
the degradation of bovine serum albumin (Rodwell, 1983). Thus, it has been 
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suggested that mycoplasma protease activity may be involved in arthritic disease 
(Cole et al., 1985; Czekalowski et al., 1973). Many mycoplasma diseases manifest 
as arthritis in animals and experimental infections in cattle with M. bovis resulted in 
the destruction of cartilage and development of fibrotic lesions within joints 
(Simecka et al., 1992). 
1.3. HABITAT AND ROLE IN DISEASE 
1.3.1. MOLLICUTES IN ARTHROPODS AND PLAWS 
A variety of mollicutes are found in arthropods and plants. These 
include the helical spiroplasmas, entomoplasmas, mesoplasmas, acholeplasmas, 
mycoplasmas and the mycoplasma-like organisms (MILOs) which are now referred 
to as phytoplasmas. Mycoplasmas and acholeplasmas, resembling those of classical 
animal species, were first reported on vegetable and floral plant surfaces in 1979 
(Eden-Green and Tully, 1979; McCoy et al., 1979). 
Spiroplasmas have been isolated from plants that show symptoms of 
chlorosis, leaf mottling, proliferation of growing points, and general stunting. Some 
spiroplasmas are involved in vector-transmitted plant diseases such as citrus 
stubborn and com stunt. These pass through a complex biological cycle that 
involves passage through an insect host before reinfection of healthy plants. 
Spiroplasmas have been reported in Hymenoptera (honey bees, wasps), Coleoptera 
(beetles), Diptera (flies, blood-sucking insects such as mosquitoes, tabanid flies, 
Drosophila spp), Lepidoptera (butterflies, which feed on flower nectar), Homoptera 
(leafhoppers) and Hemiptera (leaf bugs) (Hackett, 1990). They have also been 
isolated from ticks (Razin, 1992). The spiroplasmas are phylogenetically most 
closely related to the M. mycoides cluster based on 16S rRNA gene sequencing 
(Figure I. Q. 
Phytoplasmas, first discovered in the 1960's (Doi et aL, 1967), are the 
most economically important group amongst the plant mollicutes. More than 300 
phytoplasma associated plant diseases transmitted by insects have been described 
(McCoy et al., 1989). Little is known about these organisms as they have not yet 
been cultivated, but they are maintained artificially in plants by vegetative 
propQgation methods, such as grafting, cuttage and tissue culture (Tanaka et al., 
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2000). Thq recent application of molecular techniques has shown that they have 
many properties in common with classical mollicutes, including a small genome size 
and a low GC content. Lim and Sears (1991) demonstrated that Phytoplasma 
genome size was similar to that of Mycoplasma and smaller than in Acholeplasma. 
However, on the basis of 16S rDNA sequence homology, phytoplasma show a 
closer evolutionary relationship to Acholeplasma (Figure 1.1). Use of 16S rDNA 
sequencing amplification of the 16-23S rDNA intergenic region, has identified 11 
major groups of phytoplasmas (Wang and Hiruki, 2000). 
1.3.2. MOLLICUTES INMAN 
The first isolation of a mycoplasma from man, probably M. hominis, was 
in 1937 (Dienes and Edshall, 1937). By 1955 three mycoplasmas associated with 
humans had been discovered (M. hominis, M. fennentans and M. salivarium) and 
many others have since been isolated (Table 1.4. ); some of these are considered to 
be part of the normal flora, but M. pneumoniae and a small number of additional 
species are associated with disease. These are described in the following sections 
(Section 1.3.2.1-1.3.2.2. ). 
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TABLE 1.4. MOLLICUTES ISOLATED FROM MAN 
Species Other hosts Site of recovery and Pathogenicity 
occurrence 
Acholeplasma Birds, domestic Oral cavity, respiratory and Not known 
laidlawii animals, other urogenital tracts; rare 
primates 
Mycoplasma Rodents Urogenital tract; only one Apparently non-pathogenic 
arthritidis report 
Mycoplasma Lung Bronchitis in immunosupressed 
A39 patients (Pitcher, 2001) 
Mycoplasma Monkey Oropharynx, vagina Apparently non-pathogenic 
buccale (monkeys); uncommon 
Mycoplasma Other primates Oropharynx; uncommon Apparently non-pathogenic 
faucium 
Mycoplasma Other primates Urogenital tract, Not known; see Section 
fermentans oropharynx; uncommon 1.3.2.3. produces chromosomal 
aberrations in cell culture and 
leukemoid disease in mice 
Mycoplasma Urogenital tract, rectum; Associated with NGU and 
genitalium uncommon possibly pelvic inflammatory 
disease (Taylor-Robinson, 
2001) 
Mycoplasma Other primates Urogenital tract; common Pyelonephritis, pelvic 
hominis inflammatory disease, 
postabortal/postparturn fever, 
arthritis, congenital pneumonia 
Mycoplasma Oral cavity; rare Not known 
lipophilium 
Mycoplasma Other primates Oropharynx, contaminated Apparently non-pathogenic 
orale cell cultures; widespread 
Mycoplasma Respiratory tract, oral Cause of primary atypical 
pneumoniae cavity; rarely middle-ear and pneumonia; other disease 
spinal fluid manifestations include bullous 
myringitis, myocarditis, 
cutaneous and neurological 
conditions 
Mycoplasma Other primates Urogenital tract; rare in man Not-known 
primatum 
Mycoplasma Other primates Oral cavity; common Apparently non-pathogenic 
salivarum 
Ureaplasma Urine, semen, urethra, Associated with NGU, 
urealyticum vagina, cervix, mouth, vaginitis, septic abortion, 
pharynx, rectum; common infertility, congenital 
pneumonia 
Table adapted from Krause and Taylor-Robinson (1992). 
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1.3.2.1. M. PNELTMONIAE 
Mycoplasma pneumoniae is the major cause of primary atypical 
pneumonia in humans and causes a febrile bronchitis or pneumonia often 
accompanied with generalised symptoms such as malaise, muscular pain, sore throat 
or headache. The organism may be carried in the throat for several months after 
natural clinical recovery. Infection is probably worldwide although most reports are 
from northern temperate zones and Australasia. The mycoplasma attaches to a 
receptor(s) on the cilia of cells of the respiratory epithelium by means of binding 
proteins that are located on a specialised terminal structure. The correct formation 
of this tip structure is a prerequisite for a successful infection (Krause, 1998). A 
165kd protein, designated P1, is involved in this cytadherence process (Kahane et 
al., 1985) but other proteins are also required (Baseman, 2000). These include P30, 
and two further membrane proteins of 40 and 90 kDa (Droesse et al., 2000), and a 
number of high molecular weight proteins that form part of the cytoskeleton-like 
structure (Krause, 1998). These proteins are proline-rich and exhibit repeat 
sequences and other motifs characteristic of eukaryotic cytoskeletal proteins (Hahn 
et al., 1998). 
1.3.2.2. M. HOMINIS 
Mycoplasma hominis is frequently found as part of the normal flora in the 
human urogenital tract. (Krause and Taylor-Robinson, 1992). However, it is 
associated with acute upper urinary tract infections, which are often accompanied by 
the development of a significant specific antibody response (Thomsen, 1978). It is 
also associated with pelvic inflammatory disease, which is a cause of infertility in 
women. This disease usually results from infection by Chlamydia trachomatis or 
Neisseria gonorrhoeae; however M. hominis is often isolated from patients and may 
have a synergistic role with these pathogens in causing disease. A review of M. 
hominis in extra-urogenital tract disease (Madoff and Hooper, 1990) identified five 
additional categories of infection: septicaernia, joint infection, central nervous 
system infection, respiratory infection, and wound infection, particularly after 
surgery. M. hominis has also been implicated in chorioamnionitis, and respiratory 
distress in the new-born (Krause and Taylor-Robinson, 1992). In the 
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immunocomprin-iised host M. hominis can cause significant morbidity and mortality 
(Meyer and Clough, 1993), which is compounded by the organism's resistance to 
erythromycin and the newer macrolides (Gass et al., 1996). It can be a significant 
problem in organ transplantation and has been reported to be transmitted from donor 
to recipient in lung aflografts (Gass et al., 1996) and bone marrow (Kane et al., 
1994), liver (Haller et al., 1993), renal (Miranda et al., 1990) and heart transplants 
(Boyle et al., 1993). 
1.3.2.3. M. FERMENTANS 
Mycoplasma fennentans was first isolated from a human genital ulcer 
(Ruiter and Wentholt, 1952) and has since been isolated most frequently from the 
urogenital tract. It has also been isolated from joint fluids and may have a role in 
rheumatoid arthritis (Somerson and Cole, 1979). More recently M. fermentans has 
been linked with autoimmune deficiency syndrome (AIDS)-associated nephropathy 
and systemic infections in AIDS patients (Lo et al., 1989). Furthermore, it has been 
shown to be a cofactor in causing fatal systemic infections in HIV-negative 
individuals (Lo, et al., 1989). It is also a known contaminant of cell cultures and has 
been recently isolated from sheep (Nicholas et al., 1998). 
1.3.2.4. M. GENITALIUM 
Humans are the natural host for M. genitalium, which has the smallest 
genome of any free-living organism (Colman et aL, 1990; Table 1.2. ). However, 
very few isolations have been reported and its primary localisation within the human 
host is still a subject for speculation (Bott and Fraser, 1998). The presence of the 
organism has been detected by PCR in arthritic joints, the blood of AIDS patients, 
the respiratory tract of an immunodeficient patient and in urethral swabs. It has a 
high level of association with non-gonococcal urethritis and pelvic inflammatory 
disease and may be a factor in the aetiology of the disease. Serological detection of 
M. genitalium infection has been hampered by its cross-reactivity with M. 
pneumoniae (Tully et aL, 1995). These organisms are morphologically similar both 
possessing a specialised terminal organelle which plays a role in attachment to host 
cells and is a prerequisite for infection (Herrmann and Reiner, 1998). 
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1.3.2. S. UREAPLASMA UREALYTICUM 
Ureaplasma urealyticum can be divided into two biotypes, based on genome 
size and rDNA sequence, and 14 serotypes (Pitcher et al., 2000). It is a common 
inhabitant of the urogenital tract and has been associated with non-gonococcal 
urethritis. In addition, compared to control groups, ureaplasma-positive placentas 
are observed more frequently from women with chorioamnionitis, premature birth, 
fetal loss, premature rupture of fetal membranes and low-weight new borns (Cunha, 
et al., 1997). Chang et al., (2000) also detected U. urealyticum DNA in cervical and 
ovarian cancer tissues and speculated that the organism may be a co-factor in cancer 
development. Ureaplasmas are also found in many animal species. 
1.3.2.6. AIDS ASSOCIATED MYCOPLASMAS 
Infectious agents other than HIV-1 appear to play an important role in 
promoting the disease progression of AIDS. Systemic mycoplasmal infections may 
explain a number of unusual disease processes, including multiple organ failure and 
autoimmune disorders (Lo, 1992). The mycoplasmas that have been linked with 
AIDS are M. fermentans, M. pirum, M. genitalium and M. penetrans (Lo, 1992). 
Interestingly, all of these mycoplasmas are glucose fermenters and only one of them, 
M. genitalium does not additionally hydrolyse arginine. M. fermentans (incognitus 
strain) was isolated during transfection studies of cells with DNA extracted from 
Kaposi's sarcoma tissue derived from an AIDS patient. This strain was shown to 
enhance the cytotoxic effect of HIV-1 on CD4 lymphocytes in culture (Lo et aL, 
1991). However, the unusual manner in which M. fermentans incognitus was 
isolated has been viewed with some scepticism; there is no precedent for nucleic 
acid from a prokaryotic organism being infective for eukaryotic cells (Van der Riet, 
1990). It is more likely that either the transfected DNA or the tissue culture cells 
were contaminated with M. fennentans (Hannan, 1997). Further work is necessary 
to establish the role of mycoplasmas in AIDS. 
1.3.3. MOLLICUTES IN ANINULS 
Since M. mycoides was first described in 1898 mollicutes have been 
isolated from almost every animal species that has been studied. Infections are often 
associated with diseases of the lung, ur ogenital tract and joints. Several diseases 
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are of economic importance in agriculture and some affect biomedical research by 
infecting animals used in experimental models. This section on mollicutes in 
animals will focus on major disease causing species. 
1.3.3.1. MOLLICUTES OF LABORATORY RODENTS 
Experimental animals need to be free of indigenous pathogens and 
subclinical infections to ensure accurate and reproducible research data. 
Mycoplasmal diseases in rats and mice are a recognised problem (Cassell and Hill, 
1979) and there is substantial evidence that infections with M. pulmonis and M. 
arthritidis have interfered with a number of studies (Lindsey et al., 1986). 
Mycoplasma pulmonis is the cause of murine respiratory mycoplasmosis 
and nearly all rat and mice colonies in the United States are infected (Ferebee et al., 
1992). Generally the disease is asymptornatic, but rhinitis, laryngitis, tracheitis, 
bronchitis, bronchiectasis and alveolitis occur, often in association with other 
pathogens (van Kuppeveld et al., 1993). Rabbits, hamsters and guinea pigs may 
also be affected. The mycoplasmas that have been isolated from rats and mice are 
listed in Table 1.5. (van Kuppeveld et al., 1993). 
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TABLE 1.5. MOLLICUTES ISOLATED FROM RATS AND MICE 
MOLLICUTE NATURAL FREQUENCY NATURAL DISEASE 
SPECIES HOST(S) OFINFECTION 
Mycoplasma Rats, mice Common Arthritis 
arthritidis 
Mycoplasma collis Rats, mice Unknown 
Mycoplasma KE2 Rats Unknown 




Mycoplasma Mice Rare Not reported but able to cause 
neurolyticum experimental infection 
Mycoplasma Rats, mice Common Infection of respiratory tract, 
pulmonis genital disease and arthritis. 
Table compiled from data in van Kuppeveld et A (1993) and Simecka et aL (1992). 
1.3.3.2. MOLLICUTES OF POULTRYAND BIRDS 
Currently, 20 mollicute species have been isolated from poultry and 
birds. The most economically important are M. gallisepticum, M. Synoviae, M. 
meleagridis and M. iowae (Fan et al., 1995). All of these pathogens are egg- 
transmitted. M. gallisepticum causes chronic respiratory disease in chickens and 
infectious sinusitis in turkeys (Simecka et al., 1992). Luttrell et al. (1996) also 
isolated M. gallisepticum from house finches affected with conjunctivitis. M. 
synoviae is recognised as a pathogen of both chickens and turkeys causing severe 
respiratory disease and synovitis (Kleven et al., 1991). M. meleagridis occurs in 
turkeys, Japanese quail and peacocks. It is considered a true venereal disease, 
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associated only rarely with respiratory disease in adults, but causing air sacculitis in 
embryos and young birds (Simecka et al., 1992). M. iowae is associated with 
reduced hatchability of turkey eggs, and possibly, immunosuppression in turkey 
poults. It has been shown to cause mortality of both turkey and chicken embryos as 
well as mild to moderate air sacculitis and leg abnormalities in experimentally 
inoculated chickens and turkeys (Abdul-Rahman et al., 1996). Other mycoplasmas 
of possible economic significance in poultry disease are M. anatis, a cause of air 
sacculitis in ducklings, and M. gallinarum. This has been reported as a potential 
pathogen in chickens, where it appears as a secondary invader following certain viral 
infections (Shah-Majid, 1996). 
A number of Mycoplasma species have been isolated from wild birds. 
Forsyth et al. (1996) named M. stumi from a starling, and Poveda et al. (1994) M. 
buteonis, M. falconis, and M. gypis from birds of prey. 
1.3.3.3. MOLLICUTES OF SWINE 
Many mollicutes have been isolated from pigs, but the main swine 
disease causing mycoplasmas are M. hyopneumoniae, M. hyorhinis and M. 
hyosynoviae. M. hyopneumoniae is the causal agent of enzootic pneumonia of 
swine, a chronic respiratory disease that occurs worldwide (Simecka et al., 1992). 
This mycoplasma is very difficult to grow on artificial media, and was not isolated 
until 1965 (Goodwin et al., 1967). Both M. hyorhinis and M. hyosynoviae are 
usually found in the upper respiratory tract of adult pigs, where they act as reservoirs 
of infection, causing severe polyarthritis in pigs aged 3 to 6 months (Simecka et al., 
1992). 
1.3.3.4. MOLLICUTES OF SHEEP AND GOA TS 
Mycoplasma infections in sheep and goats often result in pneumonic 
disease, however arthritis and septicaernia are also common. Some mycoplasma 
infections are specifically associated with mastitis or keratoconjunctivitis. One of 
the most important pneumonic diseases is contagious caprine pleuropneumonia 
(CCPP) caused by M. capricolum subsp. capripneumoniae, formerly known as 
Mycoplasma F38 (Bonnet et al., 1993). This is characterised by red and grey 
hepatization of the lung with characteristic haemorrhagic infarction that may involve 
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an entire lobe. Previously, CCPP had been linked to other mycoplasmas including 
M. capricolum subsp. capricolum, M. mycoides subsp. capri and M. mycoides subsp. 
mycoides LC (large colony), which cause a disease similar to CCPP. However, 
MacOwan (1984) showed that only M. capricolum subsp. capripneumoniae fulfilled 
Koch's postulates in causing the classical signs of disease, which include a 
characteristic highly infectious pulmonary pneumonia. Recently, it has been 
concluded that M. mycoides subsp. capri and M. mycoides subsp. mycoides (large 
colony) should be classified within the same taxon (Anon, 2000). This is based on 
genetic, biochemical and serological evidence although DNA homology studies 
(Table 1.8; Section 1.5.3. ) are able to separate the two groups. 
Mycoplasma mycoides subsp. mycoides SC (small colony) has also been 
isolated from sheep and goats (Cottew and Yeats, 1978; Branddo, 1995) and has 
recently been associated with contagious caprine pneumonia in India and Eastern 
Tanzania (Kusiluka et al., 2000; Srivastava et al., 2000). This organism is the cause 
of contagious bovine pleuropneumonia (CBPP) in cattle and its isolation from other 
animals has implications for disease control (see Section 1.5). 
Contagious agalactia (CA) is an important disease of sheep and goats 
that occurs worldwide, particularly where herds are intensively reared. M. 
agalactiae is the classical agent of CA, but M. capricolum subsp. capricolum, M. 
mycoides subsp. mycoides (large colony) and M. putrefaciens also contribute to this 
syndrome. The disease is predominantly chronic and causes agalactia, mastitis, 
keratoconjunctivitis, arthritis and septicaernia, which may result in mortality. The 
financial loss is considerable with one recent estimate for Greece alone of 
approximately 24.5 million ECU per annum (Legakis, 1995). 
Mycoplasma ovipneumoniae is found as a commensal organism of the 
respiratory and genital tracts of sheep and goats, but can produce a primary 
pneumonic infection that may be complicated by secondary invaders such as 
Mannheimia (Pasteurella) haemolytica (Jones et al., 1982). 
Infectious keratoconjunctivitis ('pinkeye) of sheep and goats is caused 
by M. conjunctivae. Once introduced into an immunologically naive herd, M. 
conjunctivae can spread rapidly, but infection tends to be self-limiting and 
permanent lesions are rare (Giacometti et al., 1996; Naglid et al., 2000). 
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Mycoplasma arginini and M. bovigenitalium have been isolated from the 
genital tracts of sheep in Nigeria (Chima et aL, 1995) and experimental infections 
with M. bovigenitalium in sheep have caused vulvovaginitis; however the role of 
mycoplasmas in naturally-acquired genital disease is not clear. The recent isolation 
of M. fermentans from a case of vulvovaginitis in a sheep is surprising (Nicholas et 
aL, 1998). VLA Weybridge has now received three separate isolates of M. 
fermentans from sheep, all associated with genital tract infections (Nicholas, R. A. 
J., Ayling, R. D., unpublished observations). 
1.3.3.5. MOLLICUTES OF CAME 
Mollicutes isolated from cattle are listed in Table 1.6. M. mycoides 
subsp. mycoides SC the causative agent of CBPP, and M. bovis, a cause of bovine 
mastitis and respiratory infection in calves, are the major organisms of study in this 
thesis and are considered separately in Sections 1.4 and 1.5 respectively. The 
significance of other species is discussed below. 
Mycoplasma alkalescens has been isolated from the synovial fluid of 
calves and has been suggested to be a rare cause of arthritis (Whithear, 1983). It 
was isolated from 8.5% of 658 cattle with respiratory disease in Northern Italy 
during 1994 to 1996 (Manfrin et al., 1998). Since nearly 80% of the tested animals 
were negative for mycoplasmas, M. alkalescens would appear to be an important 
member of the mycoplasma flora of cattle and might potentially be important in 
disease (Reeve-Johnson, 1999). 
Mycoplasma bovigenitalium appears to be ubiquitous having been 
reported throughout the world (Reeve-Johnson; 1999). It is associated with 
respiratory disease and has been isolated from the lower respiratory tract. It has also 
been isolated from mastitic milk and the genital tract and prepuce of bulls with 
symptoms of infertility (Atef and Mohy, 2000). Interestingly, recent work on UK 
sheep isolates, identified as Mycoplasma ovine serogroup 11, has shown that this 
group is not distinct from M. bovigenitalium and should be considered as part of the 
same species (Nicholas et al., in press). 
Mycoplasma bovirhinis is frequently isolated from cattle in the UK and 
has been shown to cause mastitis (Simecka et al., 1992). It has also been isolated 
from the respiratory tract, joints and eyes (Thomas and Smith, 1972; Reeve-Johnson, 
47 
1999), but is not considered to be pathogenic at these sites; possibly it outgrows 
more fastidious pathogenic mycoplasmas in isolation media. 
Mycoplasma canadense and M. californicum are known to cause mastitis 
in cattle (Simecka et al., 1992). M. canadense was first isolated in Canada from 
cases of mastitis, swollen joints and umbilicus of a calf, vaginal discharge of a cow 
and semen of a bull (Ruhnke and Onoviron, 1975). Ball et al. (2000) investigated an 
outbreak of clinical mastitis in newly-born calves in Northern Ireland and isolated 
M. canadense; however antigen to M. califomicum was also detected in serum 
samples using a sandwich ELISA. Kaur et al. (1998) recently reported in India, the 
first isolation of M. canadense from the milk of mastitic cows and buffaloes. 
Mycoplasma dispar can induce pneumonia (Ross, 1993), although it has 
also been isolated from healthy cattle. Diagnosis is difficult, as the disease is often 
subclinical and the organism takes up to 14 days to grow, often being 'outgrown' by 
more prolific but less important mycoplasmas. This poor growth rate may account 
for its apparent restricted geographic distribution, with isolations only being made in 
Western European countries, the USA and Australia (Reeve-Johnson, 1999). The 
use of an antigen-capture ELISA on bronchoalveolar lavage fluids from Belgium 
cattle suggested that M. dispar was more common than M. bovis (Thomas et al., 
2000). 
Mycoplasma sp. bovine serogroup 7 is one of six recognised members of 
the M. mycoides cluster (See Table 1.8, Section 1.5.3. ). It was first isolated from 
arthritic calves in South Queensland, Australia in the early 1960's. It has a history 
of causing sporadic outbreaks of arthritis in calves and mastitis in cows but has also 
been recovered from pneumonic bovine lungs and lymph nodes (Cottew, 1970). In 
a recent severe outbreak of polyarthritis, mastitis and abortion in three large dairies 
in New South Wales, Australia, bovine serogroup 7 was the only pathogenic agent 
recovered (Djordjevic et al., 2000). 
Mycoplasma bovoculi is associated with keratoconjunctivitis in cattle 
(Simecka et al., 1992). M. canis is normally associated with dogs but is increasingly 
being isolated from pneumonic cattle (Nicholas et al., 1995; 2000b) and recently has 
been identified in bovine mastitic milk samples (Ayling R., unpublished data). 
Other Mycoplasma species isolated from cattle include M. arginini, M. alvi and M. 
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verecundum. However, although these organisms may be isolated from diseased 
cattle, it is unclear whether they cause disease. 
Acholeplasma laidlawff is frequently isolated from cattle and its rapid 
growth in media commonly used for isolating mycoplasmas may obscure other more 
important organisms. Its role as a pathogen has not been shown. 
Ureaplasma species are known to cause calf pneumonia, genital disease 
and conjunctivitis (Simecka et A, 1992). Ureaplasma diversum can be isolated 
from both acute and chronically diseased respiratory tracts, and is capable of 
producing mild sub-clinical pneumonia. It is possible that its main role is in 




TABLE 1.6. MOLLICUTES THAT AFFECT CATTLE 
MOLLICUTE SPECIES DISEASE 
Mycoplasma mycoides subsp. Contagious bovine pleuropneumonia (CBPP). 
mycoides SC See Section 1.5. 







Not reported to be pathogenic 
Arthritis 
Mastitis and genital disease 
Mastitis 
Calf pneumonia, mastitis and arthritis, See 
Section 1.4. 
Mycoplasma bovoculi Conjunctivitis 
Mycoplasma canis Calf pneumonia?, mastitis? 
Mycoplasma califomicum Mastitis 
Mycoplasma canadense Mastitis 
Mycoplasma dispar Calf pneumonia and mastitis 
Mycoplasma verecundum Not reported to be pathogenic 
Acholeplasma spp Not reported to be pathogenic 
Ureaplasma spp. Calf pneumonia, genital disease, and 
conjunctivitis 
Table adapted from Simecka et A (1992). 
1.3.3.6. MOLLICUTES OF OTHER ANIMALS 
A number of mycoplasma species have been isolated from horses. Their 
true pathogenic significance is unknown, but there is evidence that M. felis causes 
pleuritis (Wood et A, 1997) and this mycoplasma has been associated with feline 
conjunctivitis and pneumonia. M. gateae and M. feliminutum have also been 
implicated in feline pneumonia. Using 16S rRNA gene sequencing and serological 
methods, a mycoplasma isolate from a seal was recently (October 2000) identified at 
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VLA (Weybridge) as M. phocacerebrale. In dogs, M. cynos causes a rapidly 
spreading respiratory infection involving the lungs and M. canis and M. spumans are 
reported to cause urinary tract infections. Recent reports by Giacometti et al. (1996) 
have described outbreaks in Switzerland of conjunctivitis in ibex, chamois and sheep 
caused by M. conjunctivae. Apparently, affected wild animals are unable to see and 
as a consequence they fall off the mountains. 
Recent developments in mycoplasmology, especially genetic typing 
methods, have also led to the description of new species from more unusual animals, 
such as: elephants (Mycoplasma elephantis sp. nov., Kirchhoff et al., 1996); 
tortoises (M. agassizii sp. nov., Brown et al., 1995); crocodiles (M. crocodyli sp. 
nov., Kirchhoff et al., 1997); and Afghan pikas (a type of small rabbit) (M. 
lagogenitalium sp. nov., Kobayashi et al., 1997). Other examples of mollicutes 
found in various animal species are given in Table 1.7. 
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TABLE 1.7. EXAMPLES OF MOLLICUTES FOUND IN DIVERSE ANIMAL 
SPECIES 
ANIMAL SPECIES MOLLICUTES SPECIES 
Camel Acholeplasma oculi 
Fish (Tench) Mycoplasma mobile 
Giraffe Acholeplasma laidlawii 
Squirrel Mycoplasma citelli 
Hedgehog Acholeplasma laidlawii 









Seal Mycoplasma phocacerebrale 
Mycoplasma phocarhinis 
Mycoplasma phocidae 
Table adapted from Rosenbusch. (1994). 
In addition, although mycoplasmas are usually host specific, the list of 
mollicute species isolated from nontypical hosts is increasing with reports of. M. 
canis in cattle (Nicholas et A, 1995); M. salivarum, a common human buccal. 
mycoplasma, in pigs; Acholeplasma oculi, a goat mycoplasma in human arnniotic 
fluid (Razin, 1992); and M. fertnentans in sheep (Nicholas et al., 1998). Whether 
these mycoplasmas cause disease, are part of the normal flora, or are opportunistic 
pathogens is unknown. 
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1.4. MYCOPLASMA BOVIS 
Mycoplasma bovis has been associated with many bovine diseases, 
including pneumonia, arthritis, mastitis, subcutaneous abscesses, 
keratoconjunctivitis, meningitis, infertility (Behrens et al., 1996; Kirby and 
Nicholas, 1996), otitis media (Walz et al., 1997) and abortion (Byrne et al., 1999). 
It was first isolated in 1961 from severe bovine mastitis in the USA and initially 
called M. agalactiae var (later subsp. ) bovis because of similarities, both clinical and 
biochemical, to M. agalactiae. Mycoplasma bovis is the most frequently occurring 
pathogenic bovine mycoplasma in Europe and America (Nicholas, 1997) and the 
second most important mycoplasma pathogen affecting cattle (Ter Laak et al., 
1992). In a survey by the OIE covering over 48 countries, M. bovis was seen as a 
major cause of loss in the cattle industry. In a US survey, M. bovis was isolated 
from one third of over 400 pneumonic lungs. In France, M. bovis is involved in 25- 
30% of pulmonary disease in fattening calves (Nicholas et al., 1999). In Britain, M. 
bovis is the most common mycoplasma pathogen of cattle and is estimated to cause 
losses of as much as E50 million per year in treatment, 'set back' costs and deaths in 
calves (Rebhun et al., 1995). The first UK isolation of M. bovis was from a severe 
case of calf pneumonia in Southern England in 1974 (Thomas et al., 1975). The 
organism has also been associated with severe arthritis, synovitis, genital tract 
lesions, and mastitis in UK herds and in 1995 about 25 % of all fatal cases of calf 
pneumonia in N. Ireland were associated with M. bovis infection (Ball et al., 1995). 
Mycoplasma bovis may act synergistically in disease with other 
organisms such as Pasteurella species, Haenzophilus somnus and Actinomyces 
pyogenes (Doherty et al., 1994; Rebhun et al., 1995). However, it is increasingly 
being considered as a primary pathogen. It has been shown that M. bovis can induce 
pneumonia and arthritis in gnotobiotic calves (Gourlay et al., 1976) and in 'normal' 
calves (Stipkovits et al., 2000b). Infected calves start to develop clinical signs 
within eight to ten days of challenge. Clinical signs include depression, hyperpnea, 
dyspnea, respiratory distress, various degrees of nasal discharge, coughing, fever 
and loss of appetite. Body weight is also significantly lower than in uninfected 
animals. The calves stand with head and neck extended and forelegs spread apart. 
Pneumonia caused solely by M. bovis is generally referred to as a 'cuffing 
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pneumonia' because lymphoid hyperplasia appears around the airways. Lesions are 
usually limited to the cranial tips of the lung lobes and there may be a purulent 
bronchiolitis (Pfutzner and Sachse, 1996). 
In experimental infections calves may die within 3 weeks -of challenge 
(Stipkovits et al., 2000b). Stipkovits et al., (2000b) described the development of 
pneumonia characterised by either: perivascular and peribronchial infiltration of 
lymphoid cells; catarrhal pneumonia with desquarnation of epithelial cells and 
accumulation of serous exudate in alveoli and bronchi; or the presence of inflamed 
foci surrounded by connective tissue. He also recovered M. bovis from the lung, 
spleen, livers, kidneys and joints. Rodriguez et al. (1996r-) described similar 
findings in experimentally infected calves; there was consolidation of lungs, 
although they observed little or no desquarnation of epithelial cells. 
Immunohistochernical findings revealed large quantities of M. bovis antigen, 
particularly at the edges of necrotic zones in association with pyknotic cells, and 
also in epithelial cells, within inflammatory cells in airway lumina, and in alveolar 
walls (Rodriguez et al., 1996b). 
Mycoplasma bovis infection is invariably brought onto a farm by 
clinically normal cattle that shed the organism in exhalation droplets. Subsequent 
transmission of M. bovis infection then occurs via the respiratory tract, by contact 
with contaminated milking equipment, or by calves suckling infected cows (Pfutzner 
and Sachse, 1996). 
Control of the disease is difficult. Currently no vaccines exist and 
antimicrobial therapy is of limited use. Specific antimicrobial treatment for 
mycoplasmas is usually considered only when treatments with antimicrobials 
effective against other pneumonia causing bacteria, such as Pasteurella and 
Haemophilus, have been unsuccessful. The most widely used antimicrobials against 
these cell-walled bacteria are penicillin and ampicillin which have modes of action 
that will not affect mycoplasmas. Thus by the time appropriate antimicrobials, such 
as tilmicosin, spectinomycin or the fluoroquinolones, are administered, M. bovis 
infection is advanced. 
An immune response is mounted against M. bovis infection. However, it 
does not usually lead to high antibody titres, although titres depend on the severity 
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of infection and the diagnostic test used (Nicholas, 1997). Feenestra. et aL (1991) 
investigated the diagnosis of M. bovis mastitis using an indirect haernagglutination 
test (H-IA) and found titres varying between less than 1/160 to greater than 1/1280 in 
affected calves. Most of the calves were culled soon after the infection was 
detected, but one cow was still shedding M. bovis 10 months later. 
Nagatomo et aL (1996) investigated the immune response using the IHA 
test for three groups of calves introduced to a farm with a history of M. bovis 
infection. One group was treated with the antimicrobial leucomycin as a 
preventative therapy. The untreated groups showed significant antibody titres and 
clinical signs of disease after 60 days. In contrast, in the leucomycin-treated group, 
antibody response and clinical signs were not noted until after 248 days. An indirect 
ELISA (Nicholas et aL, 2000b) for M. bovis has been in use at VLA (Weybridge) 
for several years to screen cattle in Britain. This has given positive results for 
approximately 20-25% of serum samples submitted from pneumonic calves. Byrne 
et aL (2000) successfully used the same ELISA to identify antibodies in milk 
samples collected from a herd with M. bovis mastitis. 
Culturing from the affected animal is the usual method of diagnosis for 
M. bovis infection. M. bovis is one of the more rapidly growing mycoplasmas. It 
characteristically does not ferment glucose, but oxidises lactate or pyruvate (Wes, 
1992) and produces a film on culture media (Poveda and Nicholas, 1998). 
Identification of isolates is usually achieved using specific polyclonal antisera in a 
disc film inhibition test or in an indirect fluorescent antibody test (Bradbury, 1998a). 
The use of PCR technique may also improve M. bovis detection (see chapter 2). 
However, several workers are currently investigating selective, chromogenic 
isolation media that will enable the rapid and direct detection of M. bovis by their 
colony colour on agar plates. (Khan et al., 2000; Windsor and Bashiruddin, 2000). 
One possible problem in the identification of M. bovis isolates by 
conventional serological methods, is surface antigenic variation. The prominent 
membrane surface lipoproteins (vsps) of M. bovis are immunogenic and undergo 
dynamic and spontaneous changes in size and expression (Behrens et al., 1996). 
Antigen size variation occurs through the gain or loss of tandem repeated units in the 
vsp gene. Oscillation in vsp expression may be due to DNA inversion or DNA 
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insertion and is currently being investigated (Citti et al., 1999). Sachse et al. (1999) 
has shown that vsp antigens are important in cytoadhesion. 
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1.5. CONTAGIOUS BOVINE PLEUROPNEUMONIA (CBPP) 
1. S. 1. THE CLINICAL DISEASE 
Contagious bovine pleuropneumonia (CBPP) is included in List A of the 
Office International des Epizooties (OIE, 1996). It is among the six most important 
diseases under the FAO Emergency Prevention System (EMPRES) (Rweyemamu 
and Benkirane, 1996) along with diseases such as rinderpest and foot and mouth 
disease. It predominantly affects cattle, but may additionally cause disease in water 
buffalo, yak, reindeer and bison (Provost et al., 1987); the causative organism 
Mycoplasma mycoides subsp. mycoides SC has also been isolated from sheep and 
goats (Cottew and Yeats, 1978; Branddo, 1995). Transmission of the organism is 
primarily by droplet infection (aerosols), fine bronchial secretions being expelled 
over short distances when diseased animals cough. In spite of this airborne mode of 
transmission, CBPP spreads slowly amongst herds but once established the disease 
persists in an endemic form. 
The range of clinical signs seen in cattle affected by CBPP vary from 
hyperacute through acute to chronic and sub-clinical forms. Respiratory distress and 
coughing, evident on physical stimulation of resting animals, are the main signs 
(Scudamore, 1995). The incubation period of the natural disease may range from 5 
to >200 days but most disease occurs within 40 days (Egwu et A, 1996). 
The earliest sign of infection in dairy cattle may be a fall in milk 
production. In the acute form, the early stages of disease are indistinguishable from 
any severe pneumonia with pleurisy (Scudamore, 1995). Animals show dullness, 
anorexia, and irregular rumination with moderate fever and may show signs of 
respiratory distress. Coughing is usually persistent and is dry. Sometimes body 
temperature rises from 40 to 42'C and the animal prostrates with difficulty of 
movement. As the lung lesions develop, the symptoms become more pronounced 
with increased frequency of coughing and the animal may become prostrate or stand 
with back arched, head extended and foreleg knee joints abducted. In calves up to 
six months old, CBPP may manifest itself as arthritis, and the chest may be free 
from lesions. A small number of affected calves die after mild exertion due to 
valvulitis, and on rare occasions myocarditis (Martel et aL, 1983). 
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Clinical signs are accelerated in the hyperacute form of the disease and 
affected animals may die within a week of exhibiting classical respiratory 
symptoms. In the sub-acute form, symptoms may be limited to a slight cough, only 
noticeable when the animal is exercised. 
In Africa mortality rates are typically between 10-70% and are 
particularly high in newly affected regions; however, in parts of Europe where the 
disease is endemic, there is no mortality and the majority of infected cattle show 
chronic lesions (Egwu et al., 1996). 
Nicholas and Palmer (1994) suggested that this difference might be due 
to European stock being housed permanently, less stressed and healthier than those 
in Africa, which often have a nomadic existence. The wider use of antimicrobials in 
Europe may also mask the clinical signs and accelerate the formation of chronic 
lesions in carrier animals (Provost et al., 1987). However, there are genetic and 
biochemical differences between European and African strains of M. mycoides 
subsp. mycoides SC, which may suggest differences in virulence (see Section 1.5.3). 
1. S. 2. PATHOLOGY 
The pathological lesions of the disease are generally confined to the 
thoracic cavity and lungs. The lesions are usually unilateral, showing no preference 
for the right or left lung although the diaphragmatic lobe is more commonly affected 
than the cranial lobe (Nunes Petisca et al., 1990). The thoracic cavity of affected 
animals may contain many litres of clear yellowish brown fluid containing some 
pieces of fibrin (Ter Laak, 1992). Caseous fibrinous deposits are observed on the 
parietal and visceral surfaces of the lungs (Provost et al., 1987). Other pneumonia 
causing organisms such as Mannheima haemolytica usually affect both lungs. 
The interlobular septa of the affected lung show distension with amber- 
coloured fluid surrounding the distended lymphatics. This fluid separates the lung 
lobules which vary in colour with red, grey and yellow hepatisation being evident 
and representing different stages of inflammatory lesions (Hudson, 1971). 
Consolidation of the lungs with typical marbled appearance, sometimes 
accompanied by adhesion of the parietal and visceral surfaces, is also characteristic. 
In chronic or advanced cases, a sequestrum. of variable size, ranging from a few mm. 
to 20 cm, and consisting of necrotic lung parenchyma surrounded by a fibrous 
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capsule, is formed (Martel et al., 1983; Trichard et al., 1989; Santini et al., 1992; 
Nicholas et A, 1996; see Chapter 4, figure 4.3). 
An immunocytochernical study of CBPP affected lungs by Scanziani et 
al. (1991) showed that the severity of lung lesions correlated with the severity of 
changes in the lymph nodes. In the acute stage of the disease, specific antigen was 
detected in the lobular periphery and in the cytoplasm of alveolar macrophages. 
Chronic lesions showed immunoreactivity in the fibrotic areas and in the 
macroPhages located in the lobular septa. Necrotic debris and macrophages located 
in the inner part of the sequestra, were specifically stained. Immunoreactive material 
was also seen in the centrofollicular areas of the broncho-associated lymphoid tissue 
structures and in the lymph follicles of fibrotic septa (Bashiruddin et al., 1999). 
Electron microscopy of the mediastinal lymph nodes of a chronically affected calf 
also showed intact and degenerating mycoplasmas within macrophages (Bashiruddin 
et al., 1999). 
In acute cases, lesions have also been observed in the kidneys (Hudson, 
1971), and calcifications as a result of CBPP are reported as distinctive and easily 
differentiated from the common forms of bovine interstitial nephritis (Scanziani et 
al., 1999). M. mycoides subsp. mycoides SC has been isolated from the kidneys and 
urine of cattle affected with CBPP (Scudamore 1976). An immunohistochemical 
study (Scanziani et al., 1999) demonstrated the presence of M. mycoides subsp. 
mycoides SC antigen in the kidneys of acute and chronically affected animals, with 
antigen detected in several renal structures including the lumen of renal vessels, 
glomeruli, interstitial cells and tubular epithelia. Scanziani et al. (1997) 
demonstrated that M. mycoides subsp. mycoides SC antigen could often be detected 
immunohistochemically in cases where mycoplasma culture had yielded negative 
results. This may suggest the presence of detectable antigen after the loss of 
mycoplasma viability. 
1.5.3. THE CAUSATIVE ORGANISM 
The causative agent of CBPP, M. mycoides subsp. mycoides SC, is one 
of six closely related mycoplasmas referred to as the M. mycoides cluster. The other 
members of the cluster are: M. mycoides subsp. mycoides LC, M. mycoides subsp. 
capri, M. capricolum subsp. capricolum, M. capricolum subsp. capripneumoniae, 
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and Mycoplasma bovine serogroup 7. All members of the cluster are pathogens of 
ruminants. M. capricolum subsp. capripneumoniae (see Section 1.3.3.4) is the 
causative agent of contagious caprine pleuropneumoniae (CCPP), an OIE list B 
disease. CCPP is highly contagious and occurs in Africa and the Middle East, 
causing fever, coughing, painful respiration, depression and up to 70% mortality 
(Rweyemamu and Benkirane, 1996). Typical CCPP pathology shows fibrinous 
pleuropneumonia and intralobular oedema in lungs. 
Mycoplasma mycoides subsp. mycoides LC, M. mycoides subsp. capri, 
M. capricolum subsp. capricolum and M. putrefaciens (see Section 1.3.3.4) are all 
associated with sheep and/or goats, causing mastitis, arthritis and 
keratoconjunctivitis; M. capricolum subsp. capricolum is also associated with 
ulcerative vulvovaginitis in sheep (Sarris, 1996). 
The relationship between the members of the M. mycoides cluster, based 
on DNA-DNA hybridisation, is shown in Table 1.8. From this table it appears that 
M. mycoides subsp. mycoides LC and SC are the most closely related, with 82% 
homology, whilst the two M. capricolum subspecies also have a high (80%) 
homology. However, based on sequence analysis, a different pattern of relationships 
has emerged. All members of the M. mycoides cluster have two rRNA operons, 
rmA and rrnB and Johansson et aL (1996a) sequenced both 16S rRNA genes. This 
revealed two subclusters: M. mycoides subsp. capri and M. mycoides subsp. 
mycoides LC, the M. capri subcluster; and M. capricolum subsp. capricolum, M. 
capricolum subsp. capripneumoniae and Mycoplasma bovine serogroup 7, the M. 
capricolum subcluster. Interestingly, M. mycoides subsp. mycoides SC was grouped 
in the M. capri subcluster using rrnA sequences and the M. capricolum subcluster 
with the rrnB sequences. Based on 16S rRNA analysis Pettersson et al. (1996) 
suggested that M. mycoides subsp. mycoides LC and M. mycoides subsp. capri 
should form a single taxon; this is also supported by biochemical and serological 
evidence. Sequence analysis of 16S rRNA genes has also shown that M. 
putrefaciens is closely related to members of the M. mycoides cluster (Johansson et 
aL, 1996a). 
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TABLE 1.8. HOMOLOGY OF STRAINS WITHIN THE M. MYCOIDES CLUSTER 
BASED ON DNA-DNA HYBRIDISATION 
DNA-DNA HYBRIDISATION 
(% of homologous hybridisation) 
ORGANISM PG1 Y-GOAT PG3 California PG50 F38 
kid 
Mycoplasma mycoides 100 
subsp. mycoides SC PG1 
Mycoplasma mycoides 82 100 
subsp. mycoides LC Y Goat 
Mycoplasma mycoides 70 75 100 
subsp. capri PG3 
Mycoplasma capricolum ND 41 40 100 
subsp. capricolum 
California kid 
Bovine serogroup 7 ND 72 57 55 100 58 
PG50 
Mycoplasma capricolum ND 36 39 80 60 100 
subsp. capripneumoniae 
F38 
ND, not determined 
Table adapted from Christiansen (1992). 
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Amongst M. mycoides subsp. mycoides SC strains, there appears to be 
marked differences between isolates from Europe and those from Africa and 
Australia. Increased mortality in African disease outbreaks compared to European 
outbreaks has already been mentioned in section 1.5.1. and may possibly be 
explained by different environmental conditions. However differences in the 
virulence of strains may also be important. Genetic analysis has revealed 
differences in the copy numbers of insertion sequence elements in African and 
European M. mycoides subsp. mycoides SC isolates (see Section 1.5.7.3. ). African 
and European isolates were also differentiated by their ability to oxidise glycerol. 
Houshaymi et al. (1997) compared rates of glucose and glycerol oxidation in 14 M. 
mycoides subsp. mycoides SC strains. Washed cell suspensions were saturated with 
air, and oxygen uptake was monitored by measuring the decline in dissolved oxygen 
tension using an oxygen electrode. The ten Italian and Portuguese strains tested 
were unable to oxidise glycerol; however, the African and Australian strains 
oxidised glycerol with oxygen uptake rates of 88 to 540 % of those for glucose. 
Glycerol oxidation leads to production of hydrogen peroxide, a potential virulence 
factor (Houshaymi et al., 1997), and this might account for mortality rate 
differences. 
A mouse model to determine the virulence of M. mycoides subsp. 
mycoides SC strains, based on mycoplasmaernia, was developed by Dyson and 
Smith (1975). This model has severe limitations as infection is not apparently 
established and only mycoplasma survival is tested. Nevertheless,. March and 
Brodie (2000) used the mouse model to suggest that a Botswanan M. mycoides 
subsp. mycoides SC isolate which had unusual growth characteristics and lacked an 
IS 1296 element was of reduced virulence! However, close examination of their data 
shows marked inconsistencies in controls, compared to those of Dyson and Smith 
(1975). 
1. S. 4. PREVALENCE AND ECONOMIC EFFECT 
Early classical writings suggest CBPP existed in the ancient world 
(Provost et aL, 1987). During the 160'Century, CBPP appeared confined to the Alps 
and Pyrenees of Europe. It was first reported in Britain by Barker in 1736, although 
it was not until 1773 that Albert de Haller recommended mass slaughter for its 
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control (Egwu et at., 1996). In 1765 Bourgelat fully described the clinical signs of 
CBPP, (Provost et al., 1987) but CBPP was not properly distinguishable from other 
diseases until the end of the 19th century, when the organism now known as M. 
mycoides subsp. mycoides SC was isolated as the causative agent (Nocard and Roux, 
1898). 
The disease spread rapidly through mainland Europe in the early 19th 
Century due to increased cattle trading. Britain became reinfected in 1840 following 
the introduction of a bull from the Netherlands. The disease then spread to 
Scandinavia, USA, Australia and South Africa in the mid 1850's, followed by New 
Zealand, India, China, Mongolia, Korea, Hong Kong and Japan in the late 19 th and 
early 20'h Centuries (Egwu et al., 1996). Hutyra et al. (1938), estimated the cost of 
the disease in Britain in the 1860's at E2 million per annum, and in Australia for the 
same period at E8.5 million per annum (Egwu et al., 1996). Some data of cattle 
losses incurred are given in Table 1.9. 
TABLE 1.9. CATTLE LOSSES DUE TO CBPP IN EUROPE IN THE 19TH 
CENTURY 
COUNTRY 
NETHERLANDS UNITED FRANCE 
KINGDOM 
Years 1833-1865 1841-1866 1827-1846 
NUMBER OF 100,000 1,187,000 212,000 
CATTLE 
LOST 
Data from Blancou (1996). 
According to Hutyra et al. (1938), CBPP was eradicated from Western 
Europe by the beginning of the 20th Century, although sporadic outbreaks continued 
on the French/Spanish borders until the 1920's. However a thorough examination of 
the literature shows that outbreaks have been reported in each decade of the 20 th 
Century (Nicholas et al., 2000a). In the 1930's outbreaks were reported in Spain, 
Poland and Russia, while in the 1940's the disease was still continuing in Iberia 
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(Curasson, 1942). Sporadic outbreaks of CBPP occurred in Portugal in 1953,1954, 
1958 and from 1983 to 1999 (Table 1.10). The disease was considered endemic in 
North-Western parts of Portugal; however only twelve cases were reported in 1998 
and just one in 1999. CBPP was also reported by: Spain, 1961 and 1989 to 1998; 
France, 1980,1982 and 1984 (Provost et al., 1987); and Italy, 1990-1993. 
In Italy the disease spread quickly and 94 outbreaks occurTed in three 
years (Bashiruddin, 1996). Abattoir surveillance and the control of animal 
movements, linked to serological monitoring and slaughter of infected and contact 
animals, effectively controlled the disease and officially no cases have been reported 
since 1993; however Stradaioli et al. (1999) reported detecting M. mycoides subsp. 
mycoides SC in bull semen from Italy in 1994. Italy was officially declared free of 
CBPP in 1996. 
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TABLE 1.10. NOTIFIED OUTBREAKS OF CBPP IN PORTUGAL BETWEEN 1985 
AND 2000 

















Data modified from Regalla et aL (1996a) and Anon (1997-2000) 
In Eastern Europe, CBPP existed in Russia, Romania, Poland, Austria 
and Germany until the late 1930's; however the current situation is unclear. 
Hungary is thought to be free of CBPP following a survey during 1998-1999 that 
tested more than one thousand sera, and nearly one thousand lung samples and nasal 
swabs using serological, cultural and PCR techniques (Stipkovits et al., 2000a). 
Little data exists for the disease in Asia and the Nfiddle East, as 
surveillance systems are ineffective or non-existent. However, sporadic outbreaks 
are believed to occur in the Yemen, United Arab Emirates, Saudi Arabia, Qatar, 
Kuwait, and Lebanon mainly as a result of cattle importation from Africa. Pakistan, 
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Nepal and Jordan are similarly thought to be affected (Egwu el aL, 1996). The 
disease also appears to be present in an area from the west of China towards 
Thailand and Vietnam and covering Mongolia, Tibet, Bangladesh, Sichun, Bhutan, 
Myanamar, Burma, Kampuchea and Assam (Lef6vre, 1991; Ter Laak, 1992). A 
report by AnZu et aL 1996 gives details of three large outbreaks of CBPP in China 
in 1956,1959 and 1964. Since then, serological surveillance in 16 counties in 
Henan, China during 1988-92 showed 1.19% of cattle (4,555 out of 380,000) were 
seropositive. A successful eradication scheme was conducted and the province was 
declared CBPP free in 1994. The disease entered Australia on two occasions in 
1858 and 1922. The disease was eradicated by a combination of slaughter and 
vaccination. No cases of CBPP were reported after 1967 but vaccination continued 
until 1972 (Anon, 1972) with freedom from CBPP being officially declared in 1973 
(Blancou, 1996). 
CBPP nearly disappeared from the African continent following a 
campaign for the control of CBPP in the 1960's and 1970's (Masiga et al., 1996). 
However, the disease is currently widespread, and is thought to affect at least 27 
countries (Masiga et al., 1998) (Table 1.11). Many factors have affected the failure 
to control the disease. Nomadism and the trekking of trade cattle together with 
economic weakness and political and military disturbances have made movement 
restrictions and other control measures difficult. There is also a lack of diagnostic 
tools and an epidemiological surveillance network. Recent vaccination campaigns 
have been generally unsuccessful (Rweyemamu and Benkirane, 1996). 
Kenya, Uganda, Mali, Rwanda and Tanzania which were free of CBPP 
are now experiencing endemic disease and Angola, Benin, Burkina Faso, Cameroon, 
Ethiopia, Ivory Coast, Ghana, Guinea, Namibia, Nigeria, Somalia, Togo, Zaire and 
Zambia are infected (0113,1993; Egwu et al., 1996; Masiga et al., 1996; 1998). In 
addition it is believed that Central African Republic, Congo, Democratic Republic 
of Congo, Djibouti, Eritrea, Somalia and Sudan are also infected (Masiga et al., 
1998). Since 1995, Mauritania has been experiencing severe CBPP epidemics 
which puts the neighbouring country of Senegal at risk (Rweyemamu and 
Benkirane, 1996). 
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The economic impact is high in those countries where the disease is 
endemic and CBPP is now the most economically important cattle disease in Africa 
(OIE, 1995). The direct losses result from mortality, reduced milk yield, vaccination 
campaign costs, disease surveillance and research programmes. The indirect costs 
are mainly due to the chronic nature of the disease and include loss of weight and 
working ability, delayed marketing, reduced fertility, losses due to quarantine and 
consequent reduced cattle trade (Egwu et al., 1996). The Botswanan veterinary 
authorities in 1995 decided to depopulate the whole district of Ngamiland, 
slaughtering 220,000 cattle. Compensation alone was estimated at $30 million. 
This was successful in eradicating the disease in Botswana, being officially declared 
free of CBPP in 2000. In Nigeria the losses of cattle in 1991 were estimated to be in 
excess of $1.5 million. Tanzania had outbreaks between 1990-1995 that resulted in 
the deaths of 14,000 cattle valued at over $1 million. 
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TABLE 1.11. REPORTED OUTBREAKS OF CBPP IN AFRICA 1987-1997 
Country 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996--Fl-9971 
Benin I +* I+I+1411+151 12 
I Burkina 1 10 1 21 1719141618171 29 1 28 1 29 1 
Cote 1719 14 1 18 1 16 191 12 17 12 11 1 10 
D'Ivoire 
I 
Ghana 10 6452+2315 50 
Guinea ? 105 49 38 82 49 20 17 48 30 + 
Mali 4 5 15 37 12 15 20 21 11 12 6 
Mauritania 0 0 0 6 5 + 
Niger 
- 
0 5 8 13 4 8 3 8 9 
1 Nigeria 49 1 46 1 114 1 48 1 55 1 27 1 17 1 18 16 + 
f Sierre Leone 0 10 10 10 1+I+ 10 10 10 0 0 
ISenegal 10 10 10 10 10 11 10 10 10 10 10 1 
Cameroon I III 11 11 11 11 0 11 121 
Chad III+10101 1 101 111+ 
Burundi IIIIIIIII+I+ 
Eritrea I I II II +I +I+1 0 01 0 
Ethiopia 1 96 1 11 +1 31 61 11 +1 10 14 55 18 
Kenya 6 2 15 39 24 11 1 10 6 63 + 
Rwanda I++++ 
Somalia 3 2 1 + 
I Sudan + + + 4 0 0 0 0 0 0 0 
Tanzania 0 + 1 + 1 3 259 41 57 
Uganda 49 56 4 11 28 5 3 + 18 6 14 
Angola 1 22 26 + 15 21 19 38 149 50 + 
r Botswana 0 0 0 0 0 0 0- 0 45 0 
I Namibia 4 6 0 1 2 3 2 7 25 47 26 
1 Zambia 0 0 0 0 0 0 0 0 0 0 = 
Blank spaces in the Table indicate that no reports were subn-ýitted. 
+*, CBPP reported but numbers of outbreaks not known. 
Table based on Masiga et al. (1998) and derived from OIE World Animal Health 
Reports, FAO-OIE-WHO Animal Health Yearbooks and PARC reports. 
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In Europe the cost of controlling the Italian outbreak of 1990-1993 was 
over 28 million ECUs. The cost of the eradication campaign lasting more than 15 
years in Portugal is probably incalculable. Costs are also incurred by countries such 
as Switzerland that are considered free of the disease but recently reactivated a 
surveillance system to provide documentation of their disease free status (Stdrk et 
aL, 1995). 
1.5.5. METHODS OF CONTROL 
Identification of affected animals using serological testing and 
observation of classical lesions in cattle at the abattoir is essential so that control 
methods can be implemented. The most effective way to control the disease is by 
elimination of affected and contact animals along with restriction of cattle 
movement in affected areas. However, this option is not practical in most 
developing countries where containment and vaccination are preferred. Vaccination 
may provide protection for up to 1 year (Egwu et al., 1996), but to be effective all 
animals within designated areas need to be vaccinated. Antimicrobials have not 
been effective in treating or controlling the disease. In Africa, their use has 
suppressed symptoms, probably aiding the spread of the disease (Egwu, personal 
communication). However, in view of the worsening situation, a FAO Emergency 
Prevention System (EMIPRES) workshop recommended that research into the role of 
chemotherapy should be pursued (Rweyernamu and Benkirane, 1996). Recent in 
vitro minimum inhibition concentration (MIC) studies (Mazzolini et al., 1997) 
showed M. mycoides subsp. mycoides SC was sensitive to chloramphenicol, 
enrofloxacin, erythromycin, lincomycin, oxytetracycline, spectinomycin, 
spiramycin, tiamulin, tilmicosin and tylosin (see Chapter 3). 
Guidelines for control of CBPP have been issued by the OIE (1993) with 
the aim of eradicating CBPP, initially from endemic regions, and eventually 
worldwide. There is a three-stage process for a country to be declared free of CBPP. 
Stage one is 'provisional freedom from disease', which is made by the national chief 
veterinary officer based on clinical evidence available. This would lead to increased 
surveillance for the disease including meat inspection by the veterinary service. In 
addition the use of vaccination would be discontinued. After two years the second 
stage of 'freedom from disease' would be confirmed subject to criteria including 
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continued absence of clinical disease, the adoption of adequate surveillance and 
disease reporting systems and effective measures to prevent re-introduction of the 
disease. After two more years, an OIE expert panel may declare 'freedom from 
infection' subject to second stage criteria being met and an undertaking for 
continued monitoring and reporting of disease. The implementation of these 
guidelines is feasible in Europe, but probably not yet possible in most of the affected 
African countries (FAO, 1999). 
1. VACCINES 
The only proven vaccine effective against CBPP is live broth culture of 
attenuated strains. The minimum vaccinating dose for the T144 vaccine was 
estimated to be 107 cfu by Gilbert and Windsor (1971). This is the standard adopted 
for the lyophilised PANVAC vaccine. To allow for loss in viability during 
lyophilisation, storage, transportation and usage of the vaccine, high initial viable 
counts are required (Litamoi, 1998). Vaccine quality control is therefore an 
essential prerequisite for any CBPP control programme. Leitch and March (2000), 
suggested that the inverse of the absorbance (A540) of broth cultures using a 0.006% 
phenol red indicator could be used to estimate the titre of T144 vaccine, thus 
improving vaccine quality control methods. This method was previously described 
by Meur et al. (1989) for use with M. mycoides subsp. capri. However, batches of 
T144 vaccine may also vary in effectiveness as this vaccine strain has been found to 
consist of an antigenically mixed population (Rweyemamu et al., 1994). A variation 
in the genome sequence of a haemolysin-like protein has also been noted amongst 
different sources of the vaccine (Chirnside et al., 1998). It has been suggested that 
this may account for the apparent failure of the Botswana vaccine (Masupu, 1999), 
but further work is required to establish this. Currently the OIE (OIE, 1996) only 
recommend strain T144, and its streptomycin resistant variant, for preparing CBPP 
vaccines. Strain T144 still retains some measure of residual virulence with 
subcutaneous inoculation causing unpredictable post vaccinal reactions which may 
lead to death in a small number of animals (Litamoi, 1998). Table 1.12. 
summarises the key characteristics of the vaccine strains in recent or current use. 
One of the major problems with all vaccine strains is the short-lived immunity, up to 
1 year (Tulasne et al., 1996). 
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There is clearly a need for a new vaccine, which is stable, risk-free, 
cheap and gives long-term protection. Abusugra and Morein (1996) described a 
CBPP experimental immunostimulating complex (ISCOM) vaccine that was used to 
stimulate aT helper cell type I (Th 1) response. Antibody responses were detected 
in four test cattle after primary experimental inoculation, and titres rose 10 fold after 
a booster inoculation. In BALB/c mice, subcutaneous and intranasal administration 
of the ISCOM produced high mucosal and systemic antibody responses (Abusugra 
and Morein, 1999). However, the vaccine has yet to be successfully tested under 
field conditions. 
TABLE 1.12. CURRENT OR RECENTLY USED CBPP VACCINES 
VACCINE 
STRAIN ADVANTAGES LIMITATIONS AVAILABILITY 
KH3-J & Inocuous Duration of Production stopped because of 
KH3-J SR* immunity (six poor immunogenicity. 
months) 
T144 Potency (immunity for May cause Senegal, Mali, Sudan, Kenya, 
1 year) severeside- Nigeria 
reactions 
TISR* Innocuous, may be Effective dose Senegal, Mali, Niger, 
combined with may be higher Cameroon, Chad, Ethiopia, 
rinderpest vaccine than T144. Botswana, Namibia, South 
Africa (fermenter grown) 
Table adapted from Rweyemanu and Benkirane (1996). 
* SR strains are streptomycin resistant. 'Ibis enables differentiation of clinical 
isolates during vaccination campaigns. 
1. S. 6. IMMUNOLOGY 
Cattle that have recovered from CBPP are resistant to further infection 
(Hudson, 1971), which suggests that they must mount a specific protective immune 
response. The majority of naturally infected cattle with lesions have a detectable 
antibody response, but there is no relationship between the severity of lesions and 
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the complement fixing antibody titre (Bygrave et al., 1968). Cattle infected by 
contact with experimentally infected animals showed similar CFr and ELISA IgM 
profiles over a 4-month period; seroconversion took place at 8-10 weeks and 
persisted for about ten weeks (Le Goff and Lef6vre, 1989). An IgG response was 
detected by ELISA one week later than the IgM response, and remained detectable 
for more than 10 weeks. In experimental infections, Miserez et al. (1996) showed 
that mycoplasmas were generally excreted before a serological reaction was 
detected. An experimental infection by Pini et al. (1999), using a European M. 
mycoides subsp. mycoides SC isolate, produced detectable immune responses (see 
Chapter 6, this thesis) although there were few clinical signs of disease. 
Cell-mediated immune responses also seem necessary for the prevention 
and resolution of CBPP (Nicholas and Bashiruddin, 1995); however, few studies 
have been reported. Windsor et al. (1972) demonstrated oedematous immediate and 
delayed-type hypersensitivity reactions in cattle after inoculation with antigens 
prepared from M. mycoides subsp. mycoides SC cultures. Dedieu et al. (1998) 
established that experimentally infected zebus developed a specific T-cell immune 
response; this used specific memory T-lymphocytes since immunological memory 
of specific M. mycoides subsp. mycoides SC antigens was retained. Investigations 
using a gamma-interferon assay failed to detect a T-cell response in sheep 
challenged with M. mycoides subsp. mycoides SC. However, it did detect a response 
in experimentally infected cattle, giving results that correlated with other serological 
indicators. Further work would be needed to develop the assay as a test for infection 
(Durdn et al., 2000). 
Studies with other mycoplasmas suggest that local immunity is very 
important in host defence. In man there is a relationship between IgA antibody in 
respiratory secretions and immunity to M. pneumoniae (Krause and Taylor- 
Robinson, 1992); and in cattle resistance to M. bovis was related to specific IgG in 
lung washings (Gourlay and Howard, 1982). Thus, the location of M. mycoides 
subsp. mycoides SC, primarily on the mucous membrane of the respiratory tract may 
explain the poor correlation between serum antibody concentration and resistance to 
infection. 
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1.5.7. DIAGNOSTIC METHODS 
1.5.7.1. SEROLOGICAL TESTS 
Many serological tests have been described for the detection of M. 
mycoides subsp. mycoides SC-specific antibodies or antigen. These include slide 
agglutination (Priestly, 1951; Turner and Etheridge, 1963), complement fixation 
(CFr) (Campbell and Turner, 1953), agar gel precipitation (Gourlay, 1965), passive 
haernagglutination (PHA) (Chima and Onoviran, 1982), growth inhibition (Clyde, 
1983) immunofluorescence (Del Giudice et al., 1967), metabolic inhibition 
(Purcell et al., 1966; Taylor-Robinson et al., 1966), enzyme linked immunosorbent 
assay (ELISA) (Onoviran and Taylor-Robinson, 1979), Western blotting (Nicholas 
et al., 1996), and immunocytochernical tests (Ferronha et al., 1988; Scanziani et al., 
1991; Ayling et al., 1998; Bashiruddin et al., 1999). 
Detection of the immune response to CBPP infections in cattle is the 
major means of diagnosis and hence control of the disease. The preferred 'classical' 
method is the CFT, although it is relatively laborious and insensitive. This test relies 
on antigen-antibody complexes fixing complement. A positive reaction is visualised 
by the failure of antibody-sensitised-sheep-erythrocytes to lyse in the presence of 
antigen-treated test serum because complement has been fixed. There is little room 
for error in this test, as any reaction at 1/10 dilution of sera or above is considered 
positive. 
Amongst the newer serological methods, ELISA techniques have 
received the most attention. The typical format is an indirect ELISA, with the 
antigen immobilised on a plastic surface. The antigen is reacted with a dilution of 
test bovine serum, which is then reacted with an anti-bovine immunoglobulin 
conjugated to an enzyme. Bound enzyme activity is then detected using a 
chromogenic substrate. The ELISA is usually sensitive and easy to use. The first 
ELISA for CBPP (Onoviran and Taylor-Robinson, 1979) used a whole cell antigen, 
which successfully distinguished between uninfected and naturally infected or 
vaccinated cattle, although background levels were high. Le Goff (1986) showed 
clearer differentiation using a sonicated antigen. Comparisons of the ELISA, the 
CFr and the PHA test for detecting antibody responses in experimentally infected 
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cattle showed the ELISA to be more specific (Le Goff, 1986). However, in addition 
to detecting antibody to M. mycoides subsp. mycoides SC, positive results were also 
obtained for M. mycoides subsp. mycoides LC and bovine serogroup 7 antisera. 
(Poumarat et al., 1989). Le Goff and Lef6vre (1989,1990) showed complement- 
fixing antibodies were detectable a few days before those detected by ELISA, but in 
contrast to CFr titres, positive ELISA titres were maintained throughout the M. 
mycoides subsp. mycoides SC excreting stage and for a period after. Other workers 
have used whole cell antigens treated with Tween 20, which removes some of the 
cross-reacting antigens making the test more specific (Ayling et al., 2000). 
The use of monoclonal antibodies to produce a specific ELISA or other 
tests for detecting antibodies to M. mycoides subsp. mycoides SC may be the best 
approach for the future. However, many monoclonal antibodies produced to date 
have not been specific to M. mycoides subsp. mycoides SC and have reacted with 
other members of the M. mycoides cluster (Ma et al., 1993). A competitive(c) 
ELISA using a monoclonal antibody to an 80 kDa protein has been developed and is 
currently being evaluated (Le Goff and Thiaucourt, 1998; OIE, 1996). The test uses 
a high cut-off point to maximise specificity, but this reduces sensitivity. The 
cELISA detected antibody in experimentally infected cattle 4 to 8 days after the CFT 
although it detected infection for longer. It is expected that the OIE will accept the 
cELISA as an alternative to the CFr. However, its sensitivity is similar to that of 
the CFI' (Yaya et al., 2000) and therefore false negative reactions will continue to 
occur, enabling the persistence of disease. 
Nicholas et al. (1996) used immunoblotting to analyse serum samples 
from the Italian CBPP outbreak. The analysis of sera using immunoblotting has 
also been described by Gongalves et A (1998), and it is this method which is used 
for confirmatory diagnosis of CBPP in Portugal. Briefly, a whole cell M. mycoides 
subsp. mycoides SC antigen is separated by electrophoresis on a5- 15% gradient 
gel and transferred to a nitrocellulose membrane (western blotting). The membrane 
is then used as a solid support for an antigen-antibody reaction similar to an ELISA. 
Sera are diluted I in 5 for the test, so many bands may be detected. It is the presence 
of specific antigenic bands at 110,95,62,60, and 48 kDa that are considered 
definitive in confirming CBPP infection. Immunoblotting is used as the standard 
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confirmatory test for detecting M. mycoides subsp. mycoides SC antibodies in 
Portugal and it has been suggested that this should be extended internationally. 
The development of tests for detection of specific antibodies may be 
aided by the cloning and expression of mycoplasma antigen genes in other 
organisms. This would enable their production in a standardised manner and in 
large quantity. Difficulties exist in cloning mycoplasma genes due to their unusual 
UGAt, p codon usage. However, Cheng et al. (1996) have cloned and expressed a 
specific immunogenic 72 kDa protein into Escherichia coli. Phage display systems 
have also been successfully used for 'shotgun cloning' of restriction fragments of M. 
mycoides subsp. mycoides SC resulting in mycoplasma polypeptides being displayed 
(Persson et al., 1998). This 'shotgun cloning' may overcome some of the 
difficulties associated with cloning directly into E. coli and may help with the 
construction of genomic libraries for M. mycoides subsp. mycoides SC. 
In the identification of M. mycoides subsp. mycoides SC cells, the 
growth inhibition test (Clyde, 1983) is most widely used. In this test, antiserum on 
filter paper discs is applied to the centre of inoculated plates and growth inhibition is 
detected after incubation. However, serological cross-reactions are observed with 
other members of the M. mycoides cluster. To overcome this Rodriguez et al. 
(1996a) used a monoclonal antibody-based sandwich ELISA that differentiated 
strains within the cluster; detection was most effective following enrichment and 
capture of cells in broth culture by antibody coated microtitre wells. However, this 
test could not distinguish between M. mycoides subsp. mycoides SC and M. 
mycoides subsp. mycoides LC. 
1. S. 7.2. ISOLATION AND CULTURE 
Mycoplasmas are dependent on their hosts for a large variety of organic 
nuffients such as vitamins, amino acids, fatty acids and lipids. In addition, M. 
mycoides subsp. mycoides SC will not grow in media lacking the preformed bases 
uracil, thymine, and guanine that it needs for nucleic acid synthesis (Razin, 1978). 
The inorganic requirements of mycoplasmas are poorly known, but it 
appears that potassium, magnesium and phosphate ions are adequately provided by 
glassware contaminants and other growth-medium components (Rodwell, 1983). 
However, high concentrations of metallic ions, for example zinc, manganese, cobalt 
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and iron are inhibitory for M. mycoides subsp. mycoides SC (Rodwell and Mitchell, 
1979). 
Mycoplasma mycoides subsp. mycoides SC is a facultative anaerobe 
growing equally well in aerobic and anaerobic environments at a pH of 6.8-7.8. 
Many of the standard media available for mycoplasma culture are suitable for its 
growth (Bradbury, 1998b; Furr, 1998; Nicholas and Baker, 1998; Taylor, 1998). 
These typically contain thallium acetate and penicillin (or other antimicrobials) for 
isolation from clinical specimens. Recently Rice et al., (2000b) optimised the 
concentrations of individual medium components including energy sources, peptone, 
yeast extract, serum, inorganic salts and buffers to develop a medium (PRM) giving 
high yields and growth rates of M. mycoides subsp. mycoides SC. M. mycoides 
subsp. mycoides SC is referred to as fermentative because it produces acid from 
glucose metabolism and this is of diagnostic value in the identification of clinical 
isolates. Fructose, N-acetylglucosamine and pyruvate may also be used as energy 
sources, but glucose supports higher growth rates (Miles et al., 1986). Miles et al. 
(1996) found that M. mycoides subsp. mycoides SC strains were metabolically 
similar and readily distinguished from other members of the cluster by their inability 
to oxidise maltose, trehalose and (at low concentrations) mannose. Utilising a 
chromogenic a-glucosidase (maltase) substrate, Rice et al. (2000a) have developed a 
rapid test which differentiates M. mycoides subsp. mycoides SC and M. capricolum 
subsp. capripneumoniae from the other M. mycoides cluster members. Houshaymi 
et al. (1997) also demonstrated differences in substrate metabolism amongst M. 
mycoides subsp. mycoides SC isolates; in particular, African and Australian, but not 
European isolates, were able to oxidise glycerol. 
1. S. 7.3. MOLECULAR TECIINIQUES 
One of the most useful advances in recent times has been the 
development and application of polymerase chain reaction (PCR) technology for the 
detection and identification of M. mycoides subsp. mycoides SC. In the first PCR 
described, primers derived from the CAP-21 genome fragment were used. These 
amplified a 0.5kb region of both M. mycoides subsp. mycoides SC and LC strains, as 
well as strains of M. mycoides subsp. capri. However, amplicons from M. mycoides 
subsp. mycoides SC could be specifically identified by restriction enzyme analysis 
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with AsnI (Taylor et al., 1992; Bashiruddin et al., 1994a). Bashiruddin et al. 
(1994b) showed that the test could detect specific DNA from clinical materials such 
as lung, nasal mucous, pleural fluid and pulmonary tissue. A related PCR system 
can also detect all members of the M. mycoides cluster (Bashiruddin et al., 1994a). 
These PCRs are useful for identifying cultured isolates and have been developed to 
include a colourimetric detection system (marketed as pleuroTRAP by AMRAD) 
useful for high throughput testing (Bashiruddin, personal communication). 
Although the tests are sensitive and specific, negative results have been obtained 
from seropositive animals suggesting that further work on sample handling may be 
required (Egwu et al., 1996). 
Further PCR systems have since been developed. Some also use the 
CAP-21 gene (Hoetzel et al., 1994), whilst others are based on the ribosomal RNA 
gene in the belief that it will yield a more sensitive PCR, as there is a higher copy 
number of target molecules (Johansson, 1993; Miserez et al., 1996). The use of 
nested or semi-nested primers has also been used with the aim of increasing 
sensitivity and specificity. Persson et al. (1999) described two PCR systems based 
on the two 16S rRNA genes; the first used laser-induced fluorescence to detect a 
unique sequence length difference between the genes in M. mycoides subsp. 
mycoides SC whilst the second relied on restriction endonuclease analysis. 
Rawadi et al. (1995) used one 18bp primer (Mlipl) and a 17bp primer 
(Mlip4) for an arbitrarily-primed (AP) PCR that differentiated some of the M. 
mycoides cluster. The assay showed that the M. mycoides cluster could be divided 
into two groups: those with high polymorphisms and those with no variation. 
Specific polymorphic bands for members of species and subspecies were identified 
but only two distinct bands at 900bp and 100bp were obtained with the four M. 
mycoides subsp. mycoides SC strains tested, although a weak band was observed at 
400bp with one strain. This test may therefore be useful for identifying M. mycoides 
cluster members, but the test would need careful optimisation. Although few M. 
mycoides subsp. mycoides SC strains were tested, AP-PCR shows little potential as 
an epidemiological tool for M. mycoides subsp. mycoides SC. 
In situ PCR was used to confirm the presence of M. mycoides subsp. 
mycoides SC in paraffin embedded tissue from affected cattle (Camma et al., 2000). 
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This technique combines the sensitivity of PCR with the possibility of locating a 
specific DNA sequence within intact cells or tissue sections. The technique is 
relatively slow and has little benefit for on-farm diagnosis, but is very sensitive 
enabling the confirmation of suspected CBPP when other tests have failed to detect 
the disease or given conflicting results. 
The use of epidemiological tools to trace sources of infection and spread 
of disease are increasingly perceived as important by the authorities. In the UK, 
research on tuberculosis, salmonellosis and campylobacteriosis has led to the 
development of molecular tools to differentiate isolates for epidemiological tracing 
and possible determination of virulence factors. Molecular tools have included 
restriction enzyme analysis (REA), pulsed-field gel electrophoresis, low-molecular 
weight RNA profiles, amplified fragment length polymorphism and insertion 
sequence analysis. Insertion sequences encode only functions involved in their 
translocation, and transpose both within and between genomes. They are capable of 
promoting various types of genome rearrangement including deletions, inversions 
and replicon fusions (Mahillon et al., 1999). Two M. mycoides subsp. mycoides SC 
specific insertion sequences, IS1634 and IS1296, have recently been identified. 
About 30 copies of IS1634 are present in the genome. It has a size of 1,872bp, 
including two 13-bp terminal inverted repeats and contains an open reading frame 
encoding a product of 533 amino acids (Vilei et al., 1999). The IS1296 is 1485bp 
long and has 30bp terminal inverted repeats and 18-20 copies are present on the 
chromosome. It has two open reading ftames that could code for transposase-like 
proteins. The copy number of this insertion sequence has been used to investigate 
the epidemiology of isolates (Frey et al., 1996) and led to the differentiation of 
African and Australian isolates from European isolates. This suggests that CBPP in 
Africa and Australia had different origins to that in Europe, or that the original 
strains are no longer found in Europe. Poumarat and Solsona, (1995) used 
restriction enzyme analysis (REA) on 27 M. mycoides subsp. mycoides SC isolates 
to obtain five different profiles with PstI and three with BamHI. Twelve out of 15 
European isolates had different profiles to those obtained with ten African isolates. 
The three isolates with the same profiles as the African strains all came from the 
Iberian Peninsula, but it was later shown that these isolates had been imported from 
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Africa for experimental work. The vaccinal strains TISR and KH3J had a unique 
REA profile. 
Pulsed-field gel electrophoresis (PFGE) has been used to construct 
genomic maps of some strains within the M. mycoides cluster (Pyle et al., 1990) but 
it has not yet been used for epidemiological typing of M. mycoides subsp. mycoides 
SC isolates. Currently no reports of amplified-fragment length polymorphism 
fingerprinting of M. mycoides subsp. mycoides SC have been published; however 
this method has been successfully used for differentiating strains of other 
Mycoplasma species (Kokotovic et al., 1999). Low-molecular weight RNA profile 
analysis of members of the M. mycoides cluster, clearly differentiated between M. 
mycoides subsp. mycoides SC and LC strains but did not reveal differences within 
isolates belonging to each group (Botelho et al., 2000). 
In the future, the development of molecular tests for M. mycoides subsp. 
mycoides SC may be aided by the publication of the complete genome sequence for 
strain PGL This sequence is almost complete and is expected to be available by the 
year 2002 (Johansson, personal communication). 
1.5.7.4. DIAGNOSTIC METHODS IN THE UK 
The United Kingdom is currently free of CBPP and it is essential to 
maintain CBPP-free status for animal health and economic reasons including trade 
with other CBPP free countries. However, the country is at risk from imported 
cattle carrying the disease. Imported cattle from suspected countries are screened 
serologically using the CFr (OIE, 1996); however asymptornatic animals in the 
early stages of infection and chronically infected animals may not have detectable 
antibodies (Provost et al., 1987). The CFI' detects only 70 % of chronically infected 
animals and may give false positive results (St5rk et al., 1994). Thus, positive or 
suspect positive sera are further tested using western blotting for the presence of M. 
mycoides subsp. mycoides SC-specific protein antigens (Nicholas et al., 1996). 
Occasionally, field workers, veterinarians or abattoir workers may 
suspect an animal has CBPP. Abattoir surveillance by experienced meat inspectors 
is a key component of CBPP-detection. It is recommended by the OIE (OIE, 1996) 
and played a major role in the control of Italian outbreaks of the disease (Regalia et 
al., 1996a). In the UK suspect cases are reported to the Department of Environment, 
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Food and Rural Affairs (DEFRA) and testing is undertaken immediately at the 
Veterinary Laboratories Agency (Weybridge). Many different samples are 
submitted, including blood, nasal swabs, pleural fluid and some lung tissue; however 
not all of these may be available as the animal may still be alive or samples may be 
lacking. 
Culture and identification of M. mycoides subsp. mycoides SC is 
necessary to confirm the disease but this may take up to two weeks. Difficulties 
may also arise with the overgrowth of the sample by other bacterial species and 
mollicutes such as Acholeplasma laidlawii that are frequently found in CBPP 
affected cattle. At VLA, Eaton's medium (Nicholas and Baker, 1998) is used with 
additional antimicrobials (see Chapter 2, Section 2. ) for primary isolation and 
several dilutions of the sample are made to avoid overgrowth. Recently, Abu- 
Amero et al. (1996) incorporated nisin into mycoplasma media to inhibit the growth 
of Acholeplasma species and this may be adopted at VLA. Identification of isolates 
of M. mycoides subsp. mycoides SC would be based on their sensitivity to digitonin; 
ability to ferment glucose; and sensitivity to growth inhibition by hyperimmune 
rabbit antiserum (Provost et al., 1987). In addition, the PCR of Bashiruddin et al. 
(1994b) is available for the detection of specific M. mycoides subsp. mycoides SC 
DNA. The use of PCR provides a more rapid and specific method of detecting the 
presence of the organism and confirming the identification of suspect isolates. 
1.6. AIMS OF THE THESIS 
This thesis is concerned with the diagnosis and control of two major 
bovine mycoplasma diseases, CBPP and M. bovis infections of cattle. The 
importance of these diseases has been described in sections 1.4. and 1.5. M. bovis 
is currently the most important disease-producing mycoplasma of cattle in the UK 
and CBPP is a major threat to the UK and European cattle industry. The current 
areas of difficulty in the detection of M. bovis infections are: 
(i). Intermittant shedding of the organism, which reduces the sensitivity of 
detection by culture; 
(ii). The inability to detect a specific immune response in calves less than 
three months of age; 
(iii). The presence of variable surface proteins (vsp's); 
so 
(iv). The potential for serological cross-reactions of M. bovis and M. 
agalactiae. This is not thought to be a serious problem, as M. bovis is 
associated almost exclusively with cattle and M. agalactiae with sheep 
and goats. However, there have recently been a number of reports of 
mycoplasma isolates from atypical hosts including M. bovis from goats 
(Chima et al., 1986) and also from man (Madoff et al., 1979). Thus, a 
test guaranteeing differentiation of M. bovis and M. agalactiae would be 
of value. 
In relation to M. bovis disease control, vaccines are in the early stage of 
development. Since, M. bovis is endemic and there is no attempt to control its 
spread by movement restriction orders, the only effective control measure in the UK 
is antimicrobial treatment. However, at the start of work reported in this thesis there 
was no published inforination giving antimicrobial resistance patterns of UK M. 
bovis isolates. 
The aim of the M. bovis work conducted in this thesis was to: 
(i). Develop a specific PCR, enabling the sensitive detection of organisms in 
culture and clinical specimens. 
(ii). Determine the antimicrobial sensitivity pattern of UK M. bovis isolates. 
In order to determine the sensitivity of a large number of strains to 
several antimicrobials, a microtitre plate method was developed for use 
with mycoplasmas. The method was used to determine both minimal 
inhibitory (MIC) and minimal mycoplasmacidal (MMC) concentrations. 
In the UK, the major concern regarding CBPP is the presence of the disease 
in imported animals. The problems of diagnosis in such animals are: 
(i). Test sensitivity; 
(ii). Test specificity; 
(iii). The presence of asymptornatic carrier animals that harbour the disease 
without developing a detectable immune response; 
(iv). The presence of animals at an early stage of infection. 
Treatment of CBPP infected animals is not an option in Europe, where the 
disease is, controlled by the slaughter of all infected and contact animals. In African 
countries where the disease is endemic, controls include the use of vaccines and 
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restriction of movement. However, these are currently ineffective (see Section 1.5). 
Thus, chemotherapy may offer an alternative option (Rweyemamu and Benkirane, 
1996). 
A major initial aim of the work on M. mycoides subsp. mycoides SC in 
this thesis was to improve the sensitivity and specificity of serological tests. The 
approaches adopted included comparing current serological test methods with 
culture, PCR and gross pathology of animals from a CBPP outbreak in Northern 
Portugal. Work was also conducted on an indirect ELISA using whole cell and 
tween 20 treated cells as antigens and a novel latex agglutination test. It was 
thought that this test would be of limited value in the UK, but it appeared to offer 
several advantages for use in African countries. Thus, optimisation and evaluation 
of the test was carried out. In addition, MIC and MMC values for various M. 
mycoides subsp. mycoides SC strains was determined as described for M. bovis 
above. 
Finally, in work covered during the early stages of this thesis, the molecular 
(16S rRNA) characterisation of potentially novel mycoplasmas from a perigrine 
falcon and an ostrich was carried out. The methods used were of relevence to the 
development of molecular diagnostic techniques and the identification of novel 
mycoplasmas and are referred to in the introduction and discussion sections of the 
thesis. The work was not included in the main body of the thesis, which was 
dedicated to M. bovis and M. mycoides subsp. mycoides SC diagnosis and control, 
but is briefly summarised in Appendix 1. 
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CHAPTER 2 
2.1. DEVELOPMENT AND VALIDATION OF A PCR FOR THE 
DETECTION OF MYCOPLASMA BOVIS 
2.1.1. INTRODUCTION 
Mycoplasma bovis is endemic in Britain, causing pneumonia, arthritis, 
mastitis, subcutaneous abscesses, keratoconjunctivitis, meningitis and infertility 
(Pfiltzner and Sachse, 1996); more recently it has also been implicated as a cause of 
abortion (Byrne et al., 1999). The significance of M. bovis as a pathogen of cattle 
was discussed in Section 1.4. Control of the disease is difficult, but correct 
diagnosis is important to differentiate it from other more readily treated diseases. 
Current diagnosis is dependent on either serological testing by ELISA (Nicholas et 
al., 2000b) or by culture and identification of M. bovis. Currently, the VLA 
annually receives 4000 sera for ELISA and 400 cultures from possible cases of M. 
bovis infection. Thus efficient diagnostic methods are clearly needed. 
2.1.2. ISOLATIONAND IDENTIFICATION OF M. BOVIS 
Diagnosis of disease caused by M. bovis on the farm is difficult, and M. 
bovis is usually suspected only if treatment with antimicrobials for other bacteria is 
unsuccessful. Serological testing by ELISA may indicate that an animal has had 
contact with M. bovis, but very young calves that are most likely to die from M. 
bovis pneumonia do not show a detectable immune response. Culture and 
identification of the causative organism is the main method of confirming the 
presence of disease. However, animals with subclinical or chronic disease only 
harbour a small number of organisms that are shed intermittantly (Mattsson et at, 
1991). Thus, the success of cultures from nasal swabs maybe limited. Culturefrorn 
bronchiolavage samples is generally more successful, but this is not done routinely 
as it is a difficult method for routine farm use. Samples taken from pneumonic 
lungs at post-mortern are most likely to enable M. bovis isolation and the gross 
pathology is also indicative of the disease (see Section 1.4). 
The culture of M. bovis requires a specialised mycoplasma growth medium. 
Eaton's broth medium (see section 2.2.2. ) is used at VLA (Weybridge) and for 
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primary isolation selective inhibitors such as thallium acetate and penicillin are 
included. However, although M. bovis is a relatively rapid growing mycoplasma, it 
may be outgrown by other less important bacteria and Acholeplasma laidlawff. 
Thus it may be necessary to filter initial broth cultures through 0.45 ýtm filters to 
remove bacterial contaminants and then re-culture the filtrate. Initial growth usually 
takes 2-3 days, although if filtration steps are required the isolation will take much 
longer. 
Isolates are first confin-ned as being Mycoplasma by demonstrating 
growth inhibition in the presence of digitonin or polyanetholsulphic acid. 
Impregnated discs are placed on an agar plate seeded with the culture and plates are 
incubated at 37*C (in 5% C02 in air) and examined daily for growth. Cultural 
characteristics are then determined. M. bovis is suspected when a cattle isolate does 
not ferment glucose or hydrolyse arginine, and produces a film on the surface of 
broth or agar media. Confirmation of identification is carried out either by an 
indirect immunofluorescent antibody test (IFAT) on colonies, or by growth or film 
inhibition tests. These methods usually rely on anti-M. bovis polyclonal rabbit 
antiserum and are described in detail by Poveda and Nicholas (1998). 
In growth inhibition tests, optimum results are obtained if several 
dilutions of culture are tested, as heavy inoculations may lead to overgrowth of 
inhibition zones. This is therefore expensive on medium and specific antiserum, 
especially if the culture is tested against more than one mycoplasma species. 
Another disadvantage of the growth inhibition test is the time taken to obtain a 
result; for M. bovis, isolates two days incubation are required before growth of the 
organism becomes visible and a result may be recorded. The film inhibition test for 
M. bovis is similar to the growth inhibition test, except that it is carried out using a 
medium containing egg yolk, which is rich in phospholipids, thereby encouraging 
film development (Poveda and Nicholas, 1998). 
The IFAT requires growth of the organism on agar medium. Sections of 
medium with colony growth are then excised from the agar plate and placed on a 
microscope slide. Negative control and mycoplasma species-specific antisera are 
added to different agar blocks from the same mycoplasma isolate and incubated. 
Blocks are then washed in phosphate buffered saline (PBS) and fluorescein 
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isothiocyanate (FITC) conjugated antiserum is added. After incubation, there is a 
further washing step in PBS. Finally colonies are examined for fluorescence using 
an ultra violet light microscope. The method is very labour intensive and critically 
dependent on washing in PBS to reduce non-specific background fluorescence. 
Cross-reactions between species occur and correct interpretation of the test requires 
an experienced investigator. Where M. bovis growth leads to film development, 
background levels of fluorescence are high making the test difficult to read. A 
further potential problem with the IFAT, and growth and film inhibition tests, is 
surface antigen variation. Behrens et al. (1996) reported that the major 
immunogenic proteins of M. bovis include variable surface proteins (vsp's) that 
undergo dynamic and spontaneous changes in size and expression. Conventional 
tests may therefore occasionally fail to identify M. bovis isolates because of this 
antigenic variation (Rosengarten et al., 1998). For example, in 1996, two bovine 
mycoplasma isolates submitted to VLA (Weybridge) could not be identified by 
serological techniques. Subsequently, they were identified as atypical M. bovis by 
Dr Konrad Sachse, BgVV, Jena, Germany. He showed using PCR with vsp gene 
specific primers and Southern blot hybridization, that they lacked typical vsP gene 
components. Immunoblotting using vsp specific monoclonal antibodies also 
demonstrated that the isolates did not possess the 'classical' vsp system as described 
for the type strain PG45. 
2.1.3. MOLECULAR TYPING METHODS 
The lengthy procedures required to isolate, biochemically characterise 
and serologically confirm isolates as M. bovis, make it extremely unlikely that a 
farmer will receive a diagnosis in less than two weeks; in practice, it may take 
longer. Thus, alternative methods are needed that will decrease identification time 
and reduce the use of expensive antiserum. 
The development of molecular typing tools for microorganisms began in 
the 1980's in the form of probes produced from genes or nucleotide sequences 
specific to a group of species, a single species or a certain strain within a species. 
Probes improved the detection and identification of infectious agents in a wide range 
of clinical material. These probes hybridised to the DNA or RNA in a sample to 
confirm the presence of the target organism (Woodward, 1989). Probes were 
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originally labelled with radionucleotides but safer labelling systems, using for 
example digoxigenin, are now available (Boehringer Mannheim, Gen-nany). 
More recently probes have been replaced by polymerase chain reaction 
(PCR) tests which are more sensitive and less labour intensive. The PCR enables 
selective amplification of a specific region of a DNA molecule so long as the 
sequences at the borders of the region are known. In the technique two short 
chemically synthesised oligonucleotides are annealed to the DNA molecule, one to 
each strand of the double helix, which delimit the region to be amplified. A heat 
stable polymerase enzyme is added to the now primed template DNA so that it 
synthesises new complementary strands. On heating, the newly synthesised strands 
detach from the templates so that when cooled more oligonucleotides anneal to their 
respective positions and a second round of DNA synthesis can begin. This cycling 
process is repeated 30 - 40 times resulting in a single DNA sequence being 
amplified over 109 times within a few hours. PCR can detect minute amounts of 
specific DNA in a sample or culture (Newton and Graham, 1994). Other than a 
thermocycler, PCR requires limited specialist equipment, but a clean laboratory area 
(cabinet) dedicated to PCR is essential to avoid DNA contamination. 
The PCR has enabled major advances in the diagnosis and identification 
of organisms including the Mollicutes; however in the development of tests, careful 
optimisation of reaction conditions and sample treatment is required. For example, 
in some samples DNA has to be extracted because of the presence of undefined 
inhibitors. One of the disadvantages of a specific PCR in the diagnostic laboratory 
is the need for many PCR systems to cope with the range of species to be identified. 
This has been partly overcome by using primers ftom the conserved regions of a 
specific gene that can amplify target DNA from a group of related species. The 
amplicon then undergoes cleavage by specific restriction enzymes that will give 
different size fragments depending on the species (Fan et al., 1995). 
Many PCRs are based on the 16S rRNA gene that has approximately 
1500 nucleotides with highly conserved regions but also many variable regions that 
are species specific. The sequences of 16S rRNA genes may be determined 
following PCR reactions using 'universal primers' based on the highly conserved 
regions of the 16S rRNA gene. Many 16S rRNA sequences are known and are 
86 
available from databanks, thus enabling the design of species-specific primers. 
Whole 16S rRNA gene sequences may also be used to identify organisms. Amongst 
Mollicutes 16S rRNA sequences are known for representative species of all genera 
(Johansson et al., 2000). In addition complete sequences for the type strains of all 
validly described Mycoplasma species (currently 102) are known or will be available 
by the end of the year 2001 (Johansson et al., 2000). 
The sequencing of the 16S rRNA gene opens a new route to the 
identification of mycoplasmas occurring in atypical hosts and the recognition of 
novel isolates as potential new species. Currently serological testing is a major 
feature among the requirements for naming a new Mollicutes species. Cells of the 
potential new species must be tested by GIT or MAT against the specific antiserum 
of all known species, and the specific antiserum of the novel species must similarly 
be tested against cells of all known species. Since there are already 102 recognised 
Mycoplasma species, few, if any, laboratories have all the required resources. 
However, 16S rRNA sequences cannot be relied on as the sole means of identifying 
new species, partly because of the confusion that would arise from the occurrence of 
polymorphisms. It has been proposed (Johansson et aL, 2000) that 16S rRNA 
sequencing could be used to determine which phylogenetic cluster a novel isolate 
belongs to and that serological analyses need only be performed with the members 
of that cluster. This would limit the number of species for serological comparison to 
a maximum of 22 (Johansson et aL, 2000). This proposal has been put to the 
Subcommittee on Taxonomy of Mollicutes and is currently awaiting their approval. 
The strategies used to obtain rRNA sequences and their application to the 
identification of unusual isolates from sheep and potential new species from 
peregrine falcons and ostrich are described in Appendix 1. 
2.1.4. PCR METHODS FOR M. BOVIS 
Bovine pneumonia caused by mycoplasmas has a major economic 
impact on cattle production worldwide (Rebhun et al., 1995). The major causes are 
M. bovis which is endemic in the UK (Section 1.4. ) and M. mycoides subsp. 
mycoides SC (Section 1.5. ) which is exotic to the UK but causes enormous losses 
particularly in African countries. PCRs for identifying M. mycoides subsp. mycoides 
SC (Bashiruddin et al., 1994a) have been used in the VLA (Weybridge) laboratory 
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for several years; a similar test for M. bovis would speed up diagnosis enabling 
control measures to be implemented rapidly. 
Chavez Gonzdlez et al. (1995) described a new PCR test system for the 
amplification of M. bovis and M. agalactiae that was based on the 16S rRNA gene. 
Since this gene occurs as two copies per genome, the PCR is potentially more 
sensitive than PCRs for other genes, for which there is only a single copy. However, 
the PCRs developed failed to distinguish M. agalactiae and M. bovis. This reflected 
the very close relationship between the two species, which show only eight different 
base pairs in the 16S rRNA gene. Although it is rare to find M. bovis in sheep and 
goats or M. agalactiae in cattle, the possibility of mis-identification may have 
serious implications. At the start of the practical work for this thesis an improved 
PCR method was described at an EC COST meeting (Thessaloniki, April 1996) 
which was later published in the proceedings (Johansson et al., 1996b). The aims of 
the work described in this chapter were to: 
* independently evaluate the PCR of Johansson et al. (1996b) for the 
identification of M. bovis 
incorporate a PCR procedure in the routine detection of M. bovis 
which would improve identification and reporting times and reduce 
the use of specific M. bovis antiserurn. 
develop a rapid PCR-based method that could differentiate M. 
agalactiae and M. bovis. 
2.2. MATERIALS AND METHODS 
2.2.1. MYCOPLASMA STRAINS USED 
The type strains of M. agalactiae (10123) and M. bovis (PG45) were 
obtained from the National Collection of Type Cultures, Colindale, London. The 
origin of all other test strains is listed in Table 2.1. Preliminary experiments to 
optimise the PCR and investigate 'hot start' PCR methods, used the strains detailed 
in section 2.2.5. The M. bovis and M. agalactiae PCR was further developed using 
DNA template from: M. agalactiae ALK 3056 and NVI 1; M. bovis 98B96,97B96, 
96B96,70B96,171B96,8OB96,119B96 and NVI 2; M. bovirhinis 12B96,62B96 
and 126B96; and M. bovigenitalum 6B640. PCR was also performed on extracted 
88 
DNA, mycoplasma cells direct from culture media and cultured mycoplasma cells 
washed once in phosphate buffered saline (PBS), from a further 15 M. bovis isolates. 
These were: 199B96,2041396,198B96,196B96,1901396,171B96,160B96, 
124B96,98B96,97B96,96B96,91B96,851396,70B96 and 58B96. The latter 
isolates were all derived from pneumonic cattle during 1996; they were identified by 
biochemical characterisation (glucose fermentation -ve, arginine hydrolysis -ve, and 
formation of a film on Eaton's broth medium), followed by a film inhibition test 
using anti-M. bovis (type strain) rabbit antiserum. 
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TABLE 2.1. DETAILS OF MYCOPLASMA ISOLATES USED FOR ESTABLISHING 
THE M. BOWS PCR 
STRAIN IDENTIFICATION SOURCE PLACE OF ISOLATION 
REFERENCE 
ALK 3056 M. agalactiae Ovine Turkey 
98B96 M. bovis Bovine lung Longstanton, Cambridgeshire 
97B96 M. bovis Bovine lung Knaresborough 
96B96 M. bovis Bovine nasal swab Aberystwyth 
70B96 M. bovis Bovine nasal swab Aylesbury 
171B96 M. bovis Bovine lung Shrewsbury 
12B96 M. bovirhinis Bovine nasal swab Thirsk 
62B96 M. bovirhinis Bovine nasal swab Coventry 
126B96 M. bovirhinis Bovine lung Thirsk 
6B640 M. bovigenitalum Bovine Not Known 
80B96 M. bovis* Bovine lung Thirsk 
119B96 M. bovis* Bovine lung Thirsk 
NVII M. agalactiae Ovine Sweden 
NV12 M. bovis Bovine Sweden 
81B96 M. bovis Bovine lung Thirsk 
82B96 M. bovis Bovine lung Thirsk 
119B96 M. bovis Bovine lung Thirsk 
120B96 M. bovis Bovine lung Thirsk 
121B96 M. bovis Bovine lung Thirsk 
58B96 M. bovis Bovine Preston 
85B96 M. bovis Bovine nasal swab Preston 
91B96 M. bovis Bovine nasal swab Preston 
124B96 M. bovis Bovine lung Bury St Edmunds 
160B96 M. bovis Bovine lung Aberystwyth 
171B96 M. bovis Bovine lung Shrewsbury 
190B96 M. bovis Bovine lung Thirsk 
196B96 M. bovis Bovine nasal Bury St Edmunds 
198B96 M. bovis Bovine lung Thirsk 
199B96 M. bovis Bovine lung Thirsk 
204B96 M. bovis Bovine lung Shrewsbury 
* Atypical M. bovis isolates see section 2.1.2. 
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2.2.2. MYCOPLASMA GROWTH 
All mycoplasmas were cultured in Eaton's broth medium (Nicholas and 
Baker, 1998) at 37'C in 5% carbon dioxide in air for 24 hours to give an 
approximate cell concentration of 5x 108 cfu per ml. Eaton's broth medium was 
comprised of (1-1): Difco PPLO broth 21.0 g; Difco yeast extract, 10.0 g; glucose 
10.0 g; DNA, 0.02 g; uninactivated horse serum, 200 cm 3; polymixin B (100,000 IU 
per cm3 solution), 5.0 CM3 ; ampicillin, 100 mg in 1.0 cm 3; phenol red indicator 
(0.2% solution) 12.5 cm 3; distilled water, approximately 780 cm 3. For primary 
isolation, the following bacterial inhibitors were also added: thallium acetate 0.05 g; 
penicillin 120 mg; and sulphadin-ýidine 0.05 g. The pH of the medium was adjusted 
to pH 7.6 to 7.8 using IM NaOH and sterilised by passing through a 0.2 gm filter. 
2.2.3. DNA EXTRACTION 
DNA was extracted from 1.5 ml of a 24-hour broth culture using a rapid 
commercial DNA extraction kit according to the manufacturer's instructions 
(Isoquick, ORCA Research, Garden Grove, USA). The kit was based on guanadine 
thiocyanate extraction followed by sodium acetate/ethanol DNA precipitation. The 
DNA was resuspended in 50 ýtl of sterile high performance liquid chromatography 
(BPLQ grade water prepared at VLA by passing distilled water through a Millipore 
ultrapure filtration unit. The presence of DNA was confirmed by horizontal agarose 
gel electrophoresis as described in section 2.2.6. 
2.2.4. TEMPLATE DNA FOR PCRs 
Except where stated, template DNA for PCRs was obtained by extraction 
from broth culture as described in Section 2.2.3. In experiments with M. bovis, to 
improve detection times, the use of whole cells was investigated. Cells were grown 
for 24 hours in Eaton's broth medium and were either diluted 10-1 in fresh medium 
or resuspended in an equal volume of PBS, pH 7.2 (Oxoid) after centrifugation at 
12,000 g for five minutes. Cells diluted (10-1) in PBS were also tested. The number 
of cells in the broth cultures was deten-nined by a surface-drop plate method 
(Postgate, 1969). The agar used was Eaton's agar with ampicillin; plates were 
incubated for 48 hours at 37"C in 5% carbon dioxide in air. 
91 
2.2. S. PRELIMINARY EXPERIMENTS AND THE TESTING OF M. BO VIS 
PCR SPECIFICITY 
Preliminary experiments were conducted using DNA (extracted as described 
in Section 2.2.3) from the type strains of M. agalactiae and M. bovis and M. bovis 
field strains 801396,81B96,821396,119B96,120B96 and 121B96 (Table 2.1). 
Three hot start methods were investigated: 
Ampliwax beads (Perkin Elmer) were used with a PCR mix containing: 
I Ox running buffer (2 ýtl), 25 mM magnesium chloride (4 [d), dNTPs (2 RI), 40 pmol 
primers (I RI each) and water (10 [LI). One wax tablet was added per tube. The wax 
was melted by heating at 70'C for 1 minute before cooling to allow the wax to set 
and form a barrier between the PCR mix and the sample mix that was added later. 
The sample mix contained: lOx running buffer (3 til), Taq (0.5 RI), DNA template (I 
RI) and water (25.5 RI). The hot start began when the PCR cycling temperature 
reached the melting point of the wax, and the two component solutions mixed. 
The TaqGold (PerkinElmer) hot start was used as described by the 
manufacturers. This hot start method is simpler than the wax beads method as it 
uses a single reagent mix, prepared by combining the mixes described, but with Taq. 
An additional heating step at 94'C for eight minutes was used before the Taq. 
enzyme was released and the PCR allowed to start. 
The final hot start method used was a manual one. The component 
solutions were as described in Table 2.2. The first solution was heated at 94'C for 
four minutes before the second solution containing the Taq enzyme was pipetted 
into the reaction tube allowing cycling to commence. 
2.2.6. PCR FORM. BOVIS AND M. AGALACTIAE 
Both PCR methods were conducted under the same conditions, but using 
different primer sequences. Details of the primers are given in Table 2.3. and the 
PCR mix in Table 2.2. Except in preliminary experiments (see Section 2.3.1. ) a hot 
start was used at 94'C for 4 minutes (Johansson et A, 1996b) using a Perkin Elmer 
thermal cycler,,, -- With every PCR a known positive DNA template was run 
as a positive control and a water sample as a negative control. 
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Except where stated the cycling conditions used were: 94"C denaturation 
for 45 seconds; 65'C annealing for one minute; followed by 72"C polymerisation for 
two minutes. This cycle was repeated 30 times before final polymerisation at 72'C 
for five minutes. 
Amplicons were separated on a1% agarose gel. The PCR reaction 
mixture (5 gl) was mixed with 2 gl of loading buffer (40 % w/v sucrose in water 
containing 0.25 % w/v bromophenol blue) and loaded onto the gel which was 
electrophoresed at 110 volts for 30 minutes. The gels were stained with ethidium, 
bromide and the DNA products were visualised by ultraviolet transillumination 
(Maniatis et al., 1982). 
2.2.7. RESTRICTION ENZYME ANALYSIS FOR DIFFERENTIATING M. 
BOVISANDM. AGALACTIAE 
The PCR product (8 [d PCR reaction mixture) was digested at 37C for 2 
hours with 3 gl Q units) of restriction enzyme, SfcI (New England Biolabs, UK) 
after addition of 2 gI lOx concentrated buffer (as supplied with the enzyme by New 
England Biolabs, UK) and 7 gl BPLC grade water. The digested products were 
separated on a 1.5 % agarose gel and visualised as described in Section 2.2.6. The 
recognition site for SfcI is 5'-... CTPuPyAG... -3' and it cuts between the cytosine and 
thymine. 
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TABLE 2.2. REAGENTS USED IN THE M. AGALACTIAEAND M. BOVIS PCR's 
REAGENT VOLUME 
BPLC grade H20 28 gI 
Buffer 4 (Perkin-Elmer): 250 mM Tris-HCI buffer (pH 8.3), 5 RI 
500 mM KCI, 20 nIM M9C127 l% Tween. 
dNTPs (Pharinacia ultrapure), 2 mM 5 gi 
Magnesium chloride (Perkin-Elmer) 25 mM 4 gl 
Primer 1 at 40 pmol/gl 0.5 ýd 
Primer 2 at 40 pmol/gl 0.5 gl 
Mineral oil 50 ýfl 
DNA template 5 gl 
After heating at 95'C for 4 minutes: - 
AmpliTaq (PerkinElmer) 5U/ýd 0.2 gl 
Buffer 4 (PerkinElmer) as above. 0.2 gl 
IHPLC grade H20 1.6 gl 
Total reaction volume 50 gl with 50 gl of mineral oil to prevent evaporation. 
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TABLE 2.3. PRIMERS USED IN THE M. AGALACTIAEAND M. BOVIS PCR's 
PRIMERNAME, PRIMER SEQUENCE 
M. agalactiae Forward 5'-GAAGAAAAAGTAGC-GTAGGAAATGA-C-3' 
M. bovis Forward 5'-GAAGAAAAAGTAGCATAGGAAATGAT-3' 
M. agalactiae Reverse 5-CGTCGTCCCTACC'I'rCCTCCCA-3' 
M. bovis Reverse 5'-CGTCGTCCCCACCTrCCTCCCG-3' 
Bases underlined in bold highlight the small differences in M. agalactiae and M. 
bovis primer design (Johansson et aL, 1996b). 
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2.3. RESULTS 
2.3.1. M. BOVIS PCR SPECIFICITY 
The PCR developed was based on the primers of Johansson et al. 
(1996b) for M. bovis. Preliminary work was carried out to establish optimal 
conditions for the PCR and to investigate specificity. With a low (55*Q annealing 
temperature it was confin-ned that optimal amplification was produced using a buffer 
containing 2 MM M902. However, the M. bovis PCR procedure also resulted in 
amplification of M. agalactiae DNA and the DNA of M. bovirhinis and M. 
bovigenitalium (Figure. 2.1. ). To overcome difficulties with non-specific 
amplification during the PCR a 'hot-start' was incorporated into the procedure. The 
first method attempted was the 'wax beads' technique (See Section 2.2.5. ). Using 
an annealing temperature of 55'C amplicons were produced by all of the cultures 
tested: M. bovis (6 strains); M. bovirhinis (2 strains); M. bovigenitalium (1 strain); 
and M. agalactiae (I strain). These amplicons were all of the expected size of 
approximately 734 base pairs. When restriction enzyme analysis was performed on 
these amplicons M. bovis and M. agalactiae could easily be differentiated from each 
other. M. bovis gave four bands of approx; 601,423,178 and 133 base pairs 
compared to M. agalactiae which gave two bands at 601 and 133 base pairs. M. 
bovirhinis appeared to be almost totally digested, giving only one low weight band. 
However, M. bovigenitalium gave a profile similar to that of M. bovis with bands at 
601,423,178 and 133 base pairs (See Figure 2.2). 
Using the TaqGold (PerkinElmer) hot start PCR method (See Section 
2.2.5. ) no amplicons were produced at an annealing temperature of 65'C. At an 
annealing temperature of 55*C amplicons of approximately 734bp were produced 
for both M. agalactiae and M. bovis, althoug Itwo of the seven M. bovis strains 
tested in this PCR, the amplicons were very weak (See Figure 2.3. ). Increasing the 
annealing temperature would therefore reduce the sensitivity of the PCR. 
In the third hot start PCR method, the sample was heated at 94'C for 
four minutes before the Taq enzyme was added and the cycling started. Using M. 
bovis specific primers, this PCR amplified only M. bovis DNA at an annealing 
temperature of 65C. DNA from other test strains was not amplified. At an 
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annealing temperature of 55'C, both M. bovis and M. agalactiae DNA were 
amplified, but no bands were obtained using M. bovirhinis and M. bovigenitalium. 
2.3.1.1. COMPARISON OF TEMPLATES FOR M. BOVIS PCR 
The 15 strains of M. bovis analysed all produced amplicons of 734 bp 
from DNA templates and from cells suspended in PBS, but only 14 produced 
amplicons from cells suspended in growth medium; six of these amplicons were 
very weak. DNA resuspended in growth medium produced amplicons in all 
samples. Details are given in Table 2.4. All of the cultures tested gave plate counts 
in the range 7x 108 to Ix 1010 cfu. These results clearly show, even when using 
DNA that there is a need to test more than one dilution of sample. In six of the 
DNA samples only one of the dilutions from that sample was positive, although the 
samples that produced amplicons showed intense staining indicating more product 
had been produced than from the cells either in PBS or medium. For cells in PBS 
only three of the sample dilutions were negative on PCR, compared with six in 
medium. The amplicons produced from cells in medium showed only weak banding 
compared to that from DNA. Only one dilution was negative in all tests, and three 
were negative in both the PCRs perfon-ned using cells in medium and extracted 
DNA. 
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FIGURE 2.1. PCR RESULTS USING A WAX BEAD HOT START AND A 55'C 
ANNEALING TEMPERATURE. 
Lanes MWt 123456789 10 11 12 13 14 15 16 MWt 
Lanes 1,2,4,6,9 to 16 shows M. bovis PCR arnplicons, 
Lanes 3 and 5 shows arnplicons frorn M. bovirhinis, 
Lane 7 shows an arnplicon from A4. bovigenitalium, 
Lane 8 shows an arnplicon from A4. agalactiae. 
The weaker bands shown in Lanes I and 12 are both from the atypical M. bovis 
strain 119B96 
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FIGURE 2.2. Sfc1 RESTRICTION ENZYME ANALYSIS OF AMPLICONS FROM 
WAXBEAD HOTSTARTAND A 55'CANNEALING TEMPERATURE. 
Lanes: MWt 123456789 10 11 12 1 ') 14 15 16 MWt 
Lane 16 Uncut PCR amplicon 
Lanes 1,3,5,8,9,10 Similar profiles, all fýom M. bovis 
12,13,14,15 
Lane 6 M. bovigenitalium, a weak profile similar to that rrom M. 
bovis. 
Lane 7 M. agalactiae, lacks bands at approx 423 and 178 base 
pairs. 
Lanes 2 and 4. show no distinguishable bands, from M. bovirhinis 
Lane II undigested product only, from atypical AJ bovis isolate. 
1191396 
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FIGURE 2.3 PCR USING TAQGOLD HOT START 
Lanes 
Lanes I to 9 No amplicons, PCR annealing temperature, 65'C 
Lane 10 Negative control, PCR annealing temperature, 55'C 
Lanes II to 17 Al. bovis amplicons. Very weak amplicons were obtained with 
the M. bovis type strain lane 11, and atypical strain 8OB96 in 
lane 16*. 
Lane 18 M. agalactiae type strain amplicon. 
*It is worth noting that the other atypical M. bovis strain 1191396 gave a strong 
amplicon in lane 13. 
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FIGURE 2.4. PCRAMPLICONS FROM CELLS IN EATON'S CULTURE MEDIA 
Details of isolates and interpretation ol'amplicons are given in I'able 2.4. 
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FIGURE 2.5. PCR AMPLICONS FROM CELLS WASHED IN PBS 
Details of isolates and interpretation of amplicons are given in Table 2.4. 
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FIGURE 2.6. PCR AMPLICONS FROM DNA EXTRACTS 
Details of isolates and interpretation ofamplicons are given inTable 2.4. 
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TABLE 2.4. COMPARISON OF PCR PRODUCTS USING DIFFERENT 
TEMPLATES 
SAMPLE / EATON'S MEDIUM- WASHED CELLS DNAEXTRACTS 
DILUTION CELLS (Figure 2.4) (Figure 2.5) (Figure 2.6) 
199B96 Neat .. ... 
-1 
2041396 Neat + .. ... 
-1 + ++ .. 
198B96 Neat Weak + 
-1 Weak + ++ 
1961396 Neat + 4+ ... 
-1 + + ++ 
190B96 Neat + ... iii 
-1 + + + 
171B96 Neat + .. ... 
-1 + ++ 
160B96 Neat + .. ... 
-1 Weak + + ii! 
1241396 Neat +++ ... 
-1 + + 
98B96 Neat Weak + ++ 
-1 Weak + ++ ++ 
97B96 Neat ++ +4+ iiI 
-1 + + 
96B96 Neat Weak + ++ ... 
-1 Weak + + ++ 
91B96 Neat Weak + ++ ... 
-1 Weak + ++ 
85B96 Neat ++ ++ 
-1 Weak + ++ 
70B96 Neat Weak + .. 
-1 + 
58B96 Neat Weak + .. 
-1 - + 
+ve DNA control ... .... ... 
+ve DNA control .. ++ ++ 
-ve control Eaton's medium - PBS - Not done 
-ve control water 
Positive, an amplicon band is visible, increasing to .... intense band, 
-= Negative. 
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2.3.2. RESTRICTION ENZYMEANALYSIS OF M. BOVISPCRAMPLICON 
Amplicons produced from either the M. agalactiae or M. bovis PCR 
when using a low 55'C annealing temperature can be differentiated by restriction 
enzyme analysis. Using the restriction enzyme SfcI gives 2 distinct bands of 601 
and 133bp with M. agalactiae see Figure 2. -1 M. bovis is clearly distinguished, 
giving 4 bands at 601,423,178 and 133bp. The number of bands is as expected 
because there is one common restriction site for SfcI and another site which is 
unique to M. bovis (Johansson et aL, 1996b). 
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Lanes: 1: MWt, 2: M. bovis, 3: M. agalactiae 4: M. bovis, 5: Al bovis 6. - M. 
agalactiae 7: MWt. 
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2.3.3. VALIDATION RESULTS 
Between June 1996 and December 1999,216 bovine mycoplasma 
cultures submitted for routine mycoplasma identification were tested using this PCR 
method. From these, 136 were positive using the PCR. All of the isolates that were 
positive using this PCR also proved to be M. bovis by GIT. Of the 83 PCR negative 
results none were identified as M. bovis in culture. These were subsequently 
identified as; M. bovirhinis (44), M. dispar (3), M. canis (17), M. arginini (5), 
Acholeplasma laidlawii (6), A. modicum (1), and seven were non-viable. 
Some PCR tests on non-incubated culture submissions were attempted 
as soon as the cultures arrived at VLA (Weybridge). These were not successful as 
lack of sufficient cells gave false negative PCR results, which later proved PCR 
positive on re-testing, when cells were clearly present in the PCR template. 
2.4. DISCUSSION 
2.4.1. DISCUSSION. M. BOVIS PCR 
From the results obtained in this study more samples were positive from 
the PBS treated group, than from DNA and direct from cells in medium. The 
template concentration may be a factor affecting this PCR. It is apparent that assay 
reliability using cells in growth medium can be affected by media components 
possibly due to the pH changes that have occurred as a result of mycoplasma growth 
or the presence of other inhibitors. Interestingly, Gibb and Wong (1998) showed 
that PCR could be inhibited by agar from bacteriological transport media. In 
addition, it is good practice within laboratories to use two dilutions, for example 
neat and 1/10 or 1150, of the DNA or cell template for PCR as it is known that 
testing one concentration may give a false negative result. This phenomenon has not 
been explained, but may be due to excess template blocking the reaction or optimum 
conditions not being realised. Decreasing the annealing temperature to 55"C, thus 
increasing the sensitivity of the test, but reducing the specificity may have increased 
the number of amplicons produced, as would using more sample dilutions. 
However, for the routine laboratory identification of M. bovis the more specific 
annealing temperature of 65'Cuk6used. The lower annealing temperature of 55"C 
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has been used without success on several occasions in an attempt to detect M. bovis 
in field samples including nasal swabs and milk, where M. bovis has been suspected 
as causing disease. Those samples have also proved to be negative on culture, on 
one occasion M. dispar was subsequently isolated from 4 of the 20 swabs examined. 
Since this development work was done, the test has been carried out in 
parallel on more than 200 samples submitted to VLA for mycoplasma identification. 
All positive PCR results have been confirmed using GIT. However, this is a bit 
surprising for two reasons. First, it would be expected that M. bovis -could be 
present in cultures where other mycoplasmas such as M. bovirhinis are growing 
rapidly, possibly outgrowing the M. bovis which would not then be detected by 
conventional culture methods, and second, that more atypical M. bovis isolates like 
those described in Section 2.1.2. would be isolated. The first may be explained, 
because the cultures submitted to VLA (Weybridge) have usually been sub-cultured 
more than once, and the second may be a rare event. 
Before establishing the exact PCR methodology, preliminary tests 
demonstrated that the use of wax beads for the hot start was not effective as the wax 
melts before reaching 94'C. The recently marketed TaqGold may be a suitable 
alternative method to providing a hot start, but the test needs re-evaluating for 
optimum temperature and specificity, before it could be used for routine testing. 
However, as TaqGold only weakly amplified two M. bovis isolates, but gave a 
intense amplicon for M. agalactiae it may not be suitable for use in this PCR 
system. This work has shown that the composition of the buffer, use of dilutions of 
the template and the correct hot start are essential. The conditions used for the M. 
bovis PCR are therefore critical for correct performance of the test. 
Restriction enzyme analysis of the PCR product was not considered 
necessary as the M. bovis was shown to be specific at high stringency, and it is 
unlikely that M. agalactiae will be isolated from cattle, although this cannot be 
totally discounted. In 1999 an isolate from a goat farm in Kent was submitted to 
VLA (Weybridge). On culture it showed the same growth characteristics as M. 
agalactiae. This PCR with SfcI restriction enzyme analysis quickly confirmed that 
this isolate was in fact M. bovis. This demonstrates the use of this PCR, which gave 
rapid results and avoided the need for implementing exotic disease control measures. 
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Since completing this work other PCR systems have been developed for 
the species identification of M. bovis and M. agalactiae (Dedieu et al., 1995; Tola et 
al., 1996; Subramaniam. et al., 1998). Subramaniarn et al. 's (1998) PCR test is 
based on a different gene, the uvrC DNA repair gene, that has significant differences 
between the two species compared with only an eight base difference in the 16S 
rRNA gene. In a recent EU interlaboratory trial, all the PCR methods were effective 
but the method based on the uvrC gene showed clearer differentiation between M. 
bovis and M. agalactiae (EC COST meeting, Budapest 1998). 
The M. bovis species specific PCR is relatively rapid in comparison with 
culture followed by serological identification methods which may take an additional 
3 days. PCR however, does have some limitations, as culture work is still part of a 
daily routine for most mycoplasma samples, whereas PCR is still regarded as a 
specialised technique, requiring different skills and time allocation. As more PCRs 
methods for identifying mycoplasma species are developed the emphasis of 
diagnostic work will change, possibly moving towards detection from clinical 
specimens. Already PCR methods for M. conjunctivae, M. canis and M. 
hyopneumoniae are used in the mycoplasma section at VLA (Weybridge). 
However, with 102 mycoplasma species now described it would be inefficient to 
have a PCR for each species. 
One recent advance is the use of 16S rRNA gene sequencing to identify 
mycoplasma species. This technique was used at the start of this project on two 
mycoplasma isolates that could not be identified, one from a peregrine falcon and 
one from an ostrich (see Appendix 1). Since then methods have advanced and cycle 
sequencing is now used with big dye labelling methods to produce larger sequence 
lengths from one reaction. This method has been used many times at VLA 
(Weybridge) to identify unusual mycoplasma isolates. This includes M. fermentans 
from a sheep and M. phocacerabrale from a seal. Of more relevence to this thesis is 
the identification and characterisation of isolates from sheep which were initially 
shown to be Mycoplasma species ovine serogroup 11. However, it has now been 
shown, initially by 16S rRNA sequencing and also by biochemical and serological 
studies that these are in fact the same species as the cattle mycoplasma M. 
bovigenitalium. Since 1995 M. canis has increasingly been isolated from cattle in 
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the LJK. However, from sequencing infonnation it is now believed that a serological 
cross-reaction may have mis-identified some of these isolates, as 16S rRNA 




3.1. EFFICACY OF ANTIMICROBIALS AGAINST M. BOVIS AND M. 
MYCOIDES SUBSP. MYCOIDES SC 
3.1.1. INTRODUCTION 
In vitro susceptibility testing is used to identify therapeutic substances or 
drugs that might be clinically effective in the treatment of microbial infections. 
Determination of the minimal inhibitory concentration (MIQ of an antimicrobial is 
the established method for comparing antimicrobial susceptibility. It is defined as 
the highest dilution of an antimicrobial agent that inhibits the growth of a particular 
micro-organism in the test period (Baffagry, 1994). The MIC50 and MIC90 values 
are respectively used to show the MIC value for 50 and 90 % of the isolates tested. 
The most widely used tests involve growth of the organism in broth medium or 
semisolid culture that is detected by turbidity or pH change. However, alternative 
end points may be used e. g. ATP-dependent lun-ýnometry (136bear and Robertson, 
1996). The reported MIC data for mollicutes are highly variable, highlighting a 
need for improved methodology (Kenny, 1996). The specific variables include: 
inoculum size, incubation period, medium composition, pH and the growth phase of 
the inoculurn. In addition, the MIC value does not necessarily reflect the cell killing 
(mycoplasmacidal) activity (Taylor-Robinson, 1996). This is determined by 
transferring cells from the MIC test into fresh medium at a sufficient dilution to 
render the antimicrobial ineffective. The lowest concentration where there is no 
subsequent growth of mycoplasma is the minimum mycoplasmacidal concentration 
(MMQ (Taylor-Robinson, 1996). 
It is known that, because they lack cell walls, mollicutes are not 
susceptible to treatment by certain antimicrobials, such as the penicillins and 
cephalosporins that inhibit the cross-linking of amino acid chains in peptidoglycan 
synthesis. Mollicutes are also resistant to sulphonaraides, which inhibit folic acid 
synthesis, and those arninoglycosides that inhibit microbial respiration (Barragry, 
1994). 
Mollicutes are more likely to be sensitive to other antimicrobials such 
as: tetracyclines, which interrupt amino acid transfer to growing peptide chains at 
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ribosome complexes; quinalones and fluoroquinolones, which affect DNA gyrase 
activity; and the macrolides and lincosamides which inhibit protein synthesis. 
However, the presence of resistant strains to these and other generally effective 
antimicrobials is well documented (B6bear, 1996). Resistant strains include those 
arising from the genetic transfer of the tetM resistance determinant to U. urealyticum 
and M. hominis in the human urogenital tract (B6b6ar, 1996). 
The majority of reports on mycoplasma antimicrobial susceptibility have 
concerned the human pathogens, although some data on porcine mycoplasmas and 
M. bovis from cattle have been published (Devriese and Haesebrouck, 1991; Cooper 
et al., 1993; Ter Laak et al., 1993; Tanner et al., 1993; Ball et al., 1995; Martel et 
al., 1995; Aduriz et al., 1996; Katoh et al., 1996; Kobayashi et al., 1996; Hannan et 
al., 1997; Pobel et al., 1997). Information on the susceptibility of Mycoplasma 
mycoides subsp. mycoides SC is limited. Lee et al. (1987) investigated the 
sensitivity and mutation rates to antibiotic resistance in M. mycoides subsp. 
mycoides strain T, for eight antimicrobials. More recently Mazzolini et al. (1997) 
reported a study in which 16 antimicrobials were tested against M. mycoides subsp. 
mycoides SC (15 isolates), and also M. alkalescens (13 isolates) and M. bovis (23 
isolates). 
Antimicrobials are used in some mycoplasma diseases, but have not 
been recommended for use in the control of CBPP. They are considered ineffective 
and may hinder the control of the disease by suppressing the symptoms so that 
infected animals are not detected; these animals may then act as reservoirs of 
infection aiding the spread of disease (Provost et al., 1987). However, new 
antimicrobials have been developed and a recent FAO Emergency Prevention 
System (EMPRES) workshop recommended that research into the role of 
chemotherapy be pursued (Rweyemamu and Benkirane, 1996). M. bovis diseases in 
cattle are often refractory to therapy. However, it is generally accepted that animal 
health measures including antimicrobial treatment must be given increased priority 
in disease prevention and control (Pfijtzner and Sachse, 1996). 
In this study, the MIC and MMC values of five antimicrobials against 62 
M. bovis and 20 M. mycoides subsp. mycoides SC isolates were determined. The M. 
bovis isolates were all from recent cases of disease in the UK, whilst the M. 
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mycoides subsp. mycoides SC contained isolates from CBPP outbreaks in Italy, 
Portugal (see Chapter 4), Spain and Africa along with the vaccine and type strain. A 
'Sensititre' microtitre plate system was used; the use of this system to determine the 
MIC measured by cell growth by turbidity with mollicutes has not previously been 
reported. Cell growth turbidity was used rather than pH indicator colour change as 
M. bovis causes only a small change in media pH (<0.5 units) during growth. 
Following MIC determination, mycoplasmacidal activity was also determined by a 
microtitre plate method based on culture turbidity. A short study to determine 
whether antimicrobial treatment would be likely to lead to the rapid selection of 
resistant mutants was also undertaken. The antimicrobials selected for testing were 
danofloxacin mesylate, oxytetracycline dihydrate, spectinomycin dihydrochloride, 
florfenicol and tilmicosin. Danofloxacin mesylate is marketed by Pfizer as 
AdvocinTm, a fluoroquinolone antimicrobial that is known to be active against gram 
positive and negative bacteria and is specifically indicated for the treatment of 
bovine respiratory disease (though not specifically for mycoplasmas). 
Oxytetracycline dihydrate, a broad-spectrum tetracycline, is also marketed by Pfizer 
as Terramycin, and is licensed for use in cattle, sheep, pigs, deer, chickens and 
turkeys. It is used to treat a large number of bacterial infections, particularly 
respiratory diseases as it has good distribution in the lung tissues and respiratory 
secretions (Barragry, 1994). It is commonly used for the treatment of infections 
caused by mycoplasmas, rickettsiae and chlarnydiae and for diseases such as ovine 
footrot, pneumonia in cattle caused by Pasteurella haemolytica (recently renamed as 
A 
Majheinx: c- haemolytica), bovine mastitis, and chronic rhinitis in pigs caused by 
Haemophilus parasuis. Spectinomycin dihydrochloride, an an-iinocyclitol, is 
marketed by Sanofii Animal Health as Spectam; it is active against a wide range of 
pathogens, particularly gram negative organisms and mycoplasmas. It is used in 
cattle, pigs, sheep, poultry, dogs and cats against respiratory and enteric infections. 
Florfenicol is marketed by Schering Plough as Nuflor. It is a structural analogue to 
thiamphenicol and is a bacteriostatic, synthetic, broad-spectrum antimicrobial 
effective against most gram positive and gram negative bacteria isolated from 
domestic animals. It is indicated for the treatment of respiratory tract infections due 
to Ma 1% eim! tj haemolytica and P. multocida and mainly used in cattle. Tilmicosin 
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is marketed by Elanco as Nficotil. It is manufactured semi-synthetically and is a 
member of the macrolide class of antimicrobials. It is indicated for treatment of 
young cattle for pneumonia, associated with Maiýeznvia haemolytica and A 
multocida. 
3.2. MATERIALS AND METHODS 
The antimicrobials tested were: danofloxacin mesylate, oxytetracycline 
dihydrate, spectinomycin dihydrochloride, florfenicol and tilmicosin. All were 
obtained in pure form from Accurned International (Horley, UK) who supplied them 
freeze-dried, in specified quantities, in the wells of 'Sensititre' microtitre plates. 
The quantities per well were such that after addition of medium and inoculum, 
antimicrobial concentration was in the range 0.008 to 128 gg/ml. 
3.2.1. PLATE DESIGN 
The 'Sensititre' plates were designed to the layout specification shown 
in figure 3.1. Each antimicrobial was tested at 15 concentrations. 
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FIGURE3. l. SENSITITRE'PLATE DESIGN 






















0.25 64 0.25 1 64 0.25 164 0.25 1 64 0.25 
32 0.125 32 0.125 32 0.125 32 0.125 32 0.125 
16 0.06 16 0.06 16 0.06 16 0.06 16 0.06 
8 0.03 8 03 0. :J 
.8 
0.03 1 8 0.03 1 8 0.03 
F 4 0.015 
, 
4 I 0.015 4 0.015 I 4 0.015 4 0.015 
G 2 0.008 2 0.008 1 2 0.008 
1 12 0.008 2 0.008 
H 1 0.000 1 1 0.000* 1 0.000* 1 0.000* 1 1 0.000* 
OX = Oxytetracycline dihydrate 
FL = Florfenicol 
DA = Danofloxacin mesylate 
SP = Spectinomycin dihydrochloride 
TI = Tilmicosin 
* negative control (no antimicrobial) 
Concentrations are expressed in gg/ml of antimicrobial when diluted to 200gl. 
Rows 11 and 12 of plates were not used in the present study. 
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3.2.2. MEDIA 
Mycoplasma bovis and M. mycoides subsp. mycoides SC were grown in 
Eaton's medium (see Section 2.2.2. for composition; Nicholas and Baker, 1998). 
3. Z 3. ISOLATES 
All of the test isolates were minimally passaged (4-5 subcultures) and 
stored at -70'C until required. M. bovis isolates (62) were all from recent 
submissions to VLA (Weybridge) and came mainly from cattle with respiratory 
symptoms. The M. mycoides subsp. mycoides SC isolates were from CBPP cases in 
Portugal, Italy, Spain, Australia and Africa. The origin of strains is given in Table 
3.1. The identity of all strains was determined or confirmed using standard 
mycoplasma identification techniques Nicholas and Baker (1998) and PCR methods 
(Bashiruddin et al., 1994a) for M. mycoides subsp. mycoides SC and the method 
described in Chapter 2 of this thesis for M. bovis. 
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TABLE 3.1. ORIGIN OF M. BOVIS AND M. MYCOIDES SUBSP. MYCOIDES 
(SMALL COLONY) ISOLATES 
No. Ref. No Species Isolate Submitting Regional Centre 
01 133B97 M. bovis Lun2 Thirsk 
02 36B97 M. bovis Lung Thirsk 
03 109B97 M. bovis Lung Bury St Edmunds 
04 33B97 M. bovis Lung Bury St Edmunds 
05 245B96 M. bovis Lung Shrewsbury 
06 171B96 M. bovis Lung Shrewsbury 
07 103B97 M. bovis Lung pool Thirsk 
08 205B96 M. bovis Lung Thirsk 
09 187B96 M. bovis Lung Shrewsbury 
10 160B96 M. bovis Lung Aberystwyth 
11 154B96 M. bovis Lung Thirsk 
12 I. B97 M. bovis Lung Starcross 
13 72B97 M. bovis Lung Luddington 
14 226B96 M. bovis Pleural Fluid Thirsk 
15 124B96 M. bovis Lung Thirsk 
16 15B97 M. bovis Lung Winchester 
17 82B97 M. bovis Lung Bury St Edmunds 
18 68B97 M. bovis Joint Luddington 
19 139B97 M. bovis Lung Penrith 
20 76B97 M. bovis Lung Winchester 
21 127B96 M. bovis Nasal swab Aberystwyth 
22 213B96 M. bovis Lung Thirsk 
23 99B97 M. bovis Lung Bury St Edmunds 
24 129B97 M. bovis Lung Aberystwyth 
25 132B97 M. bovis Lung Luddington 
26 13 lB97 M. bovis Lung Starcross 
28 119B97 M. bovis Lung Shrewsbury 
29 117B97 M. bovis Lung Preston 
30 106B97 M. bovis Lung Bury St Edmunds 
31 107B97 M. bovis Lung Truro 
32 101B97 M. bovis Pericardium/ Bury St Edmunds 
Trachea 
33 95B97 M. bovis Lung Winchester 
34 8OB97 M. bovis Lung Bury St Edmunds 
35 79B97 M. bovis Lung Preston 
36 78B97 M. bovis Lung Shrewsbury 
37 77B97 M. bovis Lung Thirsk 
38 70B97 M. bovis Uterine Fluid Penrith 
39 68B97 M. bovis Joint Luddington 
40 46B97 M. bovis Nasal Swab Aberystwyth 
41 40B97 M. bovis Lung Luddington 
42 39B97 M. bovis Lung Shrewsbury 
43 27B97 M. bovis Lung Thirsk 
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No. Ref. No Species Isolate Submitting Regional Centre 
44 211397 M. bovis Luniz Preston 
45 171397 M. bovis Lung Aberystwyth 
46 96B96 M. bovis Lung Aberystwyth 
47 1OB97 M. bovis Lung Thirsk 
48 2331396 M. bovis Lung Winchester 
49 230B96 M. bovis Lung Thirsk 
50 1991396 M. bovis Lung Thirsk 
51 217B96 M. bovis Lung Shrewsbury 
52 124B96 M. bovis Lung Thirsk 
53 1861396 M. bovis Lung Preston 
54 1931396 M. bovis Lung Bristol 
55 2041396 M. bovis Lung Shrewsbury 
56 1761396 M. bovis Lung Starcross 
57 1961396 M. bovis Nasal swab Bury St Edmunds 
58 2141396 M. bovis Lung pool Thirsk 
60 71B96 M. bovis Lung Thirsk 
61 1531397 M. bovis Lung Penrith 
62 1611397 M. bovis Lung Luddington 
63 6302 M. mycoides subsp. mycoides SC Portugal 
64 6526 M. mycoides subsp. mycoides SC Portugal 
65 M545/91 M. mycoides subsp. mycoides SC Portugal 
66 130/20P M. mycoides subsp. mycoides SC Italy 
67 Afade M. mycoides subsp. mycoides SC Chad 
68 V5 M. mycoides subsp. mycoides SC Australia 
69 T144 M. mycoides subsp. mycoides SC Unknown Africa 
70 375 M. mycoides subsp. mycoides SC Botswana 
71 Segonia M. mycoides subsp. mycoides SC Spain 
72 Astercous M. mycoides subsp. mycoides SC Spain 
73 57/13 M. mycoides subsp. mycoides SC Italy 
74 192 M. mycoides subsp. mycoides SC Italy 
75 400 M. mycoides subsp. mycoides SC Portugal 
76 427 M. mycoides subsp. mycoides SC Portugal 
77 197 M. mycoides subsp. mycoides SC Italy 
78 403 M. mycoides subsp. mycoides SC Portugal 
79 NCTC 10 114 M. mycoides subsp. mycoides SC NCTC Type strain 
80 B 103 M. mycoides subsp. mycoides SC Portugal 
81 6512 M. mycoides subsp. mycoides SC Portugal 
82 Santander M. mycoides subsp. mycoides SC Spain 
118 
3.2.4. INOCULATIONAND INCUBATION OF'SENSITITRE'PLATES 
Culture of the test strains was in 3ml quantities of Eaton's medium 
(without phenol red) for 24 hours at 37'C, in a C02 incubator (5% C02 in air). The 
medium was inoculated with approximately 100 ptl of frozen culture (-700C). After 
growth, optical density was measured and adjusted to OD450 of 0.1, equivalent to 
approximately 1X 108 colony forming units (cfu) per ml. Before dilution, the OD of 
all cultures was in the range 0134500.085 to 0.110. 
To prepare 'Sensititre' plates, one hundred and ninety gl of Eaton's 
medium (without phenol red) were first dispensed into wells of plates and 10 gl of 
inoculum (OD450 0-1) were then added to each well. The plates were sealed with a 
film plate sealer and incubated for 48 hours at 37'C. 
3.2. S. DETERMINATION OF MIC AND MHC VALUES 
'Sensititre' plates were incubated and MIC values determined following 
the assessment of growth (See Section 3.2.6). To determine MMC values, 10 RI of 
culture from each well of the 'Sensititre' plate, was transferred to the corresponding 
well of a further round bottom microtitre plate. These wells each contained 190 [d 
of medium, thus diluting the antimicrobial 1 in 20, i. e. to below the antimicrobials 
effective level. Plates were then incubated as described in Section 3.2.4. for 48 
hours. 
3.2.6. READING OF TESTS 
To detennine the presence of absence of growth, 'Sensititre' and 
microtitre plates were centrifuged at 8OOg for 3 minutes to concentrate cells at the 
bottom of the wells. Plates were then illuminated and examined using an inverted 
mirror. 
3.2.7. SELECTION OF RESISTANT MUTANTS 
The selection of antimicrobial resistant mutants was investigated using 
three M. mycoides subsp. mycoides SC isolates: 400; B 103 and 192 after MIC values 
had been detennined. Fresh 'Sensititre' plates were inoculated with cells from the 
highest antimicrobial concentration at which growth occurred. This was repeated 
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for 11 successive cultures; in each subculture, the ability of cells to grow at an 
antimicrobial concentration above the previous MIC was determined. 
3.2.9. DETERMINING MULTIPLE RESISTANCE 
Cultures grown in 'Sensititre' plate wells containing the highest 
concentration of each antimicrobial were subcultured in Eaton's medium. The MIC 
values of these cultures for each of the antimicrobials was then determined as 
described in sections 3.2.4 to 3.2.6. 
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FIGURE 3.2. DETERMINATION OF MIC VALUES FOR M. MYCOIDES SUBSP. 
MYCOIDES SC USING A 'SENS1 T/ TREMICRO T/ TRE PLA TE 
:.: 
0--0 
The plate was set up as described in Section 3.2.4. using tile grid from Figure 3.1. 
The plate shows MIC values of 0.03 [tg/ml; 8.0 ýLghnl; 0.5 ýig/rnl; 0.0 15 ltg/ml; and 
0.25 ýtg/m I fo r antimicrobials oxytetracycline dihydrate, spectinomycin 
dihydrochloride, florfenicol, tilmicosin and danotloxacin mesylate respectively. 
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3.3. RESULTS 
3.3.1. DEVELOPMENT OF METHODOLOGY 
Antimicrobial MIC values for mollicutes are typically determined by 
inoculating the test strain into a series of bijou bottles containing approximately 4 ml 
of growth medium, with a range of antimicrobial concentrations. After inoculation, 
growth is determined by visual inspection of bottles for an increase in turbidity 
compared to uninoculated controls. In the development of methodology attempts 
were made to reduce preparation time and the consumption of medium and 
consurnables by using a microtitre plate system, which has proved useful with cell- 
walled bacteria (Franklin and Wierup, 1982). In addition, the procedure used for the 
determination of growth was investigated, since mollicutes grow poorly, and the 
presence of growth in broth medium is sometimes difficult to determine in an 
objective manner. 
The microtitre plate system described in Section 3.2.1. was evaluated using 
M. mycoides subsp. mycoides SC strain B103 and M. bovis strain 961396. Using the 
standardised procedure in Section 3.2. With a variety of methods for determining 
growth, reproducible results were obtained for all of the test antimicrobials. In five 
experiments of this type, the MICs determined were in all cases within one doubling 
dilution of each other for any particular antimicrobial combination. 
Detection of growth in microtitre plates using Eaton's medium without 
phenol red, was difficult after 24 hours, particularly for M. bovis strains. In many 
cases, it was impossible to accurately define the end point. It was easier to read 
plates after 48 hours, but still required some objectivity. 
In Eaton's medium with phenol red, (initial pH 7.6) M. mycoides subsp. 
mycoides SC gave a clear colour change (red - yellow) within 24 - 48 hours, but the 
colour change observed with M. bovis cells was slight (red - orange red). 
Measurement of pH confirmed that for M. bovis, the fall in pH during growth 
was less than 0.3 units. In contrast, for M. mycoides subsp. mycoides SC, the pH 
declined to values of <6.0. Thus, although the use of a pH change system might 
improve detection of growth for certain mycoplasmas it was not adopted here. 
However it was found that by centrifuging plates in a standard laboratory centrifuge 
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with a plate adapter, it was relatively easy to to determine the presence or absence of 
a cell pellet. When plates were observed using an inverted microtitre plate reader, 
MIC values could be rapidly recorded. This procedure was adopted throughout the 
study. 
Mycoplasmacidal values are reported relatively infrequently for 
mycoplasmas. MMCs are often determined by incubating cultures for prolonged 
periods (e. g. 21 days) (Cooper et al., 1993). It is assumed that the antimicrobial 
activity declines with incubation time, such that where growth is initially inhibited 
antimicrobial concentrations will fall below MIC values. This approach clearly has 
limitations in relation to the kinetics of antimicrobial decay, the loss of unstable 
medium components and the possible growth of resistant mutants, initially present in 
very low numbers. Thus to determine MMC values in this study, the viability of 
mycoplasmas exposed to antimicrobial concentrations above MIC values was 
determined by subculture to fresh medium. The method finally adopted was an 
adaptation of the iriicrotitre system described above. Using a multichannel pipette, 
transfer of inocula from all the wells of incubated MIC plate, to plates containing 
fresh medium required only approximately one minute. After incubation, growth 
was detected as described above. 
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TABLE 3.2. ANTIMICROBIAL MIC AND MMC VALUES OF 62 STRAINS OF M. 
BOVIS 
Minimum Inhibitory Concentration Mycoplasmacidal Activity 
pg/m, pg/ml "? 
Range micso MIC90 Range MMC50 mmcgo 
Danofloxacin 0.125-2 0.5 0.5 0.25-8 0.5 1 
Florfenicol 1-64 4 16 4-128 16 32 
Oxytetracycline 1-128 32 64 2- >128 64 128 
Spectinomycin I- >128 4 >128 2- >128 16 >128 
TiImicosin 4- >128 >128 >128 16 - >128 >128 >128 
TABLE 3.3. ANTIMICROBIAL MIC AND MMC VALUES OF 20 STRAINS OF M. 
MYCOIDESSUBSP. MYCOIDESSC 
Minimum Inhibitory Concentrations MYcoplasmacidal Activity 
pg/ml pg/ml 
Range MIC50 MIC90 Range MMC50 NIMC90 
Danofloxacin 0.125-1 0.25 0.5 0.25-4 0.5 2 
Florfenicol 0.25 -8 1 2 1-16 8 16 
Oxytetracycline 0.125-4 0.5 1 0.5-32 8 32 
Spectinomycin 4- >128 8 16 4- >128 16 128 
Tiln-ticosin <0.008 - 0.25 0.015 0.03 <0.008 - >128 0.06 16 
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3.3.2. ANTIMICROBIAL RESISTANCE IN M. BOVIS 
Sixty-two test strains of M. bovis were used. The distribution of NEC 
and MMC values is shown in Figure 3.3. and the data are summarised in Table 3.2. 
Danofloxacin mesylate showed the lowest MIC values with values from 0.125 to 2 
pgln-A; mycoplasmacidal concentrations ranged up to 8 ýtg/ml. Florfenicol appeared 
to be the next most effective antimicrobial with a range of MIC values from I to 64 
pg/ml and a mycoplasmacidal affect at 4 to 128 gg/ml. Oxytetracycline dihydrate 
was effective in preventing growth at 1 to 128 gg/ml, but a mycoplasmacidal effect 
required greater than 128 ýtg/ml for two strains. Interestingly, spectinomycin 
showed no effect on approximately 20% of the isolates tested and tilmicosin was 
also ineffective for 85% of the isolates over the concentration range tested. 
There was no obvious correlation of antimicrobial resistance patterns 
with the source of M. bovis isolates nor was resistance to any one antimicrobial 
correlated with resistance to other antimicrobials. A detailed table showing the MIC 
and MMC values for each individual test strain is given in Appendix 2. 
3.3.3. ANTIMICROBIAL RESISTANCE IN M. MYCOIDES SUBSP. 
MYCOIDES SC 
Twenty test strains of M. mycoides subsp. mycoides SC were used. The 
distribution of NUC and MMC values are given in Figure 3.4. and the data 
summarised in Table 3.3. Antimicrobial sensitivity patterns of M. mycoides subsp. 
mycoides SC differed from those of M. bovis. Danofloxacin mesylate gave the 
narrowest range of MIC values (0.125 to 1 gg/ml) with a mycoplasmacidal effect at 
0.25 to 4 gg/ml. In most cases, tilmicosin was more effective than danofloxacin, 
with 90% of isolates having an MIC value of less than 0.03 gg/ml; however, three 
isolates had mycoplasmacidal concentrations above 16 pg/ml. Florfenicol and 
oxytetracycline dihydrate gave similar results with MIC values of 0.125 to 4 gg/ml 
and mycoplasmacidal concentrations of 0.5 to 32 gg/ml. For spectinomycin 
dihydrochloridc, the majority (60%) of isolates had a MIC value of less than 8 Rg/ml 
but the vaccine strain, T144 had a value in excess of 128 gg/ml. As observed for M. 
bovis, there was no clear correlation of antimicrobial resistance patterns with the 
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source of M. mycoides subsp. mycoides SC isolates and resistance to individual 
antimicrobials did not appear to correlate with resistance to other antimicrobials. 
3.3.4. SELECTION OF ANTIMICROBIAL RESISTANT MUTANTS 
To determine whether antimicrobial resistance was rapidly selected for 
in vitro, three M. mycoides subsp. mycoides SC isolates were successively 
subcultured 11 times in the presence of increasing antimicrobial concentrations 
(Table 3.4. ). 
Subculturing the three isolates of M. mycoides subsp. mycoides SC at the 
MIC level of the antimicrobial demonstrated that resistance was rapidly selected for 
in spectinomycin, little or no change was observed with oxytetracycline and the 
remaining antimicrobials showed an increase in the MIC by one or two dilutions. 
The results are given in Table 3.4. 
The determination of cross-resi stance which followed a single passage 
without antimicrobials before inoculating fresh 'Sensititre' plates showed that the 
induced resistance to spectinomycin was not lost, although the MIC value for isolate 
B103 was reduced to 32 gg/ml from >128 Rg/ml. For the other two isolates 
spectinomycin MIC value remained at >128 Rg/ml. No cross-resi stance was 
observed, and remaining MIC values were no higher than two dilutions of the 
original MIC value (Table 3.5. ), with the exception of B103 in Tiln*osin which 
went from 0.008 to 0.125 Rg/ml. Some MIC values obtained were lower than the 
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Previous MIC tests carried out at VLA (Weybridge) used 4 ml volumes 
of medium in bijoux. That method used large volumes of medium, antimicrobials 
and inoculum making it expensive to perfon-n. All dilutions and inoculations had to 
be performed individually, with the added inconvenience of unscrewing and 
replacing bijou lids. In addition the comparison of growth was again done 
individually either looking for swirls of growth, or pH change in comparison with 
the controls. Whereas the methodology used in this thesis was extremely effective 
and results obtained for a control M. bovis isolate compared favourably, within one 
dilution, with previous tests using broth dilutions in bottles (unpublished results). 
The microtitre plate method had several advantages. It was more economical with 
reagents, more efficient to set up than broth dilutions in bottles, as multichannel and 
repeating pipettes could be used. The inoculurn was also standardised. Reading of 
results was easy, as all dilutions could be viewed at one time and did not require 
manipulation of bottles and shaking to observe cell growth. The MMC 
determination used in this study relied upon diluting the antimicrobial below its 
effective level to assess the killing effect of the antimicrobial, whereas Cooper et at. 
(1993) read the MIC tests after a further 14 or 21 days to give an indication of 
mycoplasmacidal action (See 3.3.1. ). In the study by Cooper et al. (1993) 2 to 4 fold 
increases above the MIC value were reported which is similar to the results obtained 
in this thesis. 
The NEC and MMC values obtained for M. bovis and M. mycoides 
subsp. mycoides SC isolates were similar for danofloxacin, but differed markedly for 
the other test antimicrobials. Oxytetracycline, spectinomycin, florfenicol and 
tilmicosin antimicrobials appeared relatively ineffective against M. bovis in-vitro, 
although they were more effective for M. mycoides subsp. mycoides SC, with 
oxytetracycline having an MIC 6 dilutions lower and tilmicosin giving the lowest 
MIC50 value obtained in this study. However, the way in which MIC values relate to 
the effectiveness of antimicrobials in animals is a complex issue. Antimicrobials 
demonstrating little or no in vitro activity are unlikely to be effective clinically in 
aiding the body's defences to eradicate infectious organisms. However, it is known 
that some classes of antimicrobials particularly the macrolides, may be actively 
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concentrated (up to 18 fold) in the phagolysosomes of cells. This may make them a 
more appropriate choice for chemotherapy than NUC or MMC data might suggest 
(Reeve-Johnson, 1999). Ter Laak et A (1993) considered that mycoplasma strains 
were susceptible to antimicrobials in vivo if MIC values were equal to or less than 1 
gg/ml; intermediately susceptible between 2 and 4 IAg/ml; and resistant at 8 gg/ml 
and above. On this basis, using the MIC50 values, M. bovis is resistant to 
oxytetracycline and tilmicosin, intermediately susceptible to florfenicol and 
spectinomycin, and susceptible to danofloxacin. However, using the MIC90 value M. 
bovis is only susceptible to danofloxacin. For M. mycoides subsp. mycoides SC, 
using the MIC50 values, it is only resistant to spectinomycin and susceptible to the 
other four antimicrobials. When the MIC90 value is used, florfenicol moves to the 
intermediately susceptible category. MMC data may be more directly related to 
clinical effectiveness than MIC values because the NIMC values relate to 'killing' 
rather than just growth inhibition. Classifying the antimicrobials using MMC90 
values gives a very different picture with both M. bovis and M. mycoides subsp. 
mycoides SC being resistant to florfenicol, oxytetracycline, spectinomycin and 
tilmicosin. Only danofloxacin remained effective with M. bovis being susceptible 
and M. mycoides subsp. mycoides SC being intermediately susceptible. 
However, most reports of MIC's use a change in pH as an indicator of 
growth, which presented a problem as M. bovis is not fermentative and only a minor 
pH change occurs during growth. Devriese and Haesbrouck (1991) used Tween 80 
hydrolysis as an indicator of growth for M. bovis by looking for the presence of 
precipitates. However, following an initial trial using Eaton's medium with and 
without phenol red, it was shown (see Section 3A. ) that Eaton's without phenol red 
was suitable for both M. bovis and M. mycoides subsp. mycoides SC. The presence 
of growth was indicated by turbidity/growth precipitate in microtitre plate wells. 
In this study danofloxacin mesylate was the most effective of the 
antimicrobials tested against M. bovis. Cooper et A (1993) previously tested ten M. 
bovis isolates against danofloxacin mesylate and obtained a MICgo of 0.25 Rg/ml 
compared with a MICgo of 0.50 gg/ml in the present study. Oxytetracycline 
hydrochloride was also tested in the study of Cooper et aL (1993) and gave an 
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MIC90 of 16 gg/ml, identical to that obtained here. Mazzolini et al. (1997) obtained 
a slightly lower MICgo of 2 gg/ml for oxytetracycline against 23 strains of M. bovis. 
Ball et al. (1995) tested 23 field isolates of M. bovis against tilmicosin 
and spectinomycin. They found spectinomycin gave a range of MIC values from 4 
to 32 ggIml. Mazzolini et al. (1997) reported a range of 4- >256 gg/ml with an 
MICgo of 2 gg/ml. The present results show two groups of isolates; 12 strains were 
resistant to >128 gg/ml whilst the remaining 50 strains were intermediately 
susceptible at I to 8 pgIml. 
Ball et al. (1995) found that isolates tested with tiln-&osin gave MICs 
from <0.06gg/ml to 0.5 gg/ml or from 4 to >32 gg/ml. Two isolates in the present 
study had MICs of 4 gg/ml, with a further seven having MICs up to 128 Vg1ml. The 
remaining 53 isolates were highly resistant with MICs >128 jtg1ml. The isolates of 
Mazzolini et al. (1997) were similarly diverse with a range of MIC values from 
0.25->32 gg/ml and a MIC90 of >32 gg/ml. Although the isolates tested in these 
three studies came from different countries (England, N. Ireland and Italy) the 
results all suggest that the use of tilmicosin in the treatment of M. bovis infections is 
leading to the emergence of resistant strains. 
Mazzolini et al. (1997) obtained the following MIC values for M. 
mycoides subsp. mycoides SC: tilmicosin <0.03 gg/ml; spectinomycin 1 to 4 jig/ml; 
and oxytetracycline 0.25 to 1 gg/ml. Corresponding values in the study reported in 
this thesis were: <0.03 [tg/ml; 4 to 32 pg/ml (with one strain >128 Rg/ml); and 0.125 
to 4 gg/ml, respectively. Comparisons between the studies are complicated as 
details of strains tested by Mazzolini et al. (1997) are not given. Although it is 
highly likely that these strains were all Italian isolates, the results are comparable to 
those of the present study that used strains from a wide range of countries. 
One of the potential problems with the use of antimicrobials is the 
development of antimicrobial resistance (Chin and Marx, 1994). In vitro trials may 
be used to assess the potential for resistance-development. In this study M. 
mycoides subsp. mycoides SC was used to determine if resistance could be selected 
for by growth at antimicrobial concentrations close to the MIC level. Similar 
experiments were not done for M. bovis as many isolates were initially relatively 
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resistant to the test antimicrobials. The results (Table 3.4) showed that slight 
increases in MIC values were obtained for tilmicosin, danofloxacin, florfenicol (2 
isolates) and oxytetracycline (I isolate). These showed a trend with I or 2 dilution 
increases, but this may fall within expected levels of test variation. However, the 
MIC value for spectinomycin increased dramatically from 4 and 8pg/ml to greater 
than 128 pg/ml within 6 passages with one isolate. Interestingly, Lee et al. (1987) 
were also able to select for spectinomycin dihyrochloride resistant mutants in M. 
mycoides subsp. mycoides SC strain T1. The initial MIC value for this strain was 
determined to be 6 pg1ml and this increased to >128 pg/ml in an apparent single step 
mutation. Interestingly, although Lee et al. (1987) used different methods, the initial 
MIC value of 6 pg/ml is similar to values for many M. mycoides subsp. mycoides SC 
isolates tested in this study. However, the strain T144 held at VLA (Weybridge) was 
resistant at >128 pg/ml to spectinomycin dihydrochloride suggesting that it may 
have acquired resistance. Resistance to spectinomycin dihydrochloride is known to 
develop rapidly. A mutation of the organism leading to an altered ribosome 
structure that no longer binds the antimicrobial would be expected to lead to high 
levels of resistance. This would require only a single mutation; however, it is also 
possible that resistant strains may have a reduced permeability towards the 
antimicrobial as to be able to inactivate it enzymatically. 
Sub-culturing at the MIC level (Table 3.5) induced no antimicrobial 
cross-resistance. Interestingly, some MIC values were lower than the initial starting 
MIC value obtained, which was also observed in Table 3.4. This can be explained, 
as the inoculum for these investigations was not standardised, which emphasises the 
need for inoculum standardisation in MIC investigations. 
The data in this thesis appears to show greater antimicrobial resistance in 
M. bovis than in M. mycoides subsp. mycoides SC. This may be because 
antimicrobials are used more widely in Europe. However, in that case one might 
have expected to see higher MIC levels in the European M. mycoides subsp. 
mycoides SC isolates than in the African isolates. With the exception of the vaccine 
strain T144 all M. mycoides subsp. mycoides SC strains had similar MIC values with 
all antimicrobials. This may be explained by European control strategies for M. 
mycoides subsp. mycoides SC, in which infected animals are not treated, but rapidly 
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slaughtered. It would be interesting to examine isolates of M. bovis from African 
countries to deten-nine their MIC levels. 
The results of the present study showed that the majority of M. bovis 
isolates have developed antimicrobial resistance. It also indicated that danofloxacin 
mesylate would be a useful antimicrobial to use in vivo against M. mycoides subsp. 
mycoides SC. However, both M. mycoides subsp. mycoides SC and M. bovis may be 
difficult organisms to target, because they locate in sites such as joints. The 
widespread use of antimicrobials would also be expected to lead to the development 
of resistant strains. Multiple antimicrobial resistance, particularly to 
fluoroquinolones, is an increasing problem in animal health, and the treatment of 
bacterial enteric diseases (Wray et al., 1991; Nijsten et al., 1993; Acar and 
Goldstein, 1997). 
In conclusion the strategic use of antimicrobials may have a role in the 
control of CBPP, but it would need careful implementation and monitoring. A trial 
would need to be carried out in the field to evaluate the true effectiveness of use of 
antimicrobials as a means of control. CBPP is a major disease problem in Africa 
and currently only Northern Portugal is affected in Europe. Observation of the 
disease and the collection of more isolates are required to continue this study into 
improving control of CBPP. 
133 
FIGURE 3.3. DISTRIBUTION OF MIC'S AND ACCUMULATIVE % MIC AND MMC 
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FIGURE 3.4. DISTRIBUTION OF MIC'S AND ACCUMULATIVE % MIC AND MMC 
VALUES FOR THE FIVE ANTIMICROBIALS TESTED AGAINST ISOLATES OF M. 
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CHAPTER 4 
4.1. A CRITICAL EVALUATION OF DIAGNOSTIC METHODS FOR CBPP 
4.1.1. INTRODUCTION 
Contagious bovine pleuropneumonia, caused by M. mycoides subsp. 
mycoides SC, is an important disease. In affected countries, it causes great 
economic losses, as control methods are difficult to implement. Vaccination using 
attenuated M. mycoides subsp. mycoides SC cells is expensive and provides only 
transient protection of up to I year (Tulasne et al., 1996). Antimicrobials have been 
considered to be largely ineffective or mask the disease symptoms so aiding the 
spread of the disease, however as discussed in Chapter 3, strategic use of 
antimicrobials may have a role in the future control of CBPP. Countries that have 
successfully eradicated the disease have all used a strict testing and slaughtering 
regime with compensation for the farmers. Control methods in countries with CBPP 
depend on correct and rapid diagnosis in the laboratory. It is therefore important 
that efficient and effective tests are used to correctly detect CBPP and the causative 
mycoplasma. Current diagnostic methods are limited and are described in Chapter 
1, section 1.5.7. Gross pathology at post-mortern. is a major diagnostic tool, but 
culture and identification of M. mycoides subsp. mycoides SC is fundamental, but 
seldom carried out in African countries. The authorities in the UK would require the 
causative organism M. mycoides subsp. mycoides SC to be isolated before 
implementing a slaughtering regime. The OIE recommended CFr serological test is 
currently the accepted form of diagnosis, although it has severe limitations as 
described in Section 1.5.7. Other diagnostic tests such as PCR, ELISA and 
immunoblotting methods are not in widespread use. During the period of this thesis, 
Portugal has further developed and used the immunoblotting method as a 
confirmatory diagnostic test in their CBPP eradication program. In addition a 
cELISA has been developed (Le Goff and Thiaucourt, 1998) which has now been 
accepted by the OIE as an alternative test to the CFT, although its diagnostic value is 
only comparable to the CFI. 
In this study, samples were extracted from CBPP positive animals at a 
Portuguese abattoir when they were slaughtered. This material was used in this 
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study which critically evaluates the current CBPP diagnostic methods, in some cases 
with developments of methodology. Methods used were: 
culture using established media 
serological test by CFr using OIE standard antigen 
gross pathology 
immunocytohistochernistry QCQ 
PCR with Southern blotting detection. 
In addition, observations were made on the farms involved in that specific CBPP 
outbreak which occurred in northwestern Portugal around Porto during January 
1996. 
4.2. SOURCES OF CLINICAL MATERIAL 
4.2.1. POST-MORTEM EXAMINATION AND SAMPLE COLLECTION 
Twenty cows were examined for gross pathology in the abattoir in Porto. 
Selections of different samples were taken from different animals. Samples of lung 
were taken from eleven cows originating from a farm designated: W and 
immediately fixed in buffered formalin for ICC examination. Seven lung samples 
were taken from cows originating from three other farms (see Table 4.1. ) and were 
stored at -80'C before being tested by culture and polymerase chain reaction (PCR). 
Nasal swabs were taken from 16 cows and were immersed in Eaton's culture 
medium before being cultured and subjected to PCR. 
4.2.2. OTHER SERUM SAMPLES 
In addition to the sera collected from the abattoir, sera samples were also 
examined from six other Portuguese farms where CBPP had been diagnosed. 
Details of these samples are given in Section 6.2.1.3. 
4.2.3. MONOCLONAL ANTIBODIES 
The Monoclonal Antibody Production unit at VLA (Weybridge) 
produced monoclonals against whole cells of M. mycoides subsp. mycoides SC 
Made strain for use in this work. Hybridomas were initially screened using a whole 
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cell antigen in an indirect ELISA. Following positive ELISA reactions, 19 
hybridomas were selected for further evaluation. 
The isotype for each Mab was detennined using the Isodetect isotyping kit 
(Stratagene Ltd, Cambridge, UK) and following the kit protocol. Briefly the Mab 
supernatant was diluted 1: 1 in PBS and 500 ýtl of sample slowly added to the sample 
well. Results were read within 5 minutes with a colloidal gold band indicating the 
specific isotype. 
As an initial screening process, an M. bovis ELISA was performed, followed 
by western blotting (Towbin et al, 1979) using two mycoplasma isolates: M. 
mycoides subsp. mycoides SC 'Afad6'; and M. bovis '107B97' to check for cross- 
reacting Mabs and the size of the cross-reacting antigen. A 12 % SDS PAGE was 
run for the two isolates at a protein concentration of 500 Rg/ml, before transferring 
to a membrane using a semi-dry blotting system ('Transblot', Bio-Rad Laboratories, 
Hemel Hempstead, UK). Control samples containing molecular weight markers and 
a strip of both antigens were stained with the protein dye, amido black (Sigma 
Chemicals, Poole, UK. ). The remaining membrane was cut into strips and blocked 
with PBS pH 7.2 containing 3% w/v dried milk powder (Marvel) and 0.05 % v/v 
tween 80 for 30 minutes at 37'C. This was followed by: incubation with the Mab 
supernatants for 60 minutes at 37'C; washing in PBS tween; incubation with anti- 
mouse polyvalent immunoglobulin labelled with alkaline phosphatase conjugate for 
60 minutes at 37cC (Sigma Chemicals, Poole, UK. ); washing four times in PBS; and 
addition of substrate 5 bromo-4-chloro-3-indoyl-phosphate/nitroblue tetrazolium. 
(BCIP/NBT). The reactions were stopped by washing the strips in water after 
sufficient colour had developed in the control samples. 
4.2.4. IMMUNOSTAINING OF LUNG TISSUE 
Selection of Mabs for immunocytohistochemistry was carried out on 
formalin fixed bovine lung tissue. Those that failed to detect antigen or gave 
unwanted staining in normal lung tissue were considered unsuitable. Further 
evaluation of ICC using potentially suitable Mabs was carried out using tissue from 
16 CBPP affected Italian cattle (Nicholas et al., 1996), from normal animals and 
from archived cases of non-CBPP respiratory disease used as controls. The 
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histopathology unit at VLA (Weybridge) carried out this work. Mab M92/20 was 
identified as detecting specific antigen in lung tissue sections from CBPP affected 
animals using immunocytochemical staining; no staining was seen with the Mab in 
tissues from normal animals or those suffering other respiratory diseases. 
Immunocytohistochernistry was undertaken basically following the 
method of Rodriguez et al. (1996c). Briefly, formalin fixed lung tissue from 11 
Portuguese cows from this study were embedded in paraffin wax. Sections of 5 lim 
were dewaxed, rehydrated and endogenous peroxidase blocked. After appropriate 
pre-treatment, sections were incubated with normal calf serum to reduce non- 
specific reactions, and then incubated with the Mab M92/20. Signal amplification 
was performed using a sensitive avidin-biotin-peroxidase-complex (ABC) technique 
and immunodetection was visualised using diaminobenzidene. Sections were 
counterstained with Mayer's hematoxylin, dehydrated, cleared and mounted in DPX 
before examination by light microscopy. 
4.2.5. CULTURE 
Culture was carried out in Eaton's broth medium (section 2.2.2. ) 
containing phenol red and the following antimicrobials: 'penbritin' (ampicillin) 
(Centaur Services, UK), 0.5 mg/ml; polymixin (Sigma, UK) 500 iu/ml; thallium. 
acetate (Sigma, UK) 0.5 mg/ml; sulphadimidine (Sigma, UK) 0.5 mg/ml. Swabs or 
lung tissue were immersed in Eaton's medium and three 10 fold dilutions were made 
before incubation at 37'C in an atmosphere of 5% carbon dioxide in air (carbon 
dioxide incubator; Hereus). Isolates were identified using conventional methods 
(see Section 1.5.7.4. ) and confirmed by PCR (B ashiruddin et A, 1994b). 
4.2.6. POLYMERASE CHAIN REACTION FOR M. MYCOIDES SUBSP. 
MYCOIDES SC 
PCR was used to identify M. mycoides subsp. mycoides SC isolates (see 
Section 4.2.5. ) and to detect M. mycoides subsp. mycoides SC specific DNA in nasal 
swabs and lung tissue. Nasal swabs were taken by inserting a sterile swab wetted in 
Eaton's medium approý. 15 cm into the nasal cavity. The swab was then removed 
and swirled vigourously in a bijou containing 3 ml of Eaton's medium. 
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DNA was extracted as described by Bashiruddin (1998). Briefly, cells 
were washed twice in TNE Buffer (0.01M Tris-HCL, pH8.0,0.01M NaCl, 0.01M 
EDTA). They were resuspended in 200 pl of TNE buffer containing 10 % sodium 
dodecyl sulphate (Sigma, UK) and 10 % sarcosine (Sigma, UK); 20 RI of proteinase 
K 20 mg/ml in water (Sigma, UK) was added before incubation for 1 hour at 37"C. 
An equal volume of buffer saturated phenol (Gibco Life Sciences, UK) was added 
before centrifugation in a microcentaur centrifuge (MSE, UK) at 13,000 rpm for 5 
minutes. The aqueous phase (supernatant) was carefully removed into another 
microcentrifuge tube before addition of an equal volume of 
phenol: chloroform: isoamyl alcohol (Gibco Life Sciences, UK) and further 
centrif6gation as before. The aqueous phase (supernatant) approx 200 gl was again 
carefully removed into another microcentrifuge tube before precipitating the DNA 
by addition of 20 gl of IOM sodium acetate pH 5.5 (Sigma, UK) and 440 ýd of cold 
100 % ethanol (Sigma, UK). This was then frozen at -20'C overnight. The tubes 
containing the DNA were then centrifuged at 13,000 rpm for 5 minutes. The 
supernatant discarded and the DNA was washed in 70 % ethanol (Sigma, UK), 
followed by further centrifugation at 13,000 rpm for 5 minutes. The supernatant was 
carefully discarded and the DNA dried for one hour at room temperature before the 
addition of 100 gI of HPLC grade water to dissolve the DNA. This was then used as 
the DNA template in PCR. 
Lung tissue was frozen at -80'C within three hours of removal from the 
carcases until it was examined in the UK. Five sections of lung tissue were 
'chipped' off the frozen stored lung tissue to give small approximately 0.5 cm 3 
which were placed in a mortar with lml of TNE buffer before being macerated with 
the pestle. Two hundred gI of this suspension was washed twice in TNE buffer 
before DNA was extracted following the method described above for nasal swabs. 
The PCR used was based on oligonucleotides designed for the CAP 21 
gene fragment (Taylor et al., 1992) and specifically amplified a region of the gene 
present in strains of M. mycoides subsp. mycoides SC and LC and M. mycoides 
subsp. capri. The 534 bp amplicon was then cut using the restriction enzyme AsnI 
to specifically identify SC isolates (Bashiruddin et al., 1994b) See figure 4.1. 
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FIGURE 4.1, M. "MYCOIDES CLUSTER" PCR AND RESTRICTION ENZYME 











Figure shows M, molecular weight marker, 1,3, and 5 uncut PCR products. Lanes 2 
and 6 show M. mycoides subsp. mycoides SC following digestion with restriction 
enzyme Asn I. Lane 4 shows M. mycoides subsp. mycoides LC following digestion 
with restriction enzyme Asn 1. 
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A Southern Blot method was used to determine if the sensitivity of the 
PCR amplicon detection could be increased. The'Southem Blot was carried out 
using a P32 radiolabelled PCR product as a probe as described. The amplicon from 
the positive PCR control was run on a3% NuSieve agarose (Flowgen, UK) gel. 
The amplicon was excised from the gel, with the agarose blocks being placed in a 
microcentrifuge tube. The DNA was extracted using a sephaglass kit method 
(Pharmacia, Sweden). The DNA was quantified by mixing 5 jil of DNA with 5 ILI 
of 2 jig/ml ethidium bromide and comparing the uv fluorescence from the spot with 
standard known concentrations (Maloy et al., 1996). The DNA concentration was 
adjusted to 30 tig in 48 lil. The standard agarose gel that was run following the PCR 
from the lung tissue samples was placed in denaturing solution (8.77 % sodium 
chloride, 2.0 % sodium hydroxide) for 1 hour. This was replaced with neutralising 
solution (8.77 % sodium chloride, 6.65 % Trizma base, 0.2 % EDTA 0.5 M pH 8.0) 
for 1 hour. The gel was then placed on a plastic film (saren wrap). A piece of 
hybond N membrane cut to the size of the gel was placed on top followed by 
blotting paper and absorbent material. A heavy lead weight was added and left for 2 
days. The membrane was then removed and fixed in uv light for 4 minutes. Unless 
stated the following prehybridisation and probing steps were all carried out at 65"C. 
The membrane was rolled with a nylon support membrane and placed in 
a hybridisation tube (Hybaid, UK) and incubated for 30 minutes with 10 ml of rapid- 
hyb buffer (Amersham. life sciences, UK). The DNA for labelling was heated at 
95*C for 5 minutes and then placed on ice for 2 minutes. This was added to a tube 
of rediprime DNA labelling system (Amersharn life sciences, UK) before addition of 
2 lil Of P32 radiolabel. This was centrifuged and then incubated at 37'C for 10 
minutes followed by 95'C for 1 minute. This was centrifuged briefly before using a 
ProbeQuant G-50 Micro Column (Pharmacia, Sweden), which was briefly 
centrifuged again. This retained the unattached radiolabel in the column, leaving the 
labelled DNA in the tube, which was then placed in the hybridisation tube with the 
membrane and incubated for 2 hours. 
The membrane was then washed for 20 minutes with 100 ml of 2x SSC 
(1.75% sodium chloride, 0.88% sodium citrate, adjusted to pH 7.0) with 1% SDS, 
followed by two further washes for 15 minutes. The membrane was then removed 
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and placed on blotting paper to dry before wrapping in saren wrap and being placed 
in a film cassette with film. The film was left for 2 hours at -70*C before being 
developed. 
4.2.7. SEROLOGY 
The CFT was carried out in the serology section at VLA (Weybridge) 
using the standard method of the OIE, (1996) with antigen obtained from LNIV 
(Portugal). 
An indirect ELISA using a whole cell antigen of M. mycoides subsp. 
mycoides SC strain B103 was used to test the sera obtained. The ELISA protocol 
was similar to that described in Section 5.2.7. The antigen was prepared by washing 
cells three times in PBS and the microtitre plates were coated with antigen at a 
concentration of 1.5 jtg/mI in bicarbonate/carbonate buffer. Sera were tested at a 
dilution of I in 320. 
4.3. RESULTS 
4.3.1. OBSERVATION ON CATTLE FROM CBPP INFECTED HERDS 
PRIOR TO SLAUGHTER 
Two CBPP affected herds from a single village approximately 30 
kilometres north east of Porto (Figure 4.2), were studied. The first outbreak in the 
village was on 'farm 3'. Subsequently the 12 other herds within the village were 
closely monitored, but only one other herd, at 'farm 4' became affected. CBPP in 
the first herd was diagnosed by the CFI' and confirmed by immunoblotting (Regalla 
et al., 1996b). Nfilk production had fallen and the cows were not 'thriving', showing 
slight loss of condition with a dull coat and heads slightly lowered. They showed 
mild clinical signs with occasional coughing when moved. One case of abortion 
was reported on the farm. The cows were kept in a semi-open barn with a fenced 
concrete yard. On one side of the barn and yard was a breeze block wall which was 
shared with the neighbouring farm. The neighbouring farm, farm W, kept cows in a 
semi-open barn with the shared breeze block wall forming the back of the barn. The 
barn was covered with a loose fitting corrugated roof that had large gaps where it 
joined the shared wall. The prevailing wind during the period of investigation meant 
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that farm W was upwind of farm '3'. This farm had purchased cattle from a dealer 
at farm '5' which was situated immediately opposite the entrance to farm W. CBPP 
was not detected on farm T. 
All the results are summarised in Table 4.1. All diagnostic tests were 
conducted at VLA (Weybridge). 
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FIGURE 4.2. LOCATION OF CBPP OUTBREAKS IN BOUGADO, PORTUGAL 
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4.3.2. GROSS PATHOLOGY OFSLAUGHTERED ANIMALS 
ýL 
Twenty cows were examined. All showed gross lung lesions varying in 
siZe from 10 cm to a whole lung. Nineteen had lesions or sequestra present on only 
one of the lungs (unilateral) whilst one cow had a small sequestra on the second 
lung. The affected lungs showed chronic signs of infection with necrotic tissue 
encapsulated by fibrous connective tissue or sequestra. In two of the cows, the 
infected lungs were almost completely necrotic. Adhesions of the lung to the body 
wall were also present in some of the carcasses. 
FIGURES 4.3. CBPP GROSS PATHOLOGY OBSERVED ATPOST-MORTEM 
Acute CBPP lesion after incision. 
Hepatisation of lobules is evident with 
oedema and thickening of interlobular 
septa (IL) giving 'marbled' 
appearance. 
Chronic CBPP lesion: incision of 
sequestra. showing fibrotic capsule 
(FC) containing necrotic lung tissue 
(N). 
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4.3.3. MONOCLONAL ANTIBODIES 
The initial screening using the M. bovis ELISA and western blotting with the 
M. bovis antigen showed reactions with nine of the 19 Mabs, making them 
unsuitable for use. Some Mabs proved unsuitable for use for 
immunohistochernistry, due to failure to detect antigen, or presence of unwanted 
staining in normal lung tissue. The Mab 92/20 was selected for use in 
immunocytohistochemistry because it appeared specific in tests and gave clear 
backgrounds in normal tissue. This Mab, 92/20 is IgG1 sub class k, and gave an 
OD450 of 0.66 in the M. mycoides subsp. mycoides SC ELISA, OD450 0.08 in the M. 
bovis ELISA, but was very unusual in giving many diffuse bands with western 
blotting. It was shown to react in the latex agglutination test (see chapters 5 and 6) 
suggesting it may be raised against the capsular polysaccharide of M. mycoides 
subsp. mycoides SC. 
4.3.4. IMMUNOCYTOCIIEMISTRY 
All eleven samples of lung tissue examined by this method were 
positive. Using the specific Mab 92/20, antigen was clearly visible in tissue sections 
with minimal background staining (Figure 4.4). 
148 
FIGURE 4.4. SECTION OF LUNG FROM CBPP INFECTED ANIMAL STAINED 
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Section of lung from CBPP affected cow. Stained section shows lesion with: 
pyknotic nuclei (PN) (right); giant (epithelial) cells (GQ in middle-, normal cells 




4.3. S. CULTURE AND PCR 
The three 10-fold dilutions from each sample were examined daily for 
up to 2 weeks, unless a mycoplasma species was isolated earlier, in which case 
further examination of cultures from that cow was discontinued. Cultures showing 
bacterial contamination were filtered through a 0.45 jim filter so that approximately 
100 jil was used to seed a fresh Eaton's broth. Otherwise any observed growth was 
sub culturing into a fresh broth before being identified (see section 2.1.2. ). 
Microbial growth was observed in cultures from 15 of the 16 nasal swabs examined. 
Only six of these isolates were identified as M. mycoides subsp. mycoides SC by 
growth inhibition test (GIT) and these were confirmed using PCR. Acholeplasma 
laidlawii was isolated from one sample where no M. mycoides subsp. mycoides SC 
was recovered and was identified using specific rabbit antiserum in a GIT. The 
remaining eight cultures were of other cell-walled bacterial species. PCR carried out 
directly on nasal swabs detected M. mycoides subsp. mycoides SC in eight of the 16 
swabs; however, four of the six samples that were positive by culture were negative 
by PCR. 
Seven frozen lung tissue samples were cultured for M. mycoides subsp. 
mycoides SC and six of these were also tested by PCR. Three samples were positive 
by culture, and all were then confinned as M. mycoides subsp. mycoides SC by 
biochemical tests and GIT. The two culture positive samples tested were also 
positive by PCR. However, the direct PCR on lung tissue was also positive for three 
samples including one that was culture negative. Use of Southern blotting further 
increased the PCR detection level to include another positive, giving four out of the 
six samples as positive. 
4.3.6. SEROLOGY 
Blood was available from thirteen of the slaughtered animals. These all 
gave positive results by both ELISA and CFI7. The ELISA results were all clear 
positives with OD450 values ranging from 0.60 to 0.95 with the negative control 
giving a value of less than 0.15. The CFr gave a range of titres from 1: 10 to 1: 160. 
However, there was little correlation between the two tests indicating that the tests 
were measuring different classes of antibody. 
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Although the CFr is the standard test, there is substantial evidence that 
it fails to detect infected animals in the early sub-clinical stages of the disease (Stdrk 
et al., 1994). Therefore a more comprehensive evaluation was undertaken using 169 
samples from 6 farms where there was evidence of CBPP infection. The results are 
given in Table 4.2. 
TABLE 4.2. COMPARISON OF CFT AND IMMUNOBLOTTING TESTS FROM SIX 
CBPP AFFECTED FARMS IN PORTUGAL 
FARM NUMBER OF NUMBER OF NUMBER OF CFT 
ANIMALS IMMUNOBLOT POSITIVES 
POSITIVES 
1 55 47 29 
2 25 12 9 
3 18 17 11 
4 19 7 6 
5 15 3 0 
6 37 35 18 
These results clearly demonstrated the increased sensitivity of 
immunoblotting compared to the CFF with 121 (71.6 %) positives by 
immunoblotting compared with 73 (43.2 %) by CFI'. 
4.4. DISCUSSION 
In CBPP infections the gross lesions and sequestra, usually present on a 
single lung, are pathognomonic (Nunes Petisca et aL, 1990), although inexperienced 
workers may mistake these for acute cases of pasteurellosis, actinobacillosis and 
Echinococcus which affects both lungs. Consequently isolation of the mycoplasma 
is necessary for confirmation. Recovery of the organism by culture is dependent on 
the type of sample taken, the culturing methods and the contaminating organisms 
present. In this study the effect of the time taken to trav6l from the abattoir in 
Portugal to the laboratory in England also adversely affected the success rate of 
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culture. Similar problems may also be expected in Africa where there are large 
distances between the herd and the diagnostic laboratory. In a study on CBPP in 
Italy (Nicholas et al., 1996) only 10 isolates of M. mycoides subsp. mycoides SC 
were recovered fron 37 affected cattle. They stated that a loss of viability during 
transit, or overgrowth of the agent by contaminants including bacteria and 
acholeplasmas during culture, or suppression by antibacterial or inflammatory 
compounds may account for the low isolation rate. 
Use of serological testing is beneficial for diagnosis. However 
serological testing is not always effective. The tests used are not conclusive as false 
results do occur, either with cross-reacting antibodies or failure to detect individual 
animals at certain stages of infection. Animals that have just been exposed to 
infection or those exposed previously may go undetected. In this study, (Table 4.2. ) 
the CFIwas insensitive when compared to the immunoblotting method. However, 
when used to detect a CBPP positive herd the CFI7 may be more suitable for use as a 
screening tool as immunoblotting is costly to perform and requires specialist 
interpretation. However in farm 5, Table 4.2. no cattle were positive by CFr on that 
farm, although 3 were positive by immunoblotting. This could have serious 
implications on a CBPP erradication scheme, as the disease would go unchecked 
and cattle movements would aid the spread of disease. In Portugal, farms are 
frequently small, many with just a few cattle. In these cases the number of samples 
tested may be too small for an insensitive serological test to detect CBPP positive 
animals. This may account for the continuing survival of CBPP in Portugal, 
although all cattle on a small farm can be tested in comparison with just a percentage 
of cattle on a larger farm. It is therefore essential to utilise different methods for 
confirming disease diagnosis. 
PCR was used successfully for confim-ýing the identification of isolates 
in this study. However, PCR was not totally effective in the detection of M. 
mycoides subsp. mycoides SC DNA, detecting only half of nasal swabs and lung 
tissue of infected animals. This failure of PCR to detect M. mycoides subsp. 
mycoides SC DNA may be related to the sensitivity of the PCR, the DNA extraction 
methods and PCR amplicon detection methods. The use of Southern blotting 
detection in this study increased the detection of amplicons and therefore the 
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sensitivity of the PCR. However, PCR was still not totally effective which may be 
due to the intermittent excretion of M. mycoides subsp. mycoides SC from the nasal 
passages, and the correct selection of a region of affected lung tissue where M. 
mycoides subsp. mycoides SC could be detected; other unknown inhibitory factors 
may affect the PCR. Verdin et al., (2000) using a PCR detection system for M. 
hyopneumoniae reported that heme, heparin, polysaccharides and highly 
glycosylated molecules such as those found in mucus are known to inhibit PCRs. 
Isolation and identification of M. mycoides subsp. mycoides SC provides 
definitive evidence that animals are infected, as serological tests may give false 
positive results and gross pathology may be ambiguous. In the event of an outbreak 
in the UK the control authorities would only slaughter if the mycoplasma was 
isolated. Consequently the need to improve cultural techniques is paramount. This 
study demonstrates the inadequacy of cultural and even PCR methods as only 39 % 
of nasal swabs were positive on culture, rising to 50 % using PCR. This also 
demonstrates the increased sensitivity and potential use of PCR in comparison with 
culture. However, results of culture and PCR detection may be improved by 
identifying regions of affected lung that may have increased concentrations of the 
target organism. In addition, developments are needed in sample handling and in 
the design of transport and culture medium that may include selective inhibitors to 
improve isolation and detection rates. 
Histology and, to an increasing extent, ICC is used to confinn the 
diagnosis of CBPP particularly where the causative organism, M. mycoides subsp. 
mycoides SC, is not recoverable, where the animal has died of an acute disease, or 
when serology is not possible or unclear (Ferronha et al., 1988; and Scanziani et al., 
1991). However the sensitivity of ICC using polyclonal serum can be low and non- 
specific results frequently occur (Nicholas and Bashiruddin, 1995). However, Di 
Francesco' et al. (1996) showed good agreement between CFr, culture and 
pathology on 11 CBPP positive samples from Italy. The use of Mabs has helped to 
overcome these problems. 
In this study, all 11 affected lungs examined by ICC using Mab M92/20 
were positive for CBPP, whereas M. mycoides subsp. mycoides SC was isolated 
from primary culture in only four of those eleven cases and specific PCR amplicons 
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were detected in five. Thus, ICC successfully identified the presence of the 
mycoplasma in these cattle, confirming the gross pathology, CFr, immunoblotting 
and ELISA results. The main disadvantage with ICC is that the animal is already 
dead, although few tests are effective once an animal is dead. 
Differences in virulence between African and European isolates of M. 
mycoides subsp. mycoides SC have been reported (Provost et al., 1987) and 
morbidity and mortality are lower in European than in African disease outbreaks 
(Nicholas et al., 1996). The difficulty in reproducing disease in experimental 
infections with European M. mycoides subsp. mycoides SC strains (Abdo et al., 
1998; Pini et al., 1999) may also indicate a reduced virulence compared to African 
strains. However the pathological lesions caused during natural outbreaks in both 
Africa and Europe are identical and follow a similar pattern: during new outbreaks, 
many cattle show acute and sub acute lesions while chronic lesions and sequestra, 
predominate in later outbreaks. The striking difference is the almost complete lack 
of mortality and obvious morbidity seen in European outbreaks which must be due 
in part to improved husbandry and better health of the cattle (Nicholas and Palmer, 
1994). 
In this study all serological tests were effective when used on the 
samples from the abbatoir, mainly because of the advanced progression of the 
disease in the herd. However, when used on the farm samples, serological tests 
were insensitive with the CFI' detecting 48/169 (28 %) fewer positive samples than 
immunoblotting. A test such as the CF17, which is known to be only 70 % sensitive 
in the early and later stage of the disease, will fail to detect partially affected herds, 
as seen in Table 4.2. A very sensitive primary screening test, which unavoidably 
produces false positive results, backed up by a highly specific test such as 
immunoblotting is required to ensure detection of all affected herds. In Africa, a 
third test, which can be performed 'at the penside' is also required. Development 
and evaluation of such a test is described in Chapters 5 and 6. 
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CHAPTER 5 
5.1. DEVELOPMENT OF A LATEX AGGLUTINATION TEST FOR CBPP 
5.1.1. INTRODUCTION 
Nficrosphere or latex agglutination tests (LAT) have been used since 
1956 when a rheumatoid factor test was developed (Singer and Plotz, 1956). In 
these tests polystyrene microspheres are used for the solid support of either antigen 
or antibody which are adsorbed onto them. These 'sensitised' microspheres act to 
amplify any antigen/antibody reaction that occurs, causing clumping of the 
microspheres in a positive test, which can be seen by eye. LAT's are portable, rapid, 
and efficient, and can be used in even the most primitive conditions, providing a 
diagnostic result within 2 minutes of starting the test. 
Currently most LAT's use 0.2 - 1.0 ttrn diameter microspheres. It is 
thought that the larger the microsphere the more sensitive the test, based on 
assumptions about the number of clumps and therefore bonding required to be seen 
by eye. Theoretical sensitivity of a 1.0 Itm diameter microsplieres has been 
calculated to be as low as 10 pM (Bangs, 1996). In practice Tilton (1987) 
determined levels of bacterial polysaccharides detected by antibody coated 
microspheres were as low as 0.1 ng/ml. 
Antigen or antibody can be used to coat the latex particles, whi ch can be 
achieved by passive or physical methods. Passive methods utilise the hydrophobic 
properties of of the latex particles, which absorb proteins strongly and irreversibly, 
via the hydrophobic domains in the proteins, which may be affected by pH. 
However, covalent attachment may be required for small molecules with weak 
adsorption characteristics (Bangs, 1996). 
The number of applications of the LAT has increased dramatically in 
recent years, mainly due to the development of specific Mabs and purified antigen 
extracts. These include more than 100 infectious diseases covering, bacterial, viral, 
fungal and protozoan infections, such as leprosy, cholera, brucellellosis, HIV, 
rinderpest, aspergillosis, and amoebiasis. Other LATs have been developed to 
detect chemical analytes, such as used in detection of drug abuse and antimicrobials 
in milk (Bangs, 1996). 
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Rurangirwa et al. (1987b) developed a LAT for field diagnosis of 
contagious caprine pneumonia caused by M. capricolum subsp. capripneumoniae. 
In this test mixed polysaccharides extracted from the mycoplasma culture 
supernatants were adsorbed onto 1.08 1trn latex beads (Sigma Chemicals). The 
mixed polysaccharide consisted of glucose, galactose, mannose, fucose, 
glucosamine and galactosamine. One ml of latex beads was mixed with I mg 
polysaccharide in 1 ml phosphate buffered saline pH 7.4, containing 0.2 % sodium 
ethylene diamine tetra-acetate and 0.01 % sodium azide. This mixture was shaken 
and incubated at 37'C for I hour and 8ml of the same buffer added. LAT was 
carried out using 10 jil volumes of serum and latex beads. 
M. capricolum subsp. capripneumoniae is a member of the M. mycoides 
cluster and is therefore closely related to M. mycoides subsp. mycoides SC. This 
suggests that it might be possible to use a M. mycoides subsp. mycoides SC 
polysaccharide extract in the development of a test to detect CBPP. However, there 
are conflicting reports as to the antigenic activity of polysaccharides from M. 
mycoides subsp. mycoides SC. 
Kurotchkin (1937) first reported the isolation of a specific carbohydrate 
substance from M. mycoides subsp. mycoides SC. He also determined that large 
quantities of that carbohydrate were present in the culture medium and in the blood 
of animals severely affected by CBPP. Buttery and Plackett (1960) analysed 
carbohydrates from M. mycoides subsp. mycoides SC strains. They found 
carbohydrates accounted for approximately 10% of the dry cell weight and galactan 
was the main product obtained by extraction with warm aqueous phenol. When 
hydrolysed by acid it released galactose and approximately 4% of a soluble lipid. 
They thought the substances were probably haptens (small non-protein parts of 
certain antigen molecules that carry the chemical group that combine specifically 
with an antibody rather than complete antigens), as they observed no antibody 
responses after injecting galactan into experimental animals. Further analysis by 
Plackett and Buttery (1964) identified the structure to be consistant with. 6-0-0-D- 
galactofuranosyl-D-galactose. 
The ability of the polysaccharide to be used as an antigen in diagnostic 
tests has given conflicting results. The original carbohydrate extract from 
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Kurotchkin (1937) was active in precipitin tests but did not fix complement with 
bovine antisera. Dafaala (1957,1959) separated two polysaccharide antigenic 
fractions, 'A' and 'B'. Fraction 'A' was found in cells, culture supernatant, 
exudates and blood of moribund animals and was similar to that obtained by 
Kurotchkin in that it did not fix complement. Fraction '13' was found attached to 
cells only, and was active in both precipitin and complement fixation tests. White 
(1958) used immunodiffusion tests to demonstrate the presence of three soluble 
antigens in extracts of M. mycoides and in material from lesions and exudates. 
These three antigens may be similar to those obtained by Yoshida (1961) who 
fractionated M. mycoides cells into protein, carbohydrate and lipid. He found the 
lipid factions contained complement-fixing antigens, whereas the protein and 
carbohydrate did not. From this it appears that the pure polysaccharide extract 
cannot fix complement but displays some antigenicity in precipitin tests. 
Interestingly, Knight and Cowan (1961) prepared an antigen by the method of 
Dafaala and found it did not fix complement unless a heat labile factor present in 
normal bovine sera was added. It appears that the method of preparation, the purity 
of the polysaccharide extract, and the test used is an important factor in determining 
the usefulness of M. mycoides subsp. mycoides SC specific polysaccharides in 
diagnostic tests. March et al., (1999) analysed the capsular polysaccharides of M. 
mycoides subsp. mycoides SC and concluded it comprised of mannose, glucose, 
galactose, fucose, glucosamine and galactosamine sugars. However, this 
contradicted previous findings by other workers. 
There is an urgent need for a rapid field test for detecting CBPP, 
particularly for use in Africa where nomadic movements of cattle and large 
distances make laboratory testing impracticable. The current CFT (Campbell and 
Turner, 1953) is the recognised antibody detection test and is laborious and needs to 
be carried out in a laboratory. Slide agglutination tests have been developed for 
CBPP (Peffeau, 1963; Priestly, 195 1; Turner and Etheridge, 1963) and are used with 
either serum or whole blood. However, they are only useful on a herd basis as they 
give false positives at low serum dilution and are reliable only early in infection 
(Rurangirwa, 1995). Thus, work to develop a LAT was undertaken. The antigen 
used in development of the test was a carbohydrate extract, as that was successfully 
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used by Rurangirwa et al. (1987b) in the development of a field test for CCPP. 
However, it was recognised that there were conflicting reports as to the antigenicity 
of carbohydrate extracts from SC strains. 
5.2. MATERIALS AND METHODS 
5.2.1. MEDIA 
Except when stated Eaton's medium was used (see Section 2.2.2. ). 
Carbohydrate production in this medium was also compared with that in PRM 
medium (Rice et A, 2000). The composition of PRM medium is: special peptone 
L-72 (Oxoid) 20.0 g/l; yeast extract (Oxoid) 5 g/l; fresh yeast extract 100 cm3/1; 
glucose 5.0 g/l; pyruvate 2.0 g1l; glycerol 5.0 g/I; sodium chloride 5.0 g/l; IHEPES 9 
g/l; and 100 ml of heat activated porcine serum. 
5.2.2. ORIGIN AND GROWTH OF M. MYCOIDES SUBSP. MYCOIDES SC 
USED FOR ANTIGEN PRODUCTION 
The strain of M. mycoides subsp. mycoides SC used was B103 that was 
isolated from cattle lung in Portugal. Houshaymi et al. (1997) characterised it as a 
European strain by its ability to oxidise glucose but not glycerol. Cultures were 
initially grown in a3 ml volume of medium before increasing stepwise to 10 in], 100 
ml and finally I litre. The inoculum size was one tenth of the medium volume. All 
cultures were incubated for 72 hours at 37'C in an atmosphere of 5% C02 in air. 
S. 2.3. TEST ANIMAL SERA USED IN THE DEVELOPMENT OF THE 
LATEX AGGLUTINATION TEST 
A positive control serum (ref 0133) was produced at VLA (Weybridge) 
by inoculation of a cow with heat killed M. mycoides subsp. mycoides SC (strain 
Afad6). The inoculurn at approximately I mg/ml was initially mixed 1: 1 with 
Freund's complete adjuvant and subsequently with Freund's incomplete adjuvant. 
An Aberdeen Angus steer was inoculated with I ml of inoculum, sub-cutaneously 
across the rib cage at 6 weekly intervals, alternating between the left and right side 
of the ribs. Ideally the inoculurn was given in four sites, however, if the animal was 
agitated this was reduced to three. A total of ten inoculations were given, and blood 
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samples were taken and tested by CFT 21 days post each inoculation. The 
maximum CFr titre of 1/40 was reached at 211 days post initial inoculation and was 
maintained until post-mortern at day 440. 
A CBPP positive control serum (ref 845), from a naturally infected 
animal, was obtained from J. Regalla, LNIV, Lisbon. A standard negative serum 
and a positive M. bovis serum, used as controls for the routine M. bovis ELISA test, 
acted as negative controls. 
In addition known CBPP negative field sera were obtained from 
British and Irish samples submitted routinely for M. bovis ELISA testing at VLA 
(Weybridge); Britain and Ireland have been free from CBPP for 100 years. 
5.2.4. PREPARATION OF CARBOHYDRATE EXTRACT 
The method of Rurangirwa et al. (1987b) was used with only minor 
modifications. In the first extraction, only the supernatant of a culture was used as 
these authors stated it to contain ten times more carbohydrate than cells; the 
supernatant from a one litre culture was adjusted to pH 5.0 with glacial acetic acid, 
boiled for one hour and filtered through Whatman paper. Two volumes of ethyl 
alcohol were added to the filtrate. This mixture was kept at 4"C overnight and the 
next day the precipitate was collected by centrifugation at 1000 g for 15 minutes. 
The precipitate was suspended in 20 ml distilled water (HPLC grade) and mixed at 
room temperature for 2 hours. The mixture was centrifuged at 3000 g for 30 
minutes, the sediment discarded and the carbohydrate extracted by adding an equal 
volume of aqueous phenol (6 g phenol plus 1 ml of BPLC grade distilled water); the 
mixture was incubated for I hour at 68'C. After holding the mixture overnight at 
4'C, it was centrifuged at 3000 g for 30 minutes. The aqueous layer was separated 
and run through a PDIO column (Pharmacia, Uppsala, Sweden) with HPLC grade 
distilled water (this replaced the dialysis steps used by Rurangirwa et al. (1987b). 
Two volumes of ethyl alcohol were added to the PD10 column void to precipitate 
the carbohydrate. The precipitate was mixed thoroughly, kept at 4C overnight and 
then collected by centrifugation at 1000 g for 15 minutes. The precipitate was 
dissolved in 2 ml of BPLC grade distilled water, and run through the PDIO column 
as before. The precipitation and PD10 column step was repeated again before 
Iyophilising the sample. The sample was resuspended in 2 ml of PBS (pH 7.2). To 
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separate the carbohydrates by size the sample was filtered through a column packed 
with BioSep Sec 3000,60 x 2.1 cm, 230 ml volume (Phenomenex, UK), using an 
M45 HPLC/low pressure system (Waters, UK). The buffer used was PBS pH 7.2 
with a flow rate of 4 ml/minute. From the first extraction 31 (4 in]) fractions were 
collected, pooled into five groups and concentrated by ethanol precipitation. 
The following polysaccharide extractions were carried out: three from 
Eaton's medium following cell growth; one from cells grown in Eaton's medium; 
one from just Eaton's medium; one from PRM medium following cell growth; and 
one from cells grown in PRM medium. In these fractionations, the fractions were 
not pooled. In addition, where stated, the starting material for carbohydrate 
extraction was whole cells and not culture supernatant. Cells were separated by 
centrifugation from 1 litre of Eaton's broth after 72 hours incubation. The cells were 
washed twice and resuspended in 20 mls of PBS. Carbohydrates extracts were then 
carried out as described above. 
5.2.5. BINDING OF POLYSACCHARIDE EXTRACT TO LATEX BEADS 
Antigen was bound to latex beads (1.08gm, Sigma Chemicals, Poole, 
UK) by the method of Rurangirwa et al. (1987b). One ml of the latex beads (10% 
v/v suspension) were mixed with 1 mg of polysaccharide extract in I ml phosphate 
buffered saline, pH 7.4, containing 0.2 % sodium ethylene diamine tetra-acetate 
(Sigma Chemicals) and 0.01 % sodium azide (Sigma Chemicals). The mixture was 
shaken and incubated for one hour at 37'C and eight ml of the same buffer added. 
Where stated, latex beads coated with antigen were incubated with 
proteinase K (Sigma Chemicals) at 20 mg/ml for 2 hours at 37'C. 
5.2.6. SDS PAGE AND IMMUNOBLOTTING 
Samples were run on a 12 % SDS PAGE using the standard technique of 
Laemmli (1970). The gels were stained using a Sigma silver staining kit exactly 
according to the manufacturer instructions. This method is more sensitive than 
Coomassie blue staining and stains both carbohydrates and proteins (Ochs et al., 
1981). Following SDS PAGE, gels were transferred to a nitrocellulose membrane 
using a semi-dry blotting system ('Transblot', Bio-Rad Laboratories, Hemel 
Hempstead, UK) for western blotting (Towbin et al, 1979). Control samples 
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containing molecular weight markers and a strip 6f both antigens were stained with 
the protein dye, amido black (Sigma Chemicals, Poole, UK) exactly following the 
manufacturer's instructions. The remaining membrane was cut into strips and 
blocked with PBS pH 7.2 containing 3% w/v dried milk powder (Marvel) and 0.05 
% v/v Tween 80 for 30 minutes at 37C. The strips were then incubated with the 
positive CBPP antiserum, ref 845, for 60 minutes at 37'C; washed four times with 5 
ml of PBS Tween; incubated with anti-6i%--m- polyvalent immunoglobulin labelled 
with alkaline phosphatase conjugate for 60 minutes at 37'C (Sigma Chemicals, 
Poole, UK); washed four times in PBS as before; and incubated at room 
temperature with 1 ml of the substrate 5 bromo-4-chloro-3-indoyl- 
phosphate/nitroblue tetrazolium. (BCIP/NBT, Kirkegaard and Perry Laboratories, 
Maryland, USA). After sufficient colour had developed in the control samples, 
which took approximately 15 minutes the reaction was stopped by washing the strips 
in water. 
S. 2.7. ELISA OF CARBOHYDRATE EXTRACTS 
The five pools obtained from the first carbohydrate extraction of culture 
supernatant were diluted 1 in 5 with carbonate/bicarbonate buffer (Sigma 
Chemicals) and 100 gI per well was used to coat a portion of a microtitre plate. 
Control wells were included that contained M. mycoides subsp. mycoides SC strain 
B103 whole cells, which had been washed three times in PBS, and were diluted to 
1.5 ug/ml in carbonate/bicarbonate buffer. The microtitre plate was incubated at 
4'C overnight. An indirect ELISA was performed with positive CBPP serum, 
negative CBPP serum and a potentially cross-reacting M. bovis positive/CBPP 
negative serum. Briefly, the coated plate was washed four times in a PBS solution 
containing 10 % milk powder and 0.5 % Tween 80. The sera were diluted 1/320 
with the same buffer, and 100 gI quantities were placed in the appropriate wells and 
incubated for one hour at 37'C. The plate was washed as before, and 100 gl per 
well of a 1/4,000 dilution of IgG anti-cow horseradish peroxidase (DAKO, 
Denmark) specific conjugate were added. The plate was incubated for another hour 
at 37C before washing and addition of 100 g] per well of 3,3', 5,5'- 
tetramethylbenzidine (TMB) substrate (Vetoquinol, UK). The reaction was stopped 
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when sufficient colour had developed (approximately OD450 1.0) by adding 50 gI 
per well of 1M citric acid. The specific OD450 for each well was measured using a 
plate reader (Labsystem, Basingstoke) 
5.2.8. LATEX AGGLUTINATION TEST 
Ten gl of latex beads with bound polysaccharide antigen were mixed 
with 10 gI of serum on a microscope slide and shaken for up to two minutes. 
Samples causing visible agglutination against a dark background were recorded as 
positive. Where stated sera were diluted 1 in 5 in PBS. 
5.2.9. ANALYSIS OF CELL EXTRACTS 
S. 2.9.1. TOTAL PROTEINAND CARBOHYDRATE 
Protein estimations on the carbohydrate extracts were carried out using a 
BCA protein estimation kit (Pierce, UK); this test is based on the Lowry method 
(Lowry et al., 1951) and uses BSA as a standard. Carbohydrate estimations were 
made using the colorimetric phenol-sulphuric acid assay (Chaplin, 1994). Galactose 
was used to obtain a curve of absorbance (490 nm) against carbohydrate 
concentration. 
S. 2.9.2. THIN LAYER CHROMA TOGRAPHY 
Thin layer chromatography (TLQ was perfon-ned using the method of 
Chaplin (1994). Control carbohydrates glucose, galactose, mannose, fucose, 
glucosamine and galactosarnine; (Sigma Chemicals) were run with the test sample at 
a concentration of 8 jig. For the test sample the concentration had to be doubled. 
The test carbohydrate extracts were hydrolysed by suspending 5 ing in bijoux bottles 
containing one ml of 4N trifluoroacetic acid (Sigma Chemicals) and heated in an 
oven for two hours at 120'C. After cooling the samples were centrifuged at 3000 g 
for 20 minutes to free acid-insoluble residues from the suspension. The supernatant 
was then diluted with 4 ml of distilled water before being frozen and Iyophilised and 
then resuspended, frozen and Iyophilised again. The product was finally dissolved 
in 0.1 ml of distilled water for TLC analysis. 
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TLC analysis was carried out using Silica gel plates (Sigma Chemicals, 
UK). Samples were loaded 1.5 cm. from the base of each plate at 1.5 cm. intervals by 
repeatedly pipetting 2 Itl volumes onto the plate and drying immediately with a hair 
drier so that dispersal was minimised. A total of 8 lil of the known sugar samples 
and 16 lil of hydrolysed extracts were loaded. Once dry, plates were placed in a 
equilibrated tank containing the buffer: butanol: pyridine: O. lM HCI in the ratio of 
50: 30: 20 respectively. The TLC plates were run until the solvent front had migrated 
approximately 17 cm, which took approximately 4 hours. The plates were removed 
and allowed to dry in air before being developed. Plates were developed by 
spraying with either ninhydrin (Sigma Chemicals) or orcinol (Sigma Chemicals), 
following the manufacturer's instructions, allowed to dry in air before being heated 
at 1 10'C for 10 minutes to allow the colour to develop. Rf values were calculated 
using the Sigma guide and then adjusted to the Rglucose value by dividing the Rf value 
by that obtained for glucose so that the Rf for glucose equals 1.0. 
5.2.9.3. QUANTITATIVE ANALYSIS OF CARBOHYDRATES 
Identification of the sugars present in cell carbohydrate extracts was 
carried out by BioMed Labs (Newcastle upon Tyne, UK), who specialise in 
glycoanalysis. Briefly, in their analysis monosaccharides were released by 
trifluoroacetic acid hydrolysis, separated using anion-exchange chromatography, and 
detected by a pulsed amperometric detection of the peaks in a Dionex Carbohydrate 
Analyser. The instrument was calibrated using a standard monosaccharide mixture. 
Measurement of sialic acids was also undertaken on one sample. This 
sample was initially hydrolysed (by BioMed Labs) under milder conditions than 
required for neutral sugars. Following release of sialic acids, the concentration of 
trifluoroacetic acid was increased. Sialic acids were determined using the Dionex 
system, as described for neutral sugars, but with different chromatographic 
conditions. The reports are attached in Appendix 3. 
Details of samples analysed by BioMcd Labs are given in Table 5.1. 
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TABLE 5.1. DETAILS OF SAMPLES ANALYSED BY BIOMED LABS 
Sample Number Description 
given by BioMed Labs 
Analysis required 
98/01 2 ud carbohydrate CBPP media extract Monosaccharide 
not preserved with sodium azide 
VLOI Carbohydrate extract from media only Monosaccharide 
VL02 Carbohydrate extract from cells Monosaccharide 
VL03 I" carbohydrate CBPP media extract Monosaccharide 
preserved with sodium azide 
VL04 2 nd carbohydrate CBPP media extract Sialic acid 
Same as 98/01 not preserved with sodium azide 
5.3. RESULTS 
S. 3.1. EXTRACTION AND FRACTIONATION OF CARBOHYDRATE 
ANTIGEN 
Carbohydrate extracts were prepared from: the supernatant of cultures 
grown in Eaton's medium; Eaton's medium only; cells grown in Eaton's medium; 
the supernatant of cultures grown in PRM medium; PRM medium only; cells grown 
in PRM medium. Extracts were prepared and purified as described in methods 
(Section 5.2.4. ). The aim was to identify the carbohydrates present in M. mycoides 
subsp. mycoides SC cells, and those secreted into the medium. Analysis of the 
medium had to be undertaken as medium contains carbohydrates. 
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5.3.1.1. FRACTIONATION OF THE ANTIGEN FROM CULTURE 
SUPERNATANT 
The carbohydrate extract from 1 litre of culture supernatant was applied 
to a Biosep Sec 3000 column and eluted with PBS pH 7.2 at a flow rate of 4 ml per 
second. Thirty-three fractions were collected. The OD280 of fractions is given in 
Figure 5.1. 
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FIGURE 5.1. THE ABSORBANCE OF FRACTIONS FOR A CARBOHYDRATE 
EXTRACT OF M. MYCOIDES SUBSP. MYCOIDES SC CULTURE 
SUPERNATANT COMPARED TO THOSE OBTAINED FROM EATON'S AND PRM 
MEDIUM ONLY 
COLUMN VOID EXTRACTS 
50- 
45- - Eaton's media growth 
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Graph shows OD28o readings for fractions collected from BioSep column. The 
samples shown compare fractions collected from Eaton's medium only, PRM 
medium only and Eaton's medium, which has grown M. mycoides subsp. mycoides 
SC cells. The circled area comprises the fractions included in Pool 1, which was 
used for the LAT. 
The fractions were collected and pooled into five groups. Pool 1 is 
circled in figure 5.1. This small peak from collection tubes 8 to 12 was present in 
all extracts from Eaton's medium which had been used to grow M. mycoides subsp. 
mycoides SC cells. 
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5.3.1.2. FRACTIONATION OF THEANTIGEN FROM WHOLE CELLS 
Mycoplasma mycoides subsp. mycoides SC strain B103 was grown for 
72 hours in both Eaton's medium and PRM medium. The carbohydrate was 
extracted as described in section 5.2.4. The column void extracts OD's are given in 
Figure 5.2. and compared to that of the extract from Eaton's medium following 
growth. 
FIGURE 5.2. THE ABSORBANCE OF FRACTIONS FOLLOWING 
CARBOHYDRATE EXTRACT FROM CELLS COMPARED TO EATON'S MEDIUM 
FOLLOWING M. MYCOIDES SUBSP. MYCOIDES SC GROWT11 
COLUMN VOID EXTRACTS 
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Figure 5.2. Graph shows 0132so readings for fractions collected from BioSep column 
which shows a clear difference in the fractions collected from carbohydrates 
extracted from cells and those collected from Eaton's medium which had supported 
M. mycoides subsp. mycoides SC growth. The fractions used for the LAT, tubes 8- 
12 are not present in cell extracts. 
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Eaton's medium on. its own gave a similar profile without the early peak 
in the circled area. Extracts from cells grown in Eaton's or PRM medium gave large 
additional peaks over collection tubes 12 to 14 and an increased peak for collection 
tubes 22 to 25, but lacked the earlier peak at tubes 8 to 12. 
5.3.2. PROTEIN CONTAMINATION OF CARBOHYDRATE EXTRACTS 
The five pools obtained from the fractionation of the culture 
supernatants were assayed for protein content, which gave concentrations of less 
than 0.1 mg/ml. Sufficient SDS PAGE gels were run on these pooled fractions to 
provide duplicate gels for coomassie blue staining, silver staining and western 
blotting. These gels when stained, using a silver stain showed a small number of 
relatively faint bands compared to whole cell profiles. Pool I and 2 gave a similar 
band at approximately 65 kDa, and Pools 3 and 4a double band at approximately 25 
kDa; pool 5 gave no bands at all. Western blotting using CBPP positive serum (ref 
845) gave no detectable bands. Following digestion with proteinase K, the protein 
content of individual pooled fractions were in all cases too small to detect, and no 
bands were visible on SDS PAGE gels stained with the silver stain (Sigma 
Chemicals, see section 5.2.6. ). 
168 
FIGURE 5.3. SDS PAGE OF POOLED EXTRACTS AND WHOLE CELLS 
I 










Lane I MWt; Lane 2, Whole M mycoides subsp. mycoides SC cells (-10 pg); Lane 
3, Pool 1; Lane 4, Pool 2; Lane 5, Pool 3; Lane 6, Pool 4; Lane 7, Pool 5; Lane 8, 
mWt. 
5.3.3. IDENTIFICA TION OF ANTIGEN IN CARBOHYDRA TE FRACTIONS 
USING ELISA 
The ELISA was used to determine if antigenic factions were present in 
the carbohydrate extracts. From the first extraction the ELISA results showed that 
all the pools gave some reaction with CBPP positive serum although none were as 
good as whole cells. All were negative with negative serum, but all reacted to sorne 
extent with M bovis positive serum; for the cell extracts the biggest difference 
between ELISA results for control positive and negative sera was observed with 
Pool I (see Table 5.2. ). These results indicated it would probably be best to use 
Pool I for the development of the LAT. This was in accord with the evidence 
169 
obtained from the fractionation of cells and supernatants that showed that this pool 
was eluted with carbohydrates derived from cells rather than medium constituents. 
TABLE 5.2. DETERMINATION OF ANTIGENICITY IN POOLED 
CARBOHYDRATE EXTRACTS USING Tl1E ELISA 
1. 2. 3. 
Positive* Negative" M. bovis +ve Ratio of columns 
serum serum serum 1 :3 
Pool 1 0.41 0.06 0.31 1: 0.76 
Pool 2 0.30 0.02 0.25 1: 0.83 
Pool 3 0.26 0.02 0.21 1: 0.81 
Pool 4 0.14 0.00 0.21 1 : 1.50 
Pool 5 0.16 0.03 0.29 1 : 1.81 
Whole cells 1.02 0.10 0.44 1: 0.43 
CBPP positive serum from Portugal (ref. 845) 
** Negative serum from Great Britain (ref. M. bovis ELISA negative control serum). 
S. 3.4. LA TEX A GGL UTINA TION TE, ST 
Latex beads were coated with antigen (polysaccharide) as described in 
methods (section 5.2.5. ). The antigen preparations used were all from Eaton's 
medium following M. mycoides subsp. mycoides SC growth. The first extract was 
used for all the evaluation work described in Chapter 6. The qualitative tests used 
CBPP positive, M. bovis positive and negative sera. Some cross-reactions were seen 
initially with some of the M. bovis positive field sera, but by diluting the bead 
concentration from 10 % to I% v/v, CBPP positive and negative sera were 
differentiated (Figure'5.4). However during the subsequent testing of 30 known 
negative sera, a batch of 20 sera from Ireland (CBPP free) gave 8 positive reactions. 
The sera remained positive after heat inactivation at 56*C for 30 minutes. By 
diluting I in 5 with PBS these sera became negative while positive controls 
remained positive. Therefore the test was modified to use a 1% v/v bead suspension 
with serum diluted 1 in 5 with PBS. Further evaluation of this test is described in 
Chapter 6. 
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FIGURE 5.4. LATEX AGGLUTINATION TEST WITH CBPP AND Al BOVIS 
POSITIVE SERUMAND NEGATIVE SERUM 
I1 1' 1" \/' 
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The figure shows a microscope slide (magnified approx. x 1.5) 2 minutes after the 
mixing of I in 5 diluted serum with I% v/v latex beads containing A/f mycoitles 
subsp. mycoides SC specific antigen. Agglutination is observed with serum From all 
animal with CBPP (Portugal, serum rer. 845). No reaction is seen with IJK ('131,11 
negative serum or of the serum from an animal with a M. bovis itirection. 
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S. 3.5. ANALYSIS OF CARBOHYDRATE EXTRACTS 
The carbohydrate extract prepared from the supematant of M. mycoides 
subsp. mycoides SC cultures from Eaton's medium was analysed for contaminating 
protein and carbohydrate components. The protein content was less than 0.1 mg/ml. 
The composition of the carbohydrate extract was investigated by TLC and by 
Dionex. carbohydrate analysis. TLC suggested the presence of three sugars that ran 
at Rglucose values of. 1.10,0.77,0.55 (see Table 5.3). 
S. 3. S. 1. ANALYSIS OF EXTRACTS: TLC 
TLC was carried out on the pooled carbohydrate extracts (pool 1) four 
times in all. Plates were developed using ninhydrin or orcinol. With the ninhydrin 
stain, all spots were blue in colour, however the test sample and the glucosamine 
were pale in comparison to the other samples. With the orcinol stain, most of the 
spots were a pinkish colour, with the glucosamine being more intense, red. The 
colour differentiation expected with the orcinol stain, as described by Chaplin 
(1994), where glucose was stained violet; galactose and mannose, blue; fucose pink; 
glucosamine and galactosamine, grey was not observed. 
The Rgl,,,,,,, values were calculated for the known and unknown samples 
and is given in Table 5.3. 
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TABLE 5.3. TLC ANALYSIS OF HYDROLYSED CARBOHYDRATE 
EXTRACTS FROM CULTURE SUPERNATANTS 
Carbohydrate 
Mean Rgl,,,,,,,. values calculated from 
duplicate TLC plates 
Actual values in brackets 
(i. e. adjusted for Glucose 1) 
Rgiu, o,. values 
(Chaplin, 1994) 
Glucose 1.00 1.00 
Mannose 1.07 1.13 
(1.07; 1.07) 
Galactose 0.95 0.89 
(0.94,0.95) 
Fucose 1.12 1.34 
(1.11; 1.12) 
Glucosamine 0.75 0.72 
(0.70,0.80) 
Galactosarnine ND 0.55 




The TLC and calculated Rgj, ýc., e values indicated that three carbohydrates 
were present in the carbohydrate extract. The values obtained indicated that 
mannose or fucose may be present as Rgl,, cs. values obtained for them were 1.07 and 
1.12 respectively compared with 1.10 for the test sample. A second test value of 
0.77 compared with glucosamine at 0.75 and the third value of 0.55 did not match 
with any controls on this plate. Comparison with data obtained by Chaplin (1994) 
using the same method would suggest that galactosamine may also be present. 
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5.3.5.2. ANALYSIS OF EXTRACTS: DIONEX CARBOHYDRATE 
ANALYSER 
Dionex carbohydrate analysis was performed (by BioMed Labs) on four 
carbohydrate extracts: 
(i). an extract from the supernatant of a culture grown in Eaton's medium 
(ii). an extract from the supernatant of a culture grown in Eaton's medium, 
but containing the preservative sodium azide. 
(iii). a cell extract from cells grown in Eaton's medium. 
(iv). an extract from uninoculated Eaton's medium. 
Sialic acid analysis was also performed (by BioMed Labs) on the 
supernatant of a culture grown in Eaton's medium, sample (i) above. 
Six different sugars were detected in one of the carbohydrate extract 
samples (see Table 5.4). These were: fucose, galactose, 'glucose, N-acetyl- 
galactosamine, N-acetyl-glucosamine and mannose. Importantly, the uninoculated 
medium contained carbohydrate, with the predominant sugars being: N-acetyl- 
galactosamine and mannose (29.0 and 34.1 % respectively). The extract from whole 
cells contained predominantly galactose. This was expected as galactose has been 
reported to be the major sugar >90 % (Plackett and Buttery, 1964) of the cell 
capsule. Glucose and fucose were also detected at 13.0 and 10.0 % of total sugars 
respectively. Glucose has been reported to contribute up to 10 % of the mass of the 
capsule of M. mycoides subsp. mycoides SC strain V5. However the finding of 
fucose was unexpected. Some fucose may be expected to be present due to 
contamination with carbohydrate material present in the medium; however, the % of 
fucose in the whole cell extract (10.0 %) was greater than that for the extract from 
the fraction from uninoculated medium (6.8 %). The low levels of N-acetyl- 
glucosamine and mannose (1.6 and 1.9 %) detected in the cell extract are, however, 
probably due to contamination from medium carbohydrates. 
The extracts from the supernatant of a culture grown in Eaton's medium 
contained predominantly galactose (83.2 %). N-acetyl-galactosamine and fucose 
were also present at 11.4 and 5.4 % respectively. These may be contaminants from 
the medium as they were found to be present at 14.7 and 6.8 % respectively in the 
uninoculated Eaton's medium; N-acetyl-galactosamine was not detected in the cell 
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extract. The other sample from the supernatant of a culture grown in Eaton's 
medium was preserved in sodium azide, which as a heavy metal may affect analysis 
by the Dionex carbohydrate analyser; it also contained predominantly galactose 
(59.5 %), at a lower level that that obtained without sodium azide in the sample. N- 
acetyl-galactosarnine and fucose was -also present at 9.0 and 6.2 % respectively, 
which is at similar levels to that detected in the previous sample. This sample also 
contained N-acetyl-glucosan-ýine and glucose at 21.4 and 3.8 % respectively, which 
are at similar levels to that found in the uninoculated Eaton's medium. However, no 
mannose was detected which was present at 34.1 % in the uninoculated Eaton's 
medium. 
Analysis of the supernatant of a culture grown in Eaton's medium for 
sialic acid showed that N-acetyl neuraminic acid was present. Another unidentified 
peak was also detected. Copies of the full reports from BioMed Labs are given in 
appendix 3. 
In summary, samples from M. mycoides subsp. mycoides SC cells and 
from medium that had supported cell growth showed elevated levels of galactose, as 
expected. The levels of galactose were shown to be as high as 83.2 %. These 
results also showed that fucose was present. Fucose is a medium component, but it 
was also present in all samples and accounted for 10 % of the total sample from the 
cell extracts. If it were not a component of the cell, then its content would be much 
lower on the cell extract, rather than higher. 
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TABLE 5.4. RESULTS OF SAMPLES ANALYSED BY DIONEX 
CARBOHYDRATE ANALYSER 
Source of extract Carbohydrate Percentage nmol/mg 
Carbohydrate extract Fucose 6.8% 30.3 
from unininoculated N-acetyl-galactosamine 14.7% 65.1 
Eaton's medium Galactose 11.7% 51.8 
Glucose 3.7% 16.4 
N-acetyl-glucosamine 29.0% 128.8 
Mannose 34.1% 151.3 
Carbohydrate extract Fucose 10.0% 4.3 
from cells grown in N-acetyl-galactosamine ND ND 
Eaton's medium Galactose 73.5% 31.7 
Glucose 13.0% 5.6 
N-acetyl-glucosamine 1.6% 0.7 
Mannose 1.9% 0.8 
Carbohydrate extract Fucose 5.4% 28.7 
from culture supernatant N-acetyl-galactosamine 11.4% 60.3 
fractions 8-12 Galactose 83.2% 441.9 
Carbohydrate extract Fucose 6.2% 1.3 
from culture supernatant N-acetyl-galactosamine 9.0% 1.9 
preserved with sodium Galactose 59.5% 12.5 
azide fractions 8-12 Glucose 3.8% 0.8 
N-acetyl-glucosamine 21.4% 4.5 
Mannose ND ND 
Carbohydrate extract Sialic acid present as: 




The aim of the work presented in this chapter was to isolate and identify 
the polysaccharide antigen(s) produced by M. mycoides subsp. mycoides SC and to 
establish whether the antigen could be used in the development of a latex 
agglutination test (LAT) for CBPP. It is known that M. mycoides subsp. mycoides 
SC strains produce large quantities of extracellular polysaccharides and this 
approach has previously been used successfully in the development of a LAT for 
CCPP. The nature of any polysaccharide isolated was also of interest as the capsular 
polysaccharide of M. mycoides subsp. mycoides SC has been associated with 
pathogenicity and there is some controversy as to its composition. 
S. 4.1. POLYSACCHARIDE MATERIAL PRODUCED BY M. MYCOIDES 
SUBSP. MYCOIDES SC 
The role of the capsule in disease is of obvious interest. Smith (1984) 
stated that there appears to be no correlation between the presence of a capsule and 
pathogenicity even though the mycoplasmas having capsules are all pathogenic. 
However, capsules are generally considered to contribute to pathogenicity by 
promoting binding to host tissue surfaces and enhancing resistance to phagocytosis. 
In addition, there is some evidence that the capsule of M. mycoides subsp mycoides 
SC might have a direct toxic effect on host cells and its structural similarity to the 
host pneumogalactan further suggests that it might induce auto-immune reactions 
(Hudson, 1971). Interestingly, mycoplasma capsules usually only comprise I to 3% 
cellular dry weight while M. mycoides subsp. mycoides SC comprises 10 %. 
The presence of a specific polysaccharide obtained from M. mycoides 
subsp. mycoides SC was described by Buttery and Plackett (1960). The earlier 
conflicting reports of Kurotchkin, (1937), Dafaala, (1957,1959), White (1958) and 
Knight and Cowan (1961), where various antigenic properties were reported, may be 
due to different extracts being examined. From the work in this study, initially using 
the ELISA method, it was found that polysaccharides have antigenic activity, with 
the minor peak seen in Figure 5.1. being the most antigenic. Other workers had 
investigated different factions that were subsequently extracted from the whole 
column void. Comparisons of void extracts from medium, medium extract and cells 
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showed that the major peak, seen in tubes 28 - 31, was also present in all samples 
including the medium only sample. The cells produced a much larger peak in tubes 
12-14 that is probably attributed to galactose extracted from the capsule. Although 
this may be, a major antigenic component, more evaluation is necessary for its use in 
serological tests. 
The presence of a sialic acid, N-acetyl neuraminic acid is also 
I. noteworthy, possibly supporting the findings of Yoshida (1961) who reported that 
lipid factions contained complement-fixing antigens. Although, Smith (1984) found 
that deacylation of glycolipids does not alter their reactivity with specific antibody, 
thus the lipid portion of the molecule is not thought to be involved in 
antigen/antibody reactions. 
More recently March et al., (1999) described the polysaccharide as 
having a complex composition, comprising of mannose, glucose, galactose, fucose, 
glucosamine, and galactosamine. In this study these components were obtained 
from the analysis of uninoculated medium, suggesting that the samples that March et 
al., (1999) analysed were contaminated with medium. Waite and March (2001), 
reported that most of the high molecular weight carbohydrates capsular 
polysaccharide extracts could be attributed to BactoTryptose in the culture medium, 
but suggested that galactose may be a major capsular polysaccharide component. In 
an attempt to confirm this finding using lectins, Waite and March, (2001) failed to 
identify the carbohydrate, as it only reacted weakly with lectins and concluded that 
the capsular polysaccharide must be present in an unusual configuration. This 
emphasises the need for care in extraction of the capsular polysaccharide and 
analysis of the data obtained. 
Electron microscopy studies on M. mycoides subsp. mycoides SC 
preparations stained with ruthenium red (Minion and Rosenbusch, 1993) provided 
evidence that these rudimentary capsules were composed of polysaccharides. 
Rurangirwa et al. (1987a) found that the polysaccharide of M. capricolum subsp. 
capriptieunioniae was also extractable from the supernatant of culture medium 
following cell growth. Whether, this is actively excreted from the cell or part of the 
natural capsule breakdown, is not known. However, the capsular polysaccharide is 
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found in large quantities in the medium, which may indicate that the polysaccharide 
is actively excreted. 
The methods described for purification of the polysaccharide from either 
cells or medium supernatant uses very similar approaches. The difficulty arises in 
removing or recognising that 'contaminating' material may be present either from 
the culture medium or other components of the cells. In this study only a fraction of 
the column void was used, thus avoiding the main medium components. 
Despite only using a fraction of the column void, when the sample was 
analysed by SDS PAGE, it was shown by the sensitive silver-staining method that 
some proteins were present in the extract, although these were not readily detectable 
by protein estimation methods. The proteins were removed by proteinase K 
digestion and were no longer visible by SDS PAGE, but the M. mycoides subsp. 
mycoides SC extract was still antigenic as measured by the ELISA and LAT. 
5.4.2. COMPOSITION AND PURITY OF THE POLYSACCHARIDE FROMM. 
MYCOIDES SUBSP. MYCOIDES SC 
As described in section 5.4.1. previous workers have reported different 
findings on the composition of the capsular polysaccharide. Plackett and Buttery, 
(1958) described it as being 90% galactose and 10% glucose, whereas March et al., 
(1999) found it comprised of mannose, glucose, galactose, fucose, glucosamine, and 
galactosamine. Interestingly, reports on other closely related organisms such as M. 
mycoides subsp. capri described it as being mainly glucose with a small amount of 
galactose (Jones et al., 1965), and Rurangirwa et al. (1987a), working on M. 
capricolum subsp. capripneumoniae (1738), reported approximately equal amounts 
of glucose, galactose, mannose, fucose, galactosamine and glucosarnine. When 
examining the column void graph (figure 5.2. ) whole cells give a different profile to 
that of medium and also medium supematant. It appeared from the ELISA and SDS 
PAGE results that Pool 1, which contained a small peak observed only in 
supernatant extracts of the Eaton's medium, was the most effective in the LAT. 
Therefore the component of this peak was of specific interest and worthy of further 
investigation. It is probable that the main polysaccharide composition of cells is in 
column void tubes 12-15, which would help explain the conflicting reports and the 
problem with medium component 'contamination'. 
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The main polysaccharide obtained in this study was galactose, which is 
broadly in agreement with the findings of Plackett and Buttery (1958). In this study 
the amount of galactose detected was lower, at 83.2 % from culture supernatant, 
73.5 % from cells and only 59.5 % (sodium azide treated extract). Glucose was 
detected in the medium and the sodium azide treated extract at 3.7 % and 3.8 % 
respectively, which rose to 13.0 % from the cell extract, suggesting glucose is 
present in the cells, but not excreted into the medium. The presence of fucose was 
not expected, although it is present in the medium-only extract at 6.8 %. The 
detection of similar levels in the culture supernatant, may be accounted for by 
medium contamination, but the higher level of 10 % in the cell extract would 
indicate that fucose is one of the carbohydrates present in the cell. 
The TLC clearly showed the presence of three components in the 
carbohydrate extract. However, this test was limited as identification of the 
components was not conclusive. The presence of more than one carbohydrate in the 
test sample may affect migration rates. One of the other major drawbacks is that 
TLC was not quantifiable. The use of Dionex carbohydrate analysis confirmed the 
presence of three major components but also quantified those components. 
Specific lectins could be used to identify carbohydrates as indicated by 
Smith (1984), however previous experience has shown that the quality and 
specificity of lectins varies from supplier to supplier (Gill, K. personal 
communication). Interestingly, Waite and March (2001) tested capsular 
polysaccharide material from M. mycoides subsp. mycoides SC and obtained weak 
reactions with lectins, specific for N-acetylglucosamine dimers and trimers, (a-1,3) 
and (a-1,6) mannose, terminal a-/P- N-acetyl glucosamine (galactose) and galactose, 
galactosyl (01-4) N-acetylglucosamine. 
The component analysis of the antigen agrees with the findings of Plackett et 
al. (1963). It would be interesting to analyse the structure of the polysaCcharide, 
although it is assumed to be similar to that reported by Plackett and Buttery (1964) 
which is shown in figure 5.5. It may be worth pursuing in future, as well as 
investieatinp- the use of ýynthetic polysaccharides. Previous workers (Buttery and 
Plackett, 1960) discovered glycolipids were present in M. mycoldes. In this thesis N- 
acetyl neuraminic acid (a sialic acid) was identified, a sugar unit often associated with 
glycoproteins and glycolipids. One of the 
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difficulties in preparing antigens and their analysis is the potential for batch to batch 
variation. The potential for variation was minimised by standardising culture 
incubation times and temperatures and also by following the same procedure for 
carbohydrate extraction and analysis. 







Molecular structure of the galactofuranosyl disaccharide repeating unit of galactan 
from Mycoplasma mycoides. 
Plackett and Buttery (1964). 
5.4.3. THE LATEX AGGLUTINATION TEST 
The extract from 'spent' medium produced carbohydrates that are 
antigenic to M. mycoides subsp. mycoides SC as measured by the ELISA and LAT. 
The extraction method used in this thesis produces antigenic components that appear 
to be specific for detection of CBPP antibodies using the LAT. The quantities and 
methods used here followed the guidelines of Rurangirwa (1995), but still required 
fine-tuning. The initial difficulties associated with the spontaneous agglutination of 
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the beads and the non-specific interactions were overcome by manipulation of the 
concentrations of beads, antigens and serum. Standardising production methods so 
that specific concentrations of the components and the coating of latex beads to give 
consistently reproducible tests is paramount. 
In addition, Mab production using the antigenic components of the 
extract may enable development of novel whole cell (antigen) detection systems. 
Such a Mab could be bound to latex beads to produce a detection system for antigen 
in nasal exudates or lungs at post-mortem, or as a rapid confirmatory identification 
test for M. mycoides subsp. mycoides SC cultures in the laboratory. 
The LAT results, using Pool I (extracts), were accurate and generally in 
agreement with CFr and ELISA results. If these results can be reproduced on future 
extracts it will be worth testing with whole blood, instead of serum. Field trials 
could then be carried out with collaborators in Portugal and Uganda. From the 
preliminary data obtained in this study it was decided to evaluate the LAT test 
further, testing more serum. This work is described in chapter 6. 
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CHAPTER 6 
6.1. CRITICAL EVALUATION OF THE CBPP LATEX AGGLUTINATION 
TEST AND COMPARISON WITH OTHER SEROLOGICAL TESTS 
6.1.1. INTRODUCTION 
The aim of the work reported in this chapter was to evaluate the newly 
developed latex agglutination test (LAT) (see chapter 5) in comparison with other 
serological tests. The LAT was compared to existing testing procedures; these were: 
the complement fixation test (CFF) (Campbell and Turner, 1953); immunoblotting 
(Nicholas et al., 1996), the competition (c) ELISA (Le Goff and Thiaucourt (1998); 
which was carried out as part of a comparative trial arranged during a workshop of 
an EC COST Action (COST Action 826 on Mycoplasmas of Ruminants); and a 
newly developed ELISA based on tween 20 treated M. mycoides subsp. mycoides 
SC cells. Details of gross pathology of the affected cattle was available for some 
samples. These tests were all carried out on serum samples. Obtaining well-defined 
and characterised sera is one of the difficulties associated with evaluating tests. In 
this study, several sources of sera were obtained and are described in Section 6.2.1. 
The CFr is the OIE recommended serological test despite giving false 
positive results and only detecting approximately 70 % of CBPP affected animals. 
Although tests such as the cELISA and immunoblotting have been developed there 
is no "gold standard" serological test. Comparisons with gross pathology are not 
always possible, and carrier animals and those in the early stages of infection may 
go undetected. 
6.2. MATERIALS AND METHODS 
6.2.1 SOURCES OF ANIMAL SERA 
6.2.1. LSERA FROMANEXIERIMENTAL INFECTION 
An experimental infection was carried out as part of the EC FAIR 
programme CT95-0711 in Italy; this provided both whole blood and sera throughout 
the experiment giving well defined material for examination. Friesian cattle (18 - 
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36 months) were screened to exclude the presence of. endoparasites; antibodies to 
M. mycoides subsp. mycoides SC; brucellosis; tuberculosis; leucosis; and MR, 
BVD/MD and P13 viruses. Culture and PCR of nasal swabs also confirmed the 
absence of the M. mycoides cluster including M. mycoides subsp. mycoides SC. 
Three animals were intubated with 10 MI Of 108.87 organisms per ml of M. mycoides 
subsp. mycoides SC strain B345/93, originally isolated from pleural fluid in 
Portugal. After one-month a fourth cow was placed in contact with the other three. 
Cow I and cow 4 were re-intubated 19 weeks after the start of the experiment. 
The animals were clinically examined daily. Blood and nasal swabs 
were taken weekly and sent to VLA (Weybridge). After 21 weeks cows 2 and 3 
were slaughtered, with cows 1 and 4 being slaughtered at 26 weeks. Post-mortem 
examinations were conducted and blood, nasal mucosa, tonsils, lung, mediastinal- 
cranial lymph nodes, tracheal scrub, spleen and kidney were collected for testing. 
The weekly serum samples from the four cattle were tested by whole cell 
ELISA, tween 20 treated ELISA and by the LAT (see section 6.3. ). Some of the 
whole blood was also tested by the LAT. 
6.2.1.2. CONTROL NEGATIVE SERA 
Sera were selected randomly from samples submitted to the VLA 
(Weybridge) for serological testing for M. bovis infection. In excess of 250 sera 
were tested. The UK has been free of CBPP for over one hundred years. 
6.2.1.3. SERA FROM CBPP AFFECTED FARMS IN PORTUGAL 
Sera from 169 cattle were collected from six herds in which CBPP was 
suspected. The sera were kindly supplied by Dr. J. Regalla, (LNIV, Lisbon, 
Portugal) and had previously been tested by CFr and immunoblotting. Post mortem 
data was also available. The LAT and ELISA were carried out 'blind' and the 
results were compared with previous tests only after testing was completed. 
6.2.1.4. OTHER SERA 
Other serum samples tested were: eight CFI' positives from Portugal 
(see chapter 4); seventeen CFr positive sera obtained from the Italian outbreaks in 
1993; and thirty-one sera obtained from clinically affected herds in Uganda. 
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A panel of 134 sera containing: CFT positive sera from Portugal which 
were negative for CBPP by immunoblotting; known positive sera supplied by 
CIRAD-EMVT, France; and 58 control negative sera from the UK. The sera were 
distributed by CIRAD-EMVT, France as part of an EC COST Action 826 testing 
programme. The serum samples were coded and the code was only revealed after 
testing. 
Two hundred and twenty five sera from cattle in Hungary with 
pneurnonic disease were also tested by LAT and the tween 20 ELISA. 
6.3. SEROLOGICAL METHODS 
The LAT was conducted on all serum samples as described in Chapter 5 
(section 5.2.8. ). The coated beads used were from a single batch of carbohydrate 
extract (I't extract reference VL03 in Table 5.1. ). 
The whole cell ELISA was carried out as previously described (sections 
5.2.7. ) on serum samples from Portugal. 
A modified whole cell ELISA was also used where stated. A tween 20 
extracted antigen was produced as follows: tween 20 solubilisation was carried out 
essentially according to Nicolet et aL (1980). Cells were harvested by centrifugation 
at 10,000 g for, 40 min at 4'C, the supernatant discarded and the cell pellet 
resuspended in 0.0125M PBS containing I% tween 20 (1 ml of buffer per mg of 
protein). Cells were incubated for two hours at 37'C with constant agitation. The 
cell fraction was separated from the soluble fraction by centrifugation at 10,000 g 
for 40 min at 4'C. The pellet was washed once in OAM PBS and resuspended in a 
final volume of 20 ml. The soluble fraction was filtered through a 0.2 gm pore 
diameter filter prior to PD-10, Sephadex-25 (Pharmacia) column purification. The 
surface antigens that were soluble in Tween 20 were found to be one of the major 
cross-reacting components with M. bovis, so the remaining component of the whole 
cells was used as an antigen and was standardised by chequer-board titration. The 
ELISA procedure was essentially the same as that described for the whole cell 
ELISA (see Section 5.2.7. ). 
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Immunoblotting was carried out on samples from Italy and Portugal (see 
chapter 4). The method was the same as described by (Nicholas et al., 1996), using 
Portuguese strain B 103 as the antigen. 
Other serological data included in the results section were obtained 
from the serological. testing section at VLA (Weybridge), or at collaborating 
laboratories in Europe. These tests were carried out as described by Campbell and 
Turner, (1953) CFT; Tittarelli et al. (1999) modified CFr; Le Goff and Thiaucourt, 
(1998) cELISA; Gongalves et al. (1998) immunoblotting. Data obtained by other 
researchers is acknowledged in all cases. 
6.4. STATISTICAL ANALYSIS 
Determination of the correlation of the results obtaioned by the LAT with 
those of other serological tests was based on kappa coefficients (Cohen, 1960). 
Kappa is determined as 
Expected agreement - Random agreement 
Maximum expected agreement - Random agreement 
Kappa is 0 if there is no evidence of agreement between tests. A value of I is 
obtained if there is perfect agreement. Standard errors for kappa were determined. 
The statistical unit at VLA (Weybridge) performed the statistical analyses on the 
data given in Table 6.2. 
6.5. RESULTS 
6.5. LSERUH SAMPLES TESTED BYLAT 
The serum samples. tested by the LAT and the results of the tests are 
summarised in Table 6.1. The samples from Hungary and the UK gave no clear 
positive agglutination, although two of 250 UK samples gave slight agglutination. 
One of the samples was turbid, due to growth of a contaminating micro-organism, 
and this may have affected the result due to cloudiness. Neither of the two UK 
samples that gave agglutination were positive in CFr or by immunoblotting. Since 
the UK and Hungary have been free of CBPP for many years, positives were not 
expected, and thus the number of false positives in European cattle would appear to 
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be less than 0.5 %. For the Hungarian serum samples the negative LAT results were 
confirmed by the tween 20 whole cell ELISA test; all samples were negative. 
The batches of serum samples obtained from Uganda, Italy and Portugal all 
contained samples that were positive by the LAT. The samples obtained from the 
Italian cattle (17 in total) gave seven LAT positive results, four were positive by 
CFI7 and five were positive by immunoblotting. All samples that were positive by 
CFr were also positive by immunoblotting, and all samples that were positive by 
immunoblotting were also positive by LAT. 
The samples obtained from Uganda (31 sera) gave 18 LAT and CFr positive 
results and whole cell ELISA gave 16 positive results with 7 samples being in the 
undetermined/suspect range, (see Table 6.1. ). However, not all tests that were 
positive by CFT were positive by ELISA or LAT and vice versa. Agreement was 
calculated as similar test/total tests X 100 %. There was an 74 %. agreement 
between the CFT and the LAT and a 75 % agreement between the ELISA and the 
LAT if the ELISA results in the suspect range are ignored, if those results are taken 
as positive then there is a 71 % agreement, or 68 % if taken as negative. 
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(Whole cell) OD 
LAT 
1 1: 160 ++ 1.40 +ve 
2 1: 160 ++ 0.36 +ve 
3 1: 20++ 0.97 +ve 
4 -ve 0.23 -ve 
5 1: 40 ++ 0.26 +ve 
6 1: 20 ++ 0.48 -ve 
7 1: 40 ... 0.28 +ve 
8 1: 160 ... 0.72 +ve 
9 1: 160++ 0.28 -ve 
10 -ve 0.19 -ve 
11 1: 160 ++ 0.75 +ve 
12 1: 20 ... 0.95 +ve 
13 -ve 0.25 -ve 
14 160 ... 0.68 +ve 
15 1: 20 +++ 0.22 +ve 
16 -ve 0.18 -ve 
17 -ve 0.22 +ve 
18 -ve 0.14 -ve 
19 1: 640 ++ 1.00 +ve 
20 1: 320 ++ 0.89 +ve 
21 1: 40 ... 0.72 +ve 
22 1: 160 +++ 0.52 -ve 
23 -ve 0.20 -ve 
24 -ve 0.37 -ve 
25 1: 20 +++ 0.59 -ve 
26 -ve 0.25 +ve 
27 1: 40 ... 0.33 +ve 
28 -ve 0.65 +ve 
29 -ve 0.25 +ve 
30 -ve 0.27 -ve 
31 -ve 0.16 -ve 
ELISA <0.25 interpreted as negative; 0.25-0.30 as suspect; >0.30 as positive. 
CFr >1: 10 ++ is interpreted as positive. 
Bold typeface highlights positive results 
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The eight samples from the Portuguese abattoir (see chapter 4) were 
examined. All of the animals were positive on gross pathology. From these, all 
eight were positive by whole cell ELISA, seven by CFT and six by LAT. These sera 
were in poor condition, and one sample was particularly viscous, which gave a 
negative result by LAT and was just positive at 1: 20 by CF17. 
The sera samples tested as part of the EC FAIR and COST projects 
including the experimental infection samples were tested by a range of serological 
tests which are described in sections 6.5.4. to 6.5.6. 
6.5.2. SERA FROM CBPP AFFECTED FARMS IN PORTUGAL 
The 169 serum samples from six CBPP affected herds in Portugal were 
analysed by CFT, immunoblotting and LAT serological tests. All animals were also 
examined for the presence of lesions at post-mortem. Results for all six farms are 
summarised in Table 6.2. and data for individual animals is given in Appendix 4. 
TABLE 6.2. SUMMARY OF SEROLOGICAL RESULTS FROM SIX CBPP 
AFFECTED HERDS IN PORTUGAL 
NUMBER OF SERA POSITIVE BY 
Farm No. of No. of LAT ELISA CFT* IBT* 
animals animals (whole cell) 
with CBPP 
lesions* 
1 55 30 38 50 29 47 
2 25 9 10 11 9 12 
3 18 9 12 17 11 17 
4 19 2 2 10 6 7 
5 37 35 17 34** 18 35 
6 15 15 03 0 3 
Data kindly provided by J. Regalla. LNIV Portugal 
** 1 sample not tested 
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Table 6.2. shows that the proportion of cattle with lesions at post- 
mortem differed considerably amongst the six farms (from 10 % to 100 %). In 
general, serological tests detected more animals as positive for CBPP than gross 
pathology. However, on Farm 6 all 15 cattle had lesions, but all were negative by 
CFT and LAT, and only 3 were positive by ELISA and immunoblotting. All the 
serological tests detected approximately equal numbers of positives although their 
was a wide discrepancy between tests for individual animals (Appendix 4). For 
example there was 55 %, 88 %, 83 %, 79 %, 65 % and 100 % agreement between 
the CFT and LAT on Farms I to 6 respectively. It is worth noting that not all of the 
tests gave positive results for the same samples. Farm 6 was unusual in that all 15 
cattle had lesions; none of them were positive by LAT or CFT, but three of the cattle 
were positive by both ELISA and immunoblotting. A summary table comparing 
total numbers of LAT positive and negative results is given in Table 6.3. 
TABLE 6.3. COMPARISON OF TESTS ON 69 SERA OBTAINED FROM SIX 
CBPP AFFECTED FARMS IN PORTUGAL 
CF]r CFr ELISA ELISA IBT IBT GROSS GROSS 
+VE -VE +VE -VE +VE -VE PATH PATH 
+VE -VE 
LAT 
69 9 76* 2* 73 5 55 23 
+VE 
LAT 
26 65 52* 38* 48 43 45 46 
-VE 
*One sample not tested by ELISA 
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6.5.3. STATISTICAL ANALYSIS ON SERA FROM CBPP AFFECTED 
FARMS IN PORTUGAL 
Correlation (kappa) coefficients showing the overall correlation between 
the tests conducted are given in Table 6.4. This shows that there was generally a 
poor correlation between the presence of lesions and any of the serological tests. 
Amongst the serological tests, a relatively high correlation (0.60 - 0.62) was 
observed between: 
LAT and the CFT; the CF17 and IBT; the LAT and ELISA; and the 11BT and ELISA. 
Thus it seems that amongst serological tests, the sensitivity and/or ability 
to detect antibodies present varies significantly. This might be predicted as the CFF 
detects mainly IgG but may also detect IgM; the ELISA detects IgG; the MT detects 
IgG to selected proteins; and the LAT detects mainly IgM, but may also detect IgG, 
but presumably only to those fractions that react with the polysaccharide capsule. 
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TABLE 6.4. COMPARISON OF SEROLOGICAL TESTS AND PRESENCE OF 
LESIONS BY KAPPA COEFFICIENT ANALYSIS 
CFT IBT ELISA LESION 
LAT 0.60 0.35 0.33 0.11* 
(0.06) (0.07) (0.08) (0.08) 
CFT 0.60 0.62 0.31 
(0.07) (0.08) (0.08) 




no significant correlation (95 % confidence level). 
A kappa value of 0 shows no correlation and a value of I shows total correlation. 
Values in brackets are standard errors. Where kappa values differ by more than 2 
standard errors, correlation coefficients are significantly different at the 95 % 
confidence level. 
192 
6.5.4. EC COST TRIAL 
One hundred and ninety two sera were tested as part of this study. These 
were: 56 UK negative sera, and 134 sera from Portugal that contained CFT 'false' 
positives in comparison with immunoblotting. It was known that eight sera were 
true positives and seven samples had been replaced with dilutions of serum from a 
goat that had been inoculated with M. mycoides subsp. mycoides SC. 
The tests compared were the LAT, CFr, modified CFr and competitive 
ELISA and immunoblotting. Each test was carried out either by the OIE recognised 
laboratory, or where the specialist tests had been developed; the CFI' and 
immunoblotting was carried out at LNIV, Portugal; the cELISA by CIRAD, France; 
the modified CFr by IZS, Teramo, Italy. The modified CFI, developed at IZS, 
Teramo used reduced concentrations of haemolysin (2 units), complement (2 units) 
and red blood cells (2 %) compared to that described by Campbell and Turner 
(1953) of 12 units, 2.5 units and 6% respectively. 
The 56 UK negative serum samples were negative in all tests. The eight 
positive control samples were all positive using the CFT; but only six were positive 
by LAT and the modified CFT; however only three were positive by the cELISA. 
The neat positive goat serum was detected by the LAT, immunoblotting (weak 
positive), the modified CFT at 1/40 and with 74 % inhibition in the cELISA. The 
cELISA also gave a positive result with goat sera diluted 1 in 4. The results from 
the Portuguese sera were more complex and are given in Table 6.5. 
The serum samples originally found to be positive by CFT but negative 
by immunoblotting contained 59 samples-that were negative by all serological tests. 
Interestingly, one sample, number 103, was positive by all the tests (other than 
immunoblotting) used in this trial. Amongst the remaining serum samples 3 were 
positive by cELISA; 31 by the modified CFT, 52 by the traditional CFT and 13 by 
LAT. Of the 13 LAT positives 9 were negative in all other serological tests and four 
were positive in one or both of the CFT tests. All 'false' positives were negative by 
cELISA. Thus, it appears that, as was concluded in the section 6.5.3. above, the 
serological tests compared vary in their sensitivity and/or specificity for detecting 
antibodies to M. mycoides subsp. mycoides SC. Analyses between all these 
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techniques showed that there was no significant correlation: a serum with a low 
value in one test can give a high value in another. 
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TABLE 6.5. COMPARISON OF RESULTS OBTAINED USING DIFFERENT 
SEROLOGICAL TESTS IN THE EC COST TRIAL 
Sample LAT Result CFT1 Modified CFT2 cELISA3 
Number Logio Logio 
M 
1 -ve 2.05 1 45 
Z.. UD 
1.08 






. 1.38 1.08 25.36 
8 -ve 1.38 
1.15 40.44 
10 -ve 1.38 
0. 31.08 
11 +ve 1.08 0 31.43 
12 -ve 1.75 
1.90 24.84 
15 -ve 1.38 
1.15 40.50 
16 -ve 1.38 
1.15 22.70 
17 +ve 1.08 0 26.11 
19 -ve 1.08 
1.38 67.76 
20 -ve 2.28 
2.65 36.11 
21 -ve 1.38 
0 28.65 
23 +ve 0 0 13.92 
24 +ve 0 1.38 
33.51 
26 +ve 0 0 
37.78 
27 -ve 1.98 
1.60 29.46 
28 -ve 1.38 
0 23.63 
32 -ve 1.38 
0 55.63 
33 -ve 1.98 
0 43.79 
34 -ve 1.75 
1.38 23.17 
35 -ve 1.38 
1.30 27.21 
36 +ve 1.75 0 24.09 
37 +ve 1.45 0 
43.67 
38 -ve 1.45 
1.30 23.22 
4l* -ve 0 
0 60.41 
42 -ve 1.15 
1.45 22.87 
45 -ve 1.68 
1.68 16.45 
46 -ve 1.68 
1.30 11.68 
48 -ve 1.45 
0 26.47 
49 -ve 1.38 
1.15 29.35 
50 -ve 1.38 
1.38 30.45 
51 -ve 1.68 
1.08 37.38 
52 -ve 1.68 
1.45 30.62 
55 -ve 1.38 
1.38 22.28 
56 -ve 1.83 
1.90 25.97 
57 -ve 1.98 
2.05 28.74 
58 -ve 1.38 
0 13.90 
59 -ve 2.05 
2,05 32.95 
60 +ve 1.68 1.08 24.64 
63 -ve 2.05 
1.30 28.52 
64 -ve 1.68 1.75 
30.95 
66 +ve 1.08 0 12.29 
68 -ve 1.45 
1.68 34.05 
69 -ve 1.98 
1.90 34.44 
71 -ve 1.15 1.60 
25.36 
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TABLE 6.5. COMPARISON OF RESULTS OBTAINED USING DIFFERENT 
SEROLOGICAL TESTS. (EC COST TRIAL CONTINUED) 
Sample LAT Result cFrl Modified CFr2 c-E-L-IS-Ar- 
Logio Logio 
72 -ve 1.45 1.60 28.52 76 -ve 138 1.38 40.59 
77 +ve 1.08 0 13.23 
79 -ve 1.45 1.38 33.11 
83 -ve 1.38 1.08 34.70 
87 -ve 1.38 0 24.57 
90 -ve 1.68 1.90 29.23 
91 -ve 1.75 1.45 35.21 
97 -ve 1.38 0 18.59 
98 -ve 1.15 1.45 26.16 
100 -ve 1.38 0 31.23 
103 +ve 1.45 1.45 54.57 
108 -ve 1.45 1.45 26.22 
109 -ve 1.68 1.98 18.25 
112 -ve 1.38 0 24.61 
113 +ve 1.15 0 31.54 
115 +ve 1.08 0 34.75 
116 -ve 1.45 0 31.02 117 +ve 0 0 35.95 
120 -ve 1.38 0 29.71 
124 -ve 1.68 0 22.95 
**127 & 131 +ve/+ve 2.58/2.58 2.65/2.65 46.88/47.91 
**128 & 132 -ve/-ve 1.98/1.98 1.98/1.75 48.48/51.63 
**129 & 133 +vel+ve 2.58/2.58 2.58/2.50 59.36/60.90 
**130 & 134 +ve/+ve 1.38/1.38 1.1511.15 35.43/37.15 
Sera from the 56 UK cattle and 59 Portuguese cattle that were negative by all tests are 
omitted from this table. 
*Goat sera from animal inoculated with M. mycoides subsp. mycoides SC antigen diluted I 
in 4. 
** Duplicated control positive M. mycoides subsp. mycoides SC samples. 
'CFT data kindly provided by J. Regalla, LNIV, Portugal; data were originally scored as 0 
to .... at each serum dilution. They were converted to loglo values by F. Thiaucourt, 
MAD, France; based on the reciprocal of the highest titre giving any positive result and 
the degree of precipitation. A reaction of + at a 1/20 dilution was converted to a loglo value 
of 1.3 and was the lowest value for a positive result. 
2The modified CFT (Tittarelli et al., 1999) was carried out by P. DeSantis, IZS, Teramo, 
Italy and converted to logio values by F. Thiaucourt, CIRAD, France as described above. 
3 The cELISA was carried out by F. Thiaucourt, CIRAD, France. A positive result was 
regarded as >50 %; 45-50 % was considered as inconclusive. 
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6.5.5. SERA FROM PNEUMONIC CATTLE IN HUNGARY - UNKNOWN 
STATUS 
All the sera tested were negative by LAT, whole cell ELISA, tween 20 
treated ELISA and CFI'for CBPP, as described in section 6.3. 
6.5.6. EC FAIR PROJECT EXPERIMENTAL INFECTION 
Cows 1 and 4 
The LAT, whole cell and tween 20 ELISA remained negative 
throughout the experiment for both animals. Other information relevant to the 
experimental infection in these cattle was provided by IZS, Italy. The CFr also 
remained negative throughout the experiment, as was culture from the nasal swabs. 
PCR gave some positive results when used directly on the nasal swabs, following 
enrichment, and directly from the blood on 7 and 8 occasions respectively. No 
clinical symptoms or disease were observed during the experiment. 
At post-mortem, in cow 1, some minor adhesions were observed on the 
chest wall, but the lungs appeared normal. In cow 4, pneumonia was observed with 
a thickening of interlobular septa and a lesion was recorded. No characteristic 
CBPP lesions were observed. Culture, PCR and ICC were negative for both cows. 
Cow 2 
The LAT became positive 1 week post intubation and remained positive 
throughout the experiment. The tween 20 ELISA became positive by week 3 and 
declined by week 10, with a slight increase for 2 weeks prior to slaughter. The 
whole cell ELISA was positive by week 1, peaking at weeks 2 and 3 before 
declining by week 5; again a slight increase was observed for 2 weeks prior to 
slaughter (see Figure 6.1. ). 
The CFT also became positive at week 1, peaked at week 3 and started 
declining by week 4 but remained positive throughout. Culture remained negative 
throughout. PCR detected positives from nasal swabs on weeks 3 and 5 and from 
blood on weeks 4,5,6,8,10,19,20 and 21. At post-mortern some congestion of 
the upper respiratory tract was observed as were minor adhesions and a general 
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thickening of pleura at the lobe level. No characteristic CBPP lesions were 
observed. Bacteriology was negative but PCR and ICC were positive on lung 
tissues. No clinical symptoms or disease were observed during the experiment. 
FIGURE 6.1. COMPARISON OF ELISA METHODS AND LAT USING SERA 
FROM EXPERIMENTAL INFECTION COW 2 
COW 2, COMPARISON OF ELISA's AND LAT 
0.60- - 
0.50- - Tween 20 ELISA 
A- - Whole cell ELISA 
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Figure 6.1 shows the comparison of ELISA's and the LAT for sera obtained from 
cow 2 during the experimental infection. 
The ELISA cut-off points may be taken as an OD of 0.3, although the exact value 
has still to be determined. 
For the LAT 0 is negative, 1 is positive. 
Cow 3 
The LAT became positive 2 weeks post intubation and remained positive 
throughout the experiment. The tween 20 ELISA remained negative, but showed an 
increased OD over the experimental period. The whole cell ELISA was positive at 
week 1, but declined and remained negative; a slight increase was observed for 2 
weeks prior to slaughter (see Figure 6.2. ). 
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The CFr became positive at week 3, peaked at week 4 and became 
negative by week 10. No clinical symptoms or disease were observed during the 
experiment. Culture remained negative throughout. PCR detected positives from 
nasal swabs on week 2 only and from blood on weeks 3,5,6,7,10,19,20 and 21. 
At post-mortem a small volume of clear exudate was seen. Filaments of organised 
fibrin of the right apical lobe were recorded, as were some adherences and a general 
thickening of pleura at the lobe level. No characteristic CBPP lesions were 
observed. Bacteriology, PCR and ICC were negative. 
FIGURE 6.2. COMPARISON OF ELISA METHODS AND LAT USING SERA 
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Figure 6.2 shows the comparison of ELISA's and the LAT for sera obtained from 
cow 3 during the experimental infection. 
The ELISA cut-off points may be taken as an OD of 0.3, although the exact value 
has still to be determined. 
For the LAT 0 is negative, I is positive. 
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6.6. DISCUSSION 
In the development of diagnostic tests, it is useful to have an idea of the 
test qualities required. Ideally tests should be highly specific, sensitive and simple 
to perforin. and interpret. In practice, for serological tests, highly specific and highly 
sensitive tests are difficult to achieve as an increase in sensitivity usually leads to 
increased numbers of false positive results and hence a decreased specificity. 
There is a place for a number of serological tests for detecting CBPP and 
for its control. In countries such as the UK, where CBPP is not present, the more 
sensitive screening test, currently the CFr, can be used either to confirm the disease 
free status, or for use in import tests. Where distance and communications is not a 
problem, these tests can be performed at central laboratories, which have the 
required expertise and the facilities for automation, and therefore the ability to 
process a large number of tests. Where positive results are obtained a more specific 
test such as immunoblotting can be used to confirm the result. However, in 
countries such as Africa, where CBPP is endemic and an increasing problem, this 
system is not effective for many reasons, including distances involved, lack of 
skilled staff and adequate testing facilities. The CFr is performed in a number of 
laboratories, but until recently no other tests were used. Thus there was no means of 
confirming CFT positive results. The use of an ELISA system such as the cELISA 
(Le Goff and Thiaucourt, 1998) in Africa offers an alternative test, which may also 
be used as a confirmatory test. However, one of the main difficulties in Africa is the 
distances involved between the animals and diagnostic laboratories, and the inability 
to retrace positive animals, as nomadism and trekking is part of the African culture. 
A pen-side test such as the LAT would be extremely useful in this situation, where 
rapid diagnosis can be made. 
In this thesis a number of CBPP serological tests have been used on a 
variety of serum sources, providing comparative data on old and new CBPP 
serological tests. The CFT, which is currently the OIE recommended test, produced 
more positive results overall than any other serological test. However, on the 
samples from the farms in Portugal, many samples were CFT negative but positive 
by other tests and by gross pathology. For example on farm one (Appendix 4), 
where 55 animals were tested, 5 samples were CFT negative, but positive for 
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lesions, and by LAT, ELISA and immunoblotting. Twenty-one additional CFT 
negative tests on farm one were positive by at least two other tests. This suggests 
that the CFI7 may only be about 53 % sensitive in comparison with the 70 % 
previously reported (Stdrk et al., 1994). On Farm 5, (where CBPP lesions were 
reported in all but two of the animals from that farm), the figure falls to 45 % 
sensitivity compared with other tests. In contrast, the CIFT tested in the EC COST 
trial gave false positive results on 52 of the 134 (39 %) samples tested. Although 
the CFT is the OIE recommended test, this work shows some of the difficulties that 
arise in diagnosing the disease, when you have a test that is neither specific or 
sensitive. In addition the CFT has many disadvantages in the standardising and 
performing of the test and can only be performed in a specialised laboratory. 
The modified CFT (Tittarelli et al., 1999) showed fewer false positive 
reactions than the conventional CFr in the EC COST trial, but also missed two of 
the positive control samples. The advantage of this test over the conventional CFI' 
is the reduction in the amount of reagents required. 
The cELISA (Le Goff and Thiaucourt, 1998) has recently been accepted 
by the OIE. The test, supplied by CIRAD, is however complicated, being supplied 
as raw reagents. Reading of the tests also requires specialist equipment, 
interpretative and data manipulation skills. In the EC COST trial the cELISA 
detected only 3 false positive results, although one of those (sample 103) was 
positive by all other tests except immunoblotting. From this information the test 
looks highly specific, but it totally missed two of the positive controls and three 
positive controls were below the cut-off point in the inconclusive range. Reports by 
Yaya et al. (2000) indicate that the cELISA has similar sensitivity to that of the 
CFr; however they also reported that in experimental infections the cELISA failed 
to detect some cattle that developed typical CBPP lesions, although an increase in 
titre was observed. 
The whole cell ELISA (see sections 5.2.7) was used for the sera tested 
from Uganda and from the 6 Portuguese farms. Sixteen of the 31 samples were 
positive by ELISA and 18 by CFr. Statistical analysis (Table 6.4) showed kappa 
coefficients of 0.61 and 0.62 between the ELISA, immunoblotting and CFr, which 
compares favourably with the other tests. However, the ELISA was not the most 
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sensitive of tests when the experimental infection was monitored, although it did 
detect immune responses in two affected cattle. Currently, this ELISA is only a 
research tool, as it is known to have some cross-reactions with M. bovis. However, 
ELISA's in general could be modified for field use, with the colour development 
and interpretation being read by eye and matched to colour cards. The use of sample 
titration could also help determine a titre. 
The tween 20 ELISA (see sections 6.3), was a development of the whole 
cell ELISA, and was used as the removed tween soluble antigens were the main 
cause of cross-reactions with M. bovis. It would appear that the sensitivity of both 
the whole cell ELISA and tween 20 ELISA could be increased, although the positive 
control for each ELISA gave an OD of 1. 
The LAT (chapter 5) has given some interesting results and shows 
potential as a screening test for CBPP. On the Portuguese farms the kappa 
coefficient was 0.60 compared to the CFT, with lower values for the immunoblot, 
ELISA and gross pathology. However, in the EC COST trial the LAT gave only 
only 13 (9.7 %) false positives compared to the 39 % of false positives in the CFr. 
It did, however, miss two of the eight positive controls; the cELISA missed five. In 
the experimental infection, the LAT detected antibody in two cattle within the first 
two weeks. The LAT remained positive throughout the experiment, showing the 
ability of the LAT to detect early infection and still record positive results, when 
other serological test titres had declined. 
There was an 81 % agreement between the CFr and the LAT and a 77 
% agreement between the ELISA and the LAT on sera from Ugandan cattle. This 
demonstrated that the LAT using an extract obtained from a European strain would 
also detect immune responses from Ugandan cattle affected with African strains, 
which have been shown to be different to European strains (Frey et al., 1996; 
Houshayami et al., 1997). 
The few sera tested from Italy showed a good correlation between 
serological tests. 
Only two false positive LAT results were detected in the Hungarian and 
UK sera tested. One of those sera was of dubious quality. This would indicate that 
the test is very specific. 
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The LAT is cheap, rapid and can be performed by relatively unskilled 
personnel and can be used in a simple mobile laboratory close to the cattle, thus 
giving it several practical advantages. As a rapid screening test, it shows 
considerable potential. Whole blood was used (data not shown) on some samples 
from the experimental CBPP infection giving identical results to those obtained 
using serum, although the agglutination was more difficult to see. This could be 
addressed by using different colour beads and waxed card. This would then make 
the test a true pen-side test. 
Evaluating test effectiveness presents several difficulties, including 
insufficient material of known status, inconclusive existing tests and the lack of a 
"gold standard" test. In this thesis a wide range of sera have been tested from 
different well-documented sources. These included the naturally occurring CBPP 
infections in Portugal, and Italy where details of lesions and other tests were known. 
Time studies were performed on the experimental infection. Samples from CBPP 
affected herds in Uganda demonstrated the LAT would work with antibodies to 
African strains. Sources of CBPP negative sera were also important for evaluating 
serological tests and bovine samples from the UK and Hungary provided plenty of 
samples where the rate of false positivity in true negative populations could be 
determined. 
6.7. CONCLUSION AND FURTHER WORK 
No single serological test detected all CBPP affected cattle. Whole cell 
ELISA and immunoblotting were more sensitive than the CFT and LAT in the trial 
carried out using sera from Portuguese farms. However, LAT gave more positive 
tests than the CFT on the sera from Portuguese farms, in contrast to the overall to 
the results obtained from the EC trial, where CFr produced the most positive 
results. Thus, as a rapid test for use in field laboratories the LAT appears to offer 
considerable potential. This test would also appear suitable for use with whole 
blood and might therefore be of great value as a 'pen-side' test. 
Field evaluation of the test is now required. In relation to tests in 
African cattle, it will be important to determine the reaction of vaccinated and or 
antimicrobial treated cattle. One would expect the vaccinated animals to give a 
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positive 1AT reaction. Whilst it would be useful to be able to differentiate between 
vaccinated and CBPP affected cattle, the test could also be used to deterinine if the 
vaccination had successfully produced an immune response that may offer 
protection against CBPP. It is unlikely that antimicrobial treatment would affect the 
outcome of the LAT. For field use, it may be possible to further increase the 
convenience of the LAT by drying the antigen-coated latex beads onto test cards. 
Test blood samples may then be simply applied to the cards. 
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CHAPTER 7 
7.1. GENERAL DISCUSSION AND FURTHER WORK 
Many mycoplasmas are important pathogens of economic significance in 
domestic animals. This thesis has been concerned with aspects of the diagnosis and 
control of CBPP and M. bovis infections. These are currently the most important of 
the mycoplasma infections of cattle (see sections 1.4 and 1.5). However strategies 
for their control differ widely. In Africa, the containment and occasional slaughter 
of affected cattle and the use of vaccines are the methods used in attempts to control 
CBPP. In contrast, a slaughter and compensation policy was used to eradicate 
CBPP from Italy and is in use in Portugal, and would be used in the UK should 
cases arise. For a slaughter and compensation scheme to be effective, efficient and 
early diagnosis of the disease is paramount. M. bovis is endemic worldwide and 
currently no effective control mechanisms are in place. Antimicrobials are widely 
used in treating infections, but they are generally not effective, although they may 
temporarily relieve the symptoms and give the animal time to develop its own 
immune defences. 
The contribution of the work described in this thesis to the diagnosis and 
control of M. mycoides subsp. mycoides SC and M. bovis infections are: 
(i) the evaluation of a PCR giving improved speed and reliability of M. bovis 
identification. 
(ii) the development of an efficient antimicrobial sensitivity assay for 
mycoplasma and its application to the determination of sensitivity amongst a 
diverse range of M. bovis and M. mycoides subsp. mycoides SC isolates. In 
this study the effectiveness of antimicrobials currently used to treat M. bovis 
infections in the LJK was determined (in-vitro). The study also identified 
potential candidate antimicrobials for treatment of CBPP in Africa and 
Europe (if such treatment became an option) and showed the likely speed 
with which increased mycoplasma antimicrobial resistance would be 
acquired. 
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a critical evaluation of a range of CBPP diagnostic methods: PCR; CFr; 
modified CFI; cELISA; whole cell ELISA; tween 20 ELISA; 
immunoblotting; and LAT. 
(iv) the development of a simple LAT for CBPP based on a culture supematant 
fraction, which was identified as the capsular polysaccharide antigen. 
7.2. CONTROL OFM. BOVISANDM. MYCOIDES SUBSP. MYCOIDES SC 
INFECTION 
It was just over 100 years ago that Nocard and Roux (1898) succeeded 
in culturing the causative organism of CBPP when the disease was having a severe 
effect on the cattle industry of many European countries. It has since been 
eradicated from most European countries, with a possible pocket of infection 
remaining in Northern Portugal. There have been no outbreaks of CBPP in Britain 
for more than 100 years but it is clear from recent outbreaks in Europe that the 
disease still presents a real threat to the British cattle industry. Although there was 
only one reported case of CBPP in Europe during 1999 and none in 2000, there have 
been reports in Europe during every decade of the last century (Nicholas et al., 
2000a). With the formation of the European Union, and increased European trading 
with fewer restrictions means the possible threat of importing the disease into 
Britain is increased. CBPP would undoubtedly have a devastating effect on the 
British cattle industry. 
In this study, the disease was observed in Portugal (chapter 4), thus 
providing an insight into what may happen if cases occurred in the UK. The way 
the disease can spread relatively easily by aerosol transmission downwind to 
neighbouring farms, the posture of the animals and the dry cough have all been 
witnessed. Aerosol transmission of CBPP infection is a major risk factor, although 
in the UK, farms are not usually in such close proximity as those observed in 
Bougado in Portugal and therefore the risk may be less. However, in the UK, the 
clinical symptoms, the cough and posture would initially be mistaken for another 
pneumonic disease and would be treated with antimicrobials, possibly masking the 
disease and facilitating its longevity and spread. At the post mortems in Portugal, 
the previously described gross pathology was recorded including unilateral lung 
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infections, presence of sequestra, and the marbled appearance of the lung. In the UK, 
routine checks by meat inspectors at the abattoir may be where CBPP is first 
detected. Meat inspectors and veterinarians are aware of CBPP but few have 
witnessed the gross pathology first-hand. Photographs of the pathology observed in 
Portugal are now shown to new veterinarians at induction courses run by VLA, and 
have also been supplied to some regional laboratories. Material was also collected 
from Portugal so that traditional diagnostic methods, culture, PCR and CFT could be 
carried out. This also provided some material to evaluate new diagnostic methods 
such as ICC, ELISA and the LAT. These tools are invaluable in diagnosing CBPP. 
When suspect cases are reported in the UK, culture and PCR are used first, on lung 
material, pleural fluid and nasal swabs and any other affected tissue. The PCR gives 
a rapid 'preliminary' result, but requires culture confirmation. In the mean time 
serology, CFr and new ELISA tests are performed on sera from the affected animal 
and any contact animals. However, as reported in chapter 6, none of these tests are 
100 % successful, but with a combination of the old and new tests it is likely that an 
affected herd, if not individual animals would be detected. If CBPP entered the UK, 
there are several scenarios of its course: 
" it is possible that it remain undetected for some time and only be detected 
at post-mortem, thus facilitating its spread by cattle movement and sales; 
" it is also possible that naYve cattle will be seriously affected and the 
disease diagnosed rapidly and the cattle slaughtered before the disease 
spreads; 
" it is probably more likely that as in Portugal, the fanner will notice the 
failure of the animals to do well, with lower milk yields and that CBPP 
will only be considered after other diseases have been discounted and the 
animals have failed to respond to antimicrobial treatment. 
Once CBPP has been diagnosed in the UK, the slaughter policy and 
tracing of animal movements would be quickly implemented, thus quickly 
eradicating the disease. This would be carried out more rapidly than was observed 
in Portugal where negotiations about slaughtering and compensation appeared to be 
pro-longed over many months, before animals were slaughtered. 
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An experimental infection with CBPP (section 6.2.1) produced two 
cattle with a detectable immune response and M. mycoides subsp. mycoides SC was 
culturable on occasions, however no 'gross pathology' was present. This 
experimental infection produced a sub-clinical infection and provided characterised 
material for evaluation (chapter 6) of the LAT developed in chapter 5. It is this level 
of infection that presents a real threat for importation of disease. 
The CBPP experimental infection carried out in Italy under the EC FAIR 
project CT95-0711 followed the infection procedure of Abdo et al. (1998) with 
direct intubation of culture into the lung. This method is probably much less 
effective than aerosol methods (Hudson, 1971), in which calves breathe in the 
challenge organisms. Even so, little information has yet been obtained on 
incubation times or how long it takes for the typical gross pathology to develop. It 
has been reported (Egwu et al., 1996) that incubation times may range from 5-207 
days although an incubation time of 207 days represents the extreme case. This 
information is based on a shipment of cattle from England to Australia more than 
100 years ago, when an animal developed the disease after arrival in Australia 
(Egwu et al., 1996). 
Much discussion has recently taken place about the differences between 
European and African M. mycoides subsp. mycoides SC isolates. Undoubtedly, 
differences exist in aspects such as Insertion Sequence (IS) elements (Frey et al., 
1996) and ability to oxidise glycerol (Houshaymi et al., 1997) and possibly 
virulence (Provost et al., 1987). Even though cattle mortality is rare in affected 
European countries compared with African countries, it is evident that the European 
M. mycoides subsp. mycoides SC still causes typical CBPP disease with affected 
cattle showing similar gross pathology (Nicholas et al., 1996). Other factors such as 
breed of cattle, husbandry, stress and possibly previous antimicrobial treatment must 
affect the pathogenesis of CBPP. 
Mycoplasma bovis was recognised as a cause of disease in cattle 
relatively recently, in 1961. Although like M. mycoides subsp. nlycoides SC it is 
associated with pneumonia in cattle, there are substantial differences between the 
organisms in relation to the nature of the disease caused and diagnostic methods for 
detection. M. bovis has been reported to be present almost world-wide and is not 
208 
only a major cause of pneumonia, but also of arthritis and keratoconjunctivitis in 
calves, and mastitis and reproductive disorders in cattle (Nicholas et at., 2000b). It 
was diagnosed in approximately 25 % of pneumonic calves in Britain using an 
indirect ELISA (Nicholas et al., 2000b). With a few notable exceptions, including 
M. mycoides subsp. mycoides SC, it has generally been assumed that mycoplasmas 
play a secondary role in infection, particularly in complex pneumonic infections 
where other bacteria and viruses are identified. However, there is increasing 
evidence that mycoplasmas, such as M. bovis may be primary pathogens. M. bovis 
causes infection experimentally (Pfutzner and Sachse, 1996; Stipkovits et al., 
2000b), and in farm studies M. bovis was associated with persistent infections in 
which other pathogens were absent (Nicholas et al., 2000b). 
Currently, diagnosis is usually based on serum ELISA tests, and a 
commercial ELISA test (Vetoquinol) is available. However, the organism grows 
well in culture and may be isolated from lungs, or joints, but is only shed and 
detected intermittently from nasal cavity swabs (Ter Laak et al., 1992). In contrast 
to M. mycoides subsp. mycoides SC, it does not ferment glucose and also produces a 
film. Generdlly, confirmation of identification is by GIT or MAT using specific 
polyclonal rabbit sera (see section 2.1.2. ). However, the presence of variable surface 
proteins (vsps) (Behrens et al., 1994) has on a few occasions complicated diagnosis 
(see Section 2.1.2. ). In addition, M. bovis and M. agalactiae are very closely 
related, both biochemically and genetically, with only -8 bases different in the 16S 
rRNA gene (Johansson et al., 1996b). An incorrect diagnosis would have political 
implications, as M. agalactiae is exotic to Britain. Although M. bovis is usually 
isolated from cattle and M. agalactiae from sheep and goats, several reports of M. 
bovis in goats have been received from Europe (Petridou et al., 1998). To overcome 
potential problems in the identification of isolates a PCR was developed (chapter 2) 
to detect and differentiate M. bovis and M. agalactiae. 
7.3. PCR METHODS FOR MYCOPLASMA IDENTIFICATION AND 
DETECTION 
Since the first PCRs were described, many have been developed for a 
wide range of mycoplasmas, including members of the M. mycoides cluster and 
some specific groups within the cluster (Bashiruddin et al., 1994a; Dedieu et al., 
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1994; Hoetzel et al., 1994; Persson et al., 1999). The most widely used M. mycoides 
subsp. mycoides SC PCR is based on the CAP21 gene fragment (Bashiruddin et al., 
1994a). At the beginning of the work described in this thesis, a PCR method for M. 
bovis had recently been described (Chavez Gonzdlez et al., 1995; Johansson et al., 
1996a). The PCR was optimised and its specificity determined using isolates of 
various Mycoplasma species. Different hot-start PCR methods were tried to 
improve the specificity of the PCR and it was determined that heating at 949C for 4 
minutes before the addition of the Taq enzyme was required for the PCR method to 
be specific. 
A further aspect considered in the development of the PCR methodology 
was the mycoplasma DNA extraction procedure. Standard DNA extraction 
procedures (Bashiruddin, 1998) require time consuming incubation, separation and 
precipitation stages, with some protocols taking 48 hours, thereby delaying 
mycoplasma species identification in the laboratory. PCR tests directly on cells in 
medium showed that some inhibitory effect was present, preventing successful PCR 
amplification. Presumably the growing cells secreted some inhibitors into the 
medium that affected the PCR. It was also shown that extracted DNA in 'fresh' 
Eaton's medium and cells washed once in PBS resulted in successful amplification. 
The PCR developed in chapter 2 was introduced for routine use at VLA in 1997, and 
has been used to confirm the identity of approximately 400 M. bovis isolates. Use of 
the M. bovis PCR has proved useful in providing an initial identification that was 
later confirmed by GIT, or in confirming GIT results. On a few occasions the PCR 
has produced amplicons from mixed cultures, which by further culturing and cloning 
were shown to contain M. bovis. 
. Subsequent to the development of the PCR based on the 16S rRNA gene 
and described in this thesis, Subramaniam, et al. (1998) published two PCR methods, 
one for M. bovis and the other for M. agalactiae. These PCRs were based on the 
uvrC gene, which showed more variation in sequence between the two organisms 
than the 16S rRNA gene. An inter-laboratory trial of the 16S rRNA and uvrC based 
PCRs was conducted as part of EC COST Action 826 on ruminant mycoplasmoses. 
DNA from M. bovis and M. agalactiae strains isolated in different countries was 
sent to participating laboratories. Results showed some inter-laboratory variation, 
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where the identification of some strains was not conclusive, but both methods were 
effective. 
The value of the PCR methods in the UK was shown in November 1999. 
A mycoplasma was isolated from milk taken from a goat with mild mastitis in Kent. 
The isolate did not ferment glucose or hydrolyse arginine and produced a film, 
suggesting M. agalactiae. However, both the M. bovis PCR procedure developed in 
this thesis and the PCR method of Subramaniam et al. (1998) showed that the isolate 
was in fact M. bovis. Further sampling at the farm investigations failed to recover 
similar isolates. 
7.4. ANTIMICROBIAL SENSITIVITY TESTING 
Antimicrobials, many of which target the bacterial cell wall, are 
frequently used to treat and control diseases in humans and animals. However, as 
mycoplasmas lack a cell wall many antimicrobials are not effective. One problem 
with antimicrobial use for disease control is that it may lead to the development of 
clinically healthy carrier animals spreading the diseases and also to the development 
of antimicrobial resistance. New more effective antimicrobials may be beneficial 
and FAO Emergency Prevention System (ENIPRES) recommended research into the 
role of chemotherapy for CBPP (Rweyemamu and Benkirane, 1996). In chapter 3 
of this thesis, the in-vitro effectiveness of five antimicrobials was tested against M. 
mycoides subsp. mycoides SC and M. bovis isolates. The MIC and MMC levels 
were determined using an improved microtitre method. This method meets all the 
recommendations made by the IRPCM chemotherapy committee for antimicrobial 
testing (Hannan, 2000). 
Results of antimicrobial testing (chapter 3) showed distinct differences 
between M. mycoides subsp. mycoides SC and M. bovis isolates. The M. bovis 
isolates, all from Britain, showed that antimicrobial resistance had developed to 
tilmicosin, oxytetracycline, spectinomycin and to a lesser extent florfenicol. In 
contrast, little resistance had been developed by M. mycoides subsp. mycoides SC, 
although some isolates were resistant to spectinomycin. Repeated sub-culturing of 
M. mycoides subsp. mycoides SC at the MIC level quickly induced substantial 
resistance to spectinomycin, but not to the other antimicrobials and no cross- 
resistance was observed. Although many differences exist between M. mycoides 
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subsp. mycoides SC and M. bovis, it may be argued that the development of 
resistance in the two groups is likely to be similar. If this is the case antimicrobial 
resistance in M. mycoides subsp. mycoides SC is likely to develop quickly, if the use 
of antimicrobials in Africa becomes widespread. The newer fluoroquinolones such 
as danofloxacin may be useful in strategic and possibly prophylactic treatment; 
however preliminary studies on a farm continually affected by M. bovis showed that 
the use of danofloxacin had little benefit, although ongoing viral diseases may have 
complicated the clinical picture (Nicholas et aL, unpublished results). 
7.5. DIAGNOSTIC METHODS FOR CBPP 
For the confirmation of important diseases such as CBPP it is still 
necessary to demonstrate the presence of the organism to the regulatory authorities 
in order for control measures to be initiated. However, culturing and identification 
of an organism is not always successful. This may be due to the phase of infection, 
the presence of sufficient organisms at the relevant site, the culturing method or 
presence of other 'contaminating' organisms that may outgrow or inhibit the in vitro 
growth of the specific disease-causing organism. Immunological diagnosis of a 
disease is often preferable although not conclusive. Animals mount a specific 
immune response against most infectious agents and it is the detection of this 
specific immune response that indicates that animals have been exposed to that 
specific antigen. However, the type and length of immune response varies from 
animal to animal, antigen to antigen and on antigen exposure levels. 
The whole cell indirect ELISA for M. bovis (Nicholas et aL, 2000b) has 
been in use at VLA (Weybridge) for many years and appears to have been very 
effective. It has often led to the diagnosis of M. bovis pneumonia before M. bovis 
isolation. In addition it has been used to detect an immune response in milk, even 
identifying affected mastitic quarters (Byme et aL, 2000). The success of this 
ELISA may possibly be attributed to the lack of cross-reacting antigens with other 
pneumonia and mastitic causing organisms. 
The limitations of the current CBPP immunodiagnostic tests are known, 
(see section 1.5.7.1. ). The CFI' is the OIE recognised test, but has serious 
disadvantages in sensitivity and ease of performance. The competitive ELISA 
developed by Le Goff and Thiaucourt (1998) has been considered for use as an OIE 
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recommended test but while easier to perform has similar sensitivity. The 
immunoblotting test (Regalia et al., 1996b) appears to be the most sensitive and 
specific laboratory test, but cannot easily be scaled up for mass screening. 
One aim of this thesis was to develop a simple field/penside test to 
rapidly identify affected herds and possibly individual animals so that immediate 
action can be taken to control the spread of CBPP. In chapter 5a specific antigen 
from M. mycoides subsp. mycoides SC was identified. This was then used to 
develop a simple immunodiagnostic test, the LAT test that could be carried out 
rapidly and in the field by 'unqualified' people. The simplicity and low cost of such 
a test may increase the level of screening for CBPP in affected countries, enabling 
quicker control action to prevent further spread of the disease. It is accepted that 
such a test is unlikely to be more specific and sensitive than laboratory based tests; 
however when evaluated in chapter 6, the test performed particularly well in 
comparison with the CFI', but also with the ELISA, cELISA and immunoblotting 
particularly in the EC trial in section 6.5.4. 
7.5.1. LATEX AGGLUTINATION TEST- CARBOHYDRATE ANALYSIS 
Conflicting reports exist about the antigenic activity of polysaccharides 
from M. mycoides subsp. mycoides SC. In this thesis, section 5.2.4., polysaccharides 
were extracted from culture media supernatant following the growth of M. mycoides 
subsp. mycoides SC. A modification of a method described by Rurangirwa et al. 
(1987b) was used. Following separation through a BioSep Sec 300 column, it was 
discovered using an ELISA test that some fractions were more immunogenic than 
others. The most immunogenic fraction was used for binding to latex beads. By 
standardising the concentration of antigen and sera used in the LAT the test 
appeared quite specific. However, it was important to understand the nature of this 
antigen. Initial analysis of the carbohydrate was carried out using TLC, however 
this was not conclusive or quantitative, although it indicated the presence of either 
mannose or fucose, glucosamine and possibly galactosamine. Further analysis was 
carried out by BioMed Laboratories, (see reports in Appendix 3). This showed that 
fucose, glucosamine and galactose were present in the ratio 1: 2: 16 respectively. A 
sialic acid, N-acetyl neuraminic acid was also detected. This is similar to the 
findings of Plackett et al. (1963), but contrasts greatly with the findings of March et 
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al. (1999) who reported that the capsule was composed of N-acetylglucosamine, 
fructose, fucose, glucosamine, glucose and mannose in approximately equal 
concentrations. The material analysed by March et al. (1999) was similar to that 
obtained in this study when uninoculated medium was analysed. This suggests that 
the carbohydrate reported by March et al. (1999) was in fact derived from a media 
component, possibly yeast extract; the yeast cell wall contains a polysaccharide 
known to be rich in glucosamine and N-acetylglucosamine. The exact structure of 
the polysaccharide was not determined in this study, but may be similar to the 
disaccharide repeating unit P-D-galactofuranosyl-(1-6)-D-galactopyranose described 
by Smith (1984), although additional carbohydrates were obtained in this study. It 
would be interesting to confirm this structure. An artificial polysaccharide could 
then be made and used to develop and detect an immune response to CBPP. It has 
potential as both a diagnostic antigen and a possible vaccine candidate, although it 
might induce an auto-immune response because of its similarity to bovine 
pneumogalactan. 
Rice and Miles, (reported by Nicholas et al., 2000a) showed that there 
was little variation in capsule production between strains but most capsule was 
produced in the early phases of growth. However, Rice et al. (2000) described 
media (PRM) formulates specifically for the growth of M. mycoides subsp. mycoides 
SC that gave high growth rates and yields. The use of such a medium may give 
increased levels of carbohydrate production and recovery. 
7.6. CONTROL STRATEGIES 
Control of M. bovis and CBPP by antimicrobials is unlikely, although 
strategic treatment might have some benefit. Generally in the UK prophylactic 
treatment is not recommended as it is considered more likely to give rise to 
antimicrobial resistance (Anon, 1999). However, in theory prophylactic treatment at 
critical times, at say 6 weeks, when matemal antibodies are declining, and also when 
introducing new stock to a farm may be beneficial in disease control. This treatment 
may cause a significant reduction in the mycoplasma population, at the same time 
giving the animals more time to develop their own immune responses. Such 
treatment may also lower or mask the detectable immune response in serological 
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tests, so other control measures can not be taken. The clinical symptoms and 
general health of M. bovis affected cattle may be improved by ensuring good 
husbandry practice, such as improving housing conditions, thus ensuring the housing 
is dry with plenty of ventilation, and not mixing older affected animals with younger 
calves. Depopulation of stock, is the only effective solution to controlling M. bovis 
and CBPP. Where new or replacement stock is being acquired, suitable quarantine 
and testing procedures may prevent the introduction of disease into the herd. This 
approach was recently successfully carried out in Ireland (O'Farrell et al., 2001). 
From the information obtained in this thesis (chapter 3) the use of 
antimicrobials in treating CBPP may be supported. However, when compared with 
the MIC values obtained for M. bovis where resistance has developed it is difficult 
to justify the widespread use of antimicrobials, which may increase the development 
of antimicrobial resistance. However, in vitro testing is only a small part of the 
overall picture and the pharmokinetics of the antimicrobials should be taken into 
consideration. Even though some antimicrobials are concentrated many times 
within the animal (Reeve-Johnson, 1999) such widely disseminated organisms must 
be hard to attack. When CBPP has affected the lung causing necrosis and the 
formation of sequestra as seen in chapter 4, antimicrobials are very unlikely to be 
effective (Provost et al., 1987). Consequently the choice of antimicrobial to treat 
cases of CBPP should not be based solely on the basis of in vitro tests. However, 
future use of antimicrobials should not be discounted as new improved 
antimicrobials, particularly derivatives of the fluoroquinolones, such as cnrofloxcin, 
a carboxylic acid derivative (Barragry, 1994) and advocin (see chapter 3) are 
continually being developed. 
The current vaccine for CBPP uses live M. mycoides subsp. mycoides 
SC (see section 1.5.5.1. ) which has many problems, such as the transient nature of 
protection, severe adverse reactions at inoculation sites and even difficulties 
ensuring sufficient dose levels of vaccine are given. There is no vaccine for M. 
bovis. Effective control is limited to removal of affected animals or whole herds. 
Early identification of affected animals by diagnostic tests is currently essential to 
prevent spread of these diseases. Development of new and improved vaccines is 
also required to control these diseases. 
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7.7. FURTHER WORK 
A major aim of this thesis was the development of improved diagnostic 
tests that could be used to diagnose two major mycoplasma bovine diseases of cattle. 
This has been achieved with the routine use of PCR for M. bovis and the 
development of the LAT. Much interest has been shown in the LAT, because of its 
potential application particularly to the African CBPP crisis where rapid results can 
be obtained in the field. Under laboratory conditions the test was shown to be as 
effective as the much more laborious CFI, which is strictly a laboratory-based test. 
The LAT now needs further development for field use. This would entail re- 
evaluating the LAT with more whole blood samples, and possibly binding the 
antigen to black latex beads to make interpretation of the test easier. In the 
laboratory the test works well with sera and the latex beads can be successfully dried 
onto a card. However, in the warmer African climate, larger volumes of blood or 
sera may be needed to reduce drying out of the latex beads-blood/serum mixture. 
The shelf life of LAT reagents, particularly if applied to cards, also needs to be 
critically evaluated. The first batch of LAT reagents have been stored at 40C for 
more than two years and still work effectively, suggesting a long shelf life for the 
product if properly stored. The LAT also needs to be evaluated against CBPP 
vaccinated cattle. 
Improved understanding of the LAT antigen would also help increase 
confidence in the test and possibly enable improvements in its preparation. The 
antigen was derived from the carbohydrate fraction of culture supernatants that 
proved most effective in initial LAT studies. It was presumed that culture 
supernatant carbohydrates were essentially capsular carbohydrates. Analysis of the 
carbohydrate showed that it was similar to the capsular material described by 
Plackett et al. (1963). The LAT antigen was treated with proteinase to ensure no 
contaminating proteins were present. Thus, the results obtained in this thesis 
suggest that the secreted M. mycoides subsp. mycoides SC polysaccharide is 
antigenic. Conflicting evidence for polysaccharide antigenicity has been presented 
previously (see section 5.1.1. ) with different fractions containing polysaccharides, 
possibly proteins and or lipids and heat labile factors. The fractions were also tested 
by a variety of serological methods that included; immunodiffusion, precipitin tests, 
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and complement fixing tests. However, the number of conflicting reports published 
suggest extraction methods are critical to obtaining a pure antigenic polysaccharide. 
To ensure reproducibility of the LAT standardisation of production methods for the 
antigenic polysaccharide will be essential. Improvements in methodology are 
required, to ensure similar, ideally improved growth yields, and to reduce and 
simplify the stages in the current purification method. The purity of the active 
antigen and the standardisation of concentrations would all benefit from additional 
investigation. Use of other culture media such as PRM may increase the yield of 
organism. A separate study on the effect of medium composition on capsular 
polysaccharide as a proportion of cell proteins is also worth investigation. Providing 
the polysaccharide structure is fully determined, a synthetic polysaccharide would 
probably be more cost effective to produce and easier to standardise. It would also 
be possible to develop a multi-disease LAT. For example, providing a specific 
antigen was identified and purified, say for M. bovis it could be bound to different 
coloured latex beads, so both CBPP and M. bovis could be tested for with one test. 
The colour of beads clumping would determine which disease was detected. 
In addition to developing the LAT for M. mycoides subsp. mycoides SC 
a number of other diagnostic methods were used in this thesis. Clearly, there are 
always ways to improve existing tests. For example the CFr was modified to use 
less reagents (Tittarelli et al., 1999). The ELISA tests can always be improved by 
using better-purified antigens or cocktails of antigens, or for the cELISA different 
Mabs could be used, or even multiple Mabs. Different Mabs could also be used for 
the ICC. The immunoblotting method can be improved. The Portuguese test 
(Gonqalves et al., 1998) uses sera diluted at I in 5, which produces many non- 
specific bands on the immunoblot that require critical interpretation, whereas 
Nicholas et al. (1996) used sera diluted at 1 in 50, so only major bands were 
detected. The dilution at which a serum is tested can be further optimised. Ideally 
the five major proteins detected by immunoblotting for CBPP could be purified and 
only those used on a membranes, thereby giving clearly defined results with a high 
concentration of sera for maximum sensitivity. 
In this thesis a PCR is described that was introduced into routine use in 
laboratory for the identification of M. bovis. This test also differentiates a closely 
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related exotic pathogen, M. agalactiae. The sensitivity of PCRs can be improved. 
Ideally the test should be sensitive enough to detect a single organisms in clinical 
samples and nasal swabs. The development of then-nocyclers in recent years has 
increased the speed of PCR, and the introduction of light cyclers (Applied 
Biosystems, UK) will further increase the speed of PCRs and reduce the volume of 
reagents and samples required for testing. One difficulty with PCR, is that it detects 
DNA, therefore one cannot be sure if the organism detected is still viable, which 
may be important in diagnosing disease if animals have been vaccinated, or 
successfully treated with antimicrobials. Reverse transcriptase PCR (Newton and 
Graham, 1994) which detects RNA, may therefore have a role in diagnosis. 
Interpretation of MIC values is difficult, and MIC cut-off points do not 
necessarily relate to effectiveness in-vivo. Further investigations of the 
pharmokinetics of antimicrobials in animal species are required. In this study the 
MIC cut-off points recommended by Ter Laak et al. (1993) have been used. In this 
thesis widespread antimicrobial resistance within the British M. bovis population has 
been reported. It is therefore important to monitor the further development and 
spread of resistance, partly to target treatment by using effective antimicrobials. It is 
also important to assess the risk of potential antimicrobial resistance entering the 
food chain, either from the accumulation of antimicrobials in the animal, or from the 
exchange of genetic resistance mechanisms between microorganisms. There is a 
need to test more antimicrobials to deten-nine the wider extent of resistance to 
mycoplasmas. It would also be of interest to test 'archived' M. bovis strains to see 
how long it has taken for antimicrobial resistance to develop. The introduction of 
routine screening methods, such as the method used in this thesis, or possibly using 
'E tests' (Cambridge Diagnostic Services, Cambridge). E tests are a quantitative 
agar method based on the transfer of a continuous concentration gradient of an 
antimicrobial agent from a plastic strip into an agar medium (Waites et al., 1998). 
Whilst the basis of some antimicrobial resistance mechanisms are known, such as 
gene mutations and the presence of plasmids for antimicrobial resistance. Modes of 
antimicrobial resistance in mycoplasmas and transfer of resistance between 
mycoplasmas and other microorganisms also require further investigation. 
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This thesis has only been directly concerned with informed diagnosis 
and the use of antimicrobials in disease control. However, vaccines are important in 
disease control. Currently there are no vaccines for M. bovis. Several attempts have 
been made to produce such a vaccine, but none have been successfully marketed. 
Several trials of different potential M. bovis vaccines have shown that they have 
enhanced the disease (Bryson et al., 1999; Rosenbusch, 1998). A vaccine for CBPP 
is in use in Africa (see section 1.5.5.1. ), however it has many problems including 
that it is live and provides only transient protection. There is clearly a need for a 
more effective vaccine, which is stable, risk free, cheap and gives long-term 
protection. 
Possibly, as the whole genome sequences for mycoplasmas become 
available it will be easier to determine pathogenicity factors and unique features of 
pathogenic species. They may in time enable identification of potential targets for 
development of new antimicrobials and protein or other gene products which may be 
suitable for use in sub-unit vaccines or to which immunity might be gained using 
DNA vaccines. It might also be possible to develop attenuated vaccine strains by 
the deletion of pathogenic determinants. Currently, sequencing of the M. mycoides 
subsp. mycoides SC genome is almost complete (Persson et A, 2000), however, no 
attempt has yet been made to sequence the M. bovis genome. 
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APPENDIX 1 
Al. IDENTIFICATION OF MYCOPLASMA SPECIES USING 16S HINA 
SEQUENCING 
Al. 1.1. INTRODUCTION 
Amplicons produced by PCR using universal primers for the 16S rRNA 
gene can be sequenced and the sequence used to identify an organism by comparing 
with others on the databanks. A sequence comparison giving a similarity of over 
98% is required to indicate significant homology with another sequence; values 
lower than 98% would generally indicate a different species (Johansson el aL, 
1998). 
A]. 1.2. ISOLATES USED FOR 16S rRNA SEQUENCING 
The 16S rRNA gene was sequenced for two mycoplasma isolates that 
could not be identified using conventional culture and serological tests. One isolate, 
reference 53V95, came from a peregrine falcon (Falco peregrinus) suffering eye 
lesions submitted to VLA (Weybridge) from VLA Starcross; the other, reference 
67A96, had been isolated at VLA (Weybridge) from a cloacal swab taken from a 
healthy ostrich (Struthio camelus) submitted for export testing. 
Al. 1.3.16S rRNA UNIVERSAL PCR 
The strategy for sequencing the 16S rRNA genes requires the use of 
universal primers. Primers corresponding to the Ul and U8 regions of the 16S 
rRNA gene were used in a first PCR to give a 1514 base pair (bp) product. This 
then provided the template for the second PCR reactions using semi-nested primers 
UI to U5 and U2 to U8 (fig. Al. 1. ) resulting in amplicons of 914bp and 1197bp, 
respectively. The U5 and U8 reverse primers were biotinylatcd. 
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FIGURE Al. 1. UNIVERSAL PRIMER BINDING POSITIONS TO THE 16S rRNA 
GENE 
The numbers (standard typeface) refer to the DNA base sequence according to the 
numbering of the International Union of Biochemistry for the 16S rRNA gene of 
Escherichia coli (Brosius et aL, 1978). The sizes of amplicon (bp) are given in bold 
typeface. 
16S rRNA gene 
------------------------------ - --------------------------- 
T--> <--T 
PCR 1: Ul (10- 34) U8B (1498-1477) 
1514bp 
T-> <-T 
PCR 2: Ul (10- 34) U5B (924-902) 
914bp 
T-> <-T 
PCR 3: U2 (327-348) U8B (1498-1477) 
1197bp 
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Al. 1.4.16S rRNA SEQUENCING 
The method used for sequencing was exactly as described by Johannsson 
et aL (1998). The biotinylated PCR products were immobilised onto streptavidin- 
coated paramagnetic beads (Dynabeads M280; Dynal AS, Oslo, Norway) and the 
strands were separated using a standard protocol. Both strands were used for 
sequencing. The sequencing primers were labelled with Cy5, (Cy5 Auto Read 
Sequencing Kit, Pharmacia) for detection with the red laser-based automated laser 
fluorescent DNA sequencing system ALFexpress (Phannacia). One pmol of 
primers were used in the sequencing reactions. Clean plates were assembled into a 
cassette. The gel was poured from ready prepared six % acrylamide solutions and 
allowed to polymerise for three hours before placing on the automated laser 
fluorescent DNA sequencer (AILF, Pharmacia LKB Biotechnology AB, Sweden). 
The temperature was raised to 550C and the laser allowed to reach optimum 
conditions before 5 gI of each Sanger sequencing reaction was loaded. The ALF 
DNA sequencer was then run at 150OV, 60 mA, 25 W for 10 hours at 55C. 
Sequences were recorded automatically. 
A]. 2. SEQUENCE ANALYSIS 
The sequences were aligned and compared by using the program 
package for sequence analysis from the Genetics Computer Group at the University 
of Winconsin, USA (Devereux et aL, 1984). 
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Al. 3. RESULTS OF DNA SEQUENCING FOR FALCON AND OSTRICH 
ISOLATES 
The 16S rRNA gene was sequenced for both the falcon and ostrich 
isolates. A total of 1457 bases were sequenced from the falcon isolate and 1347 
bases from the ostrich isolate. As bidirectional sequencing was used, the sequences 
required manipulation, i. e. reversing, aligning and joining to produce the sequence 
for the majority of the gene. Data from overlapping segments meant that the 
majority of the gene was in effect sequenced twice. The sequences obtained from 
the falcon had seven bases that were unresolved and the ostrich had six; these 
occurred near the ends of the sequence where errors are most frequent (K-E 
Johansson, personal communication). Unresolved bases were allocated a code letter 
suggesting the likely base(s), details are given in Table Al. 1. 
TABLE Al. 1. CODE LETTERS FOR UNRESOLVED BASES IN THE 
SEQUENCES REPORTED IN FIGURES Al. 2 and Al. 3 
CODE M R w S Y K V 11 D B N 
POSSIBLE AC AG AT CG CT GT AC AC AG CG AC 
BASES GTTT GT 
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FIGURE Al. 2. THE DNA SEQUENCE OF THE 16S rRNA GENE FROM THE 
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* Unresolved bases code shown in Table Al. I. 
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FIGURE Al. 3. THE DNA SEQUENCE OF THE 16S rRNA GENE FROM THE 
OSTRICH ISOLATE 
T*B*BGCATGAA GTTAATATAA AAGGAGCGTT TCTTCGCTAG 40 
AGGATCGGGG TGCGTAACAT TAGTTAGTTG GTGAGGTAAT 80 
GGCTCACCAA GACGATGATG TTTAGCGGGG TTGAGAGACT 120 
GATCCGCCAC ACTGGGACTG AGATACGGCC CAGACTCCTA 160 
CGGGAGGCAG CAGTAGGGAA TTTTCCACAA TGGGCGAAAG 200 
CCTGATGGAG CGACACAGCG TGCGCGATGA AGGCCTTCGG 240 
GTTGTAAAGC GCTGTTATAA GGGAAGAAAA AGCAGTAGAG 280 
GAAATGCTAT TGCCTTGACG GTACCTTGTC AGAAAGCAAC 320 
GGCTAACTAT GTGCCAGCAG CCGCGGTAAT ACATTAGGTT 360 
GCAAGCGTTA TCCGGAATTA TTGGGCGTAA AGCGTCTGTA 400 
GGTTGTTTGT TAAGTCTGGT GTGAAAACTT GGAGCTCAAC 440 
TCCAAATTGC ATTGGATACT GGCAAACTAG AGTTATGTAG 480 
AGGTAAGCGG AATTCCTTGT GAAGCGGTGG AATGCGTAGA 520 
TATAAGGAAG AACACCAACC TGGCGAAGGC AGCTTACTGG 560 
ACATATACTG ACACTGAGAG ACGAAAGCGT GGGGAGCAAA 600 
CAGGATTAGA TACCCTGGTA GTCCACGCCG TAAACGATGA 640 
TGATTAGCTG ATGGGGAGCT CATCGGCGCA *STAACGCATT 680 
AAATCATCCG CCTGAGTAGT ATGCTCGCAA GAGTGAAACT 720 
TAAAGGAATT GACGGGGATC CGCACAAGCG GTGGAGCATG 760 
TGGTTTAATT TGAAGATACG CGTAGAACCT TACCCACTCT 800 
TGACATCTTC CGCAAAGCTA TAGAGATATA GTGGAGGCTA 840 
ACGGAATGAC AGATGGTGCA TGGTTGTCGT CAGCTCGTGT 880 
CGTGAGATGT TCGGTTAAGT CCTGCAACGA GCGCAACCCT 920 
TGTCCTTATT TAGATGATAT AAGGAGACTG CCCGGGTAAC 960 
TGGGAGGAAG GTGGGGACGA CGTCAAATCA TTCATGCCTC 1000 
TTACGAGTGG GGCAACACAC GTGCTACAAT TGGACGGTAC 1040 
AAAGAGAAGC AATACGGCGA CGTTGAGCAA ATCTCAAAAA 1080 
ACCGTTCTCA GTTCGGATTG TAGTCTGCAA CTCGACTACA 1120 
TGAAGTCGGA ATCGCTAGTA ATCGTAGATC AGCTACGCTA 1160 
CGGTGAATAC GTTCTCGGGT CTTGTACACA CCGCCCGTCA 1200 
CACCATGGGA GCTGGTAATG CCCGAAGTCG GTTTTGTTAA 1240 
CTACGGAGAC AACTGCCTAA GGCAGGACCG GTGACTGGGG 1280 
TGAAGTCGTA ACAAGGTATC CCTACGAGAA CGTGCGG*RTG 1320 
GA*W*HACCTCC TTTCGGTCAT AGCTGTT 1347 
* Unresolved bases code shown in Table Al. 1. 
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Al. 4. DNA SEQUENCE, ANALYSIS 
Sequence comparisons showed the best fit with 50 mycoplasma species, 
indicating the isolate belonged to the mycoplasma group. Details of the closest best- 
fit comparisons are given in Table A1.2. 
TABLE Al. 2. BEST FIT COMPARISONS FOR THE PEREGRINE FALCON AND 
THE OSTRICH 16S rRNA SEQUENCE 
PEREGRINE FALCON OSTRICH 
SPECIES % SIMILARITY SIE CIE, S% SIMILARITY 
M. gallinaceum 96.1% M. gallinaceunt 94.6% 
M. coragypsum 94.3% M. coragypsum 93.4% 
M. leocaptivus 94.0% M stumidae 92.9% 
M. stumidae 93.8% M. leocaptivus 92.5% 
M. gallinarum 93.3% M. synoviae 92.0% 
M. bovis (Donetta) 93.2% M. gallinanim 91.8% 
M. lipophilum 92.9% M. meleagridis 91.5% 
M. meleagridis 92.8% M. arginini 87.3% 
M. synoviae 92.8% 
M. fermentans 92.8% 
M. agalactiae 92.7% 
M. felifaucium 92.6% 
A californicum 92.4% 
M. bovigenitaliunt 92.3% 
M. simbae 91.3% 
M. leopharyngis 92.0% 
M. gatae 89.3% 
M. lzyopneumoniae 87.9% 
For the peregrine falcon no identical sequence was found and the highest 
sin-djarity (96.1%) was with M. gallinaceum. Of the 1457 bases sequenced, 423 
were A (29.03 %), 400 were G (27.45 %), 337 were T (23.13 %), and 290 were C 
(19.90 %); 7 were unresolved (0.48 %). 
Like the peregrine falcon isolate, no identical sequence was found for 
the ostrich. Of the 1347 bases sequenced, 373 were A (27.69 %), 387 were G (28.73 
310 were T (23.01 %), and 271 were C (20.12 %) and 6 were unresolved (0.45 
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Comparison of the sequences obtained for the ostrich and falcon isolates 
gave a 94.5% similarity showing that they are different Afycoplasina species. 
Al. 5. DISCUSSION 
Knowledge of the pathogenicity of the isolates would also be useful. 
Interestingly, several isolates from ostriches have since been submitted to the VLA, 
all of which reacted with the antisera raised against this ostrich isolate. One of these 
recent isolates came from a 13-14 week old ostrich from a group of 12 birds, which 
were sneezing and coughing; some also had a white or clear nasal discharge. They 
had all lost weight and failed to respond to antimicrobial treatment with enrofloxacin 
and oxytetracycline. Three birds died but only one was examined. The sinuses 
contained a clear mucoid content but no gross abnormalities of the trachea, lungs or 
air sacs was seen and the cause of death was not established. Thus, the mycoplasma. 
may be associated with disease. The isolation of a potential pathogen from ostriches 
is commercially important as the number of ostrich farms is increasing to meet 
export demands and requirements for alternative foods. 
Since this work was done 16S rRNA sequencing has also been 
successfully used to identify a number of unusual isolates submitted to VLA 
(Weybridge). M. fermentans was identified from a sheep (Nicholas et al., 1998); M. 
auris from a Nepalese goat; isolates from penguins have been shown to have 
sequences similar to the avian species, AL galliseplicum and AL inlitans. A 
commercial kit MicroSeq (Perkin Elmer) has recently been marketed to aid bacteria 
identification that provides all the necessary reagents to carry out PCR and cycle 
sequencing reactions. However, in preliminary trials, not all mycoplasmas were 
amplified by the PCR from this kit. 
The 16S rRNA sequencing is a useful method that aids identification of 
unusual isolates or indicates the possibility of new species being isolated. Although 
this study used isolates from non-bovine hosts it may also be useful for mycoplasma 
isolates from cattle, including those associated with bovine pneumonia. The 
identification of the two isolates sequenced here is continuing but is outside the 
scope of this project. 
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APPENDIX 2 
MIC AND MMC VALUES 
TABLE A2.1. MIC AND MMC VALUES FOR STRAINS OF M. BOVIS (STRAINS 
1-62) AND M. MYCOIDES SUBSP MYCOIDES SC (STRAINS 63-82) 












1 16 64 4 4 4 16 >128 >128 0.25 0.25 
2 32 64 8 8 8 32 >128 >128 0.25 0.5 
3 64 128 >128 >128 4 16 >128 >128 0.5 0.5 
4 64 64 8 >128 4 8 >128 >128 0.5 1 
5 8 16 4 4 16 16 >128 >128 0.5 0.5 
6 32 64 >128 >128 2 16 >128 >128 0.5 0.5 
7 16 128 4 8 16 32 >128 >128 0.25 0.5 
8 2 64 4 32 4 16 >128 >128 0.25 0.5 
9 32 128 4 32 4 32 >128 >128 0.25 0.25 
10 32 128 4 64 4 32 >128 >128 0.5 2 
11 16 128 4 32 32 64 >128 >128 0.25 0.5 
12 32 32 4 16 8 8 128 >128 0.25 0.5 
13 32 64 2 16 8 8 >128 >128 0.25 0.5 
14 32 64 2 2 4 32 >128 >128 0.5 0.5 
15 32 64 4 32 8 64 >128 >128 0.25 0.5 
16 2 2 8 8 8 8 >128 >128 0.5 0.5 
17 32 64 4 4 64 128 >128 >128 0.25 0.5 
18 4 4 8 16 8 8 4 16 0.25 0.5 
19 1 32 4 8 2 16 >128 >128 0.25 0.25 
20 32 32 4 4 32 32 >128 >128 0.5 0.5 
21 128 128 4 8 8 16 >128 >128 0.5 0.5 
22 32 64 >128 >128 2 16 >128 >128 0.5 0.5 
23 16 64 2 16 16 32 >128 >128 0.5 0.5 
24 32 64 4 8 4 16 >128 >128 0.5 0.5 
25 16 32 8 8 64 32 >128 >128 0.25 0.5 
26 16 64 >128 >128 4 16 >128 >128 0.5 0.5 
27 4 64 2 64 8 32 >128 >128 0.25 4 
28 16 >128 >128 >128 4 16 >128 >128 0.5 1 
29 32 32 >128 >128 8 16 >128 >128 0.5 0.5 
30 32 64 2 4 4 16 >128 >128 0.25 0.5 
31 64 >128 8 128 4 32 >128 >128 1 4 
32 32 128 >128 >128 16 16 >128 >128 0.5 0.5 
33 32 128 4 16 1 8 16 >128 0.5 8 
34 81 128 4 4 4 16 >128 >128 0.5 0.5 
35 64 64 >128 >128 16 16 >128 >128 0.5 0.5 
36 8 32 8 8 2 8 >128 >128 0.125 0.5 













38 32 64 4 4 4 16 4 32 0.5 0.5 
39 8 32 4 32 4 16 128 >128 0.5 0.5 
40 8 32 1 8 1 8 8 32 0.25 0.5 
41 4 16 4 4 4 8 >128 >128 0.5 0.5 
42 64 64 >128 >128 4 32 >128 >128 0.5 0.5 
43 32 64 4 4 4 32 >128 >128 0.25 0.5 
44 32 64 128 >128 8 16 >128 >128 1 1 
45 32 64 2 8 4 16 >128 >128 0.25 0.25 
46 8 64 2 2 4 32 >128 >128 0.25 0.25 
47 64 64 >128 >128 8 16 >128 >128 1 0.5 
48 32 64 4 8 4 16 >128 >128 0.25 0.5 
49 32 64 4 16 16 64 128 >128 0.5 0.5 
50 16 64 >128 >128 8 16 >128 >128 0.5 0.5 
51 16 64 4 >128 16 64 >128 >128 0.5 1 
52 32 64 4 4 8 16 >128 >128 0.25 0.5 
53 16 32 4 32 4 8 >128 >128 0.25 0.5 
54 8 32 2 8 4 16 >128 >128 0.5 0.5 
55 16 64 4 4 4 32 >128 >128 0.25 0.5 
56 64 128 4 32 8 16 >128 >128 0.25 0.5 
57 16 128 2 16 8 32 >128 >128 0.25 0.5 
58 4 16 2 8 4 8 >128 >128 0.25 0.5 
59 32 64 4 8 8 16 128 >128 0.125 0.5 
60 1 2 4 4 4 4 32 32 0.25 0.25 
61 16 64 >128 >128 4 16 >128 >128 0.5 0.5 
62 1 64 128 >128 1 32 >128 >128 2 2 
63 0.25 8 8 32 0.25 4 <0.008 0.03 0.25 0.5 
64 0.125 1 4 4 0.5 1 0.015 0.03 0.25 0.5 
65 0.125 8 16 64 1 8 0.015 0.06 0.25 0.5 
66 1 32 16 16 1 16 0.03 0.125 0.5 0.5 
67 0.5 8 8 64 1 16 0.03 0.125 0.25 2 
68 0.5 8 8 8 2 8 0.015 16 0.25 0.25 
69 4 32 >128 >128 8 16 0.125 0.5 0.5 4 
70 0.5 8 8 16 1 8 0.015 0.125 025 0.5 
71 0.5 8 8 8 1 8 <0.008 <0.008 0.25 0.5 
72 1 1 8 8 1 2 0.015 0.03 0.125 0.25 
73 1 8 16 64 1 8 0.015 0.06 0.5 1 
74 1 8 8 128 2 16 0.015 0.06 0.5 0.5 
75 1 
.8 
8 128 1 8 <0.008 0.015 0.5 4 
76 0.5 8 8 16 1 8 0.015 0.25 0.254 0.25 
77 0.125 1 8 8 1 4 0.015 0.03 0.25 0.25 
78 1 2 8 16 0.5 4 0.03 0.125 0.5 0.5 
79 0.5 0.5 16 16 2 1 0.015 0.015 1 2 
80 0.5 4 4 8 0.5 1 <0.008 >128 0.25 0.25 
81 1 32 16 16 0.5 8 0.03 64 0.5 1 
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Compositional Analysis Report on sample from 
Veterinary Laboratories Agency 
One sample was supplied by the customer in dried form for analysis of neutral 
monosaccharides. The amount of sample was estimated at I mg by the customer 
Details as supplied by customer 
The sample is an extract from media from mycoplasma culture and was prepared for analysis 
by re-precipitation from water and supplied in Iyophilised form. This material has not been 
hydrolysed. Upon receipt at BioMed labs the sample was stoýed at -20" before analysis. 
Hydrolysis of sample 
The total sample was dissolved in 760AI of 0. IM TFA. From this 380p] wcre removcd for 
acid hydrolysis and as described in the protocol below. Compositional analysis for ncutral 
monosacchajides was then performed on the Dionex carbohydrate analysis systcm (DX300) 
against reference monosaccharide standards using a PA I column. The remaining solution was 
stored frozen at -20' 
Protocol for analysis 
1. Dissolve sample in 380glO. IM TFA and transfer to an acid-washed tube, Cap the tube 
and heat for Ih at I OOT in a heating-block for I hour. 
2. Remove 80gl and store at -20'C for analysis of sialic acid if required in the future. 
3. Add 300 pI of 4M TFA and heat sample for a further 4h at I OOT in a heating-block. 
4. Cool tubes and centrifuge at 1500 rpm for 5 min. 
S. Freeze sample in liquid nitrogen and lyopWlize in freeze-dryer overnight. 
6. Dissolve dried material in 250p 1 of water and store frozen until required. 
7. Prior to monosaccharide analysis, pass sample through a Microcon filter (10 kD cut off, 
PVDF) 
S. Analyze samples on Dionex machine with PAI column and pulsed amperometric detection 
at voltage settings recommended by manufacturer for the separation of monosaccharides, 
9. Use a flow rate of I ml/min of 22 rnM NaOl L 
10. Set detection at 1000 nA 
11. Sample injection volume So 
12. Injection sequence standard, sample, blank injection 
13. Compare each sample injection with adjacent standard to compensate for any drift in 
position of peaks. 
14. Washcolumn after each run with 200rnM NaOll and rc-equilibrate with 22mNiNaOll. 
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Results of Analysis 
Dionex monosacchn ride stand. irds used 
Monosaccharide Source Reference 
Number 
Con Ce 0 1-. 11 it I [I 
(11111ol /ý11) 
I. Fucose Dionex 6696-11-9 1 
(x-D Galactosamine Dionex 17.72-03-8 1 
(x-D Glucosamine Dionex 66-84-2 
(x-D Galactose Dionex 59-23.4 
(x-D Glucose Dionex 492-02-0 1 
(x-D Mannose Dionex 3,458-28-4 1 
The chromatograms obtained frorn the standard nionosacchandes and the saillples ale shoNýll 
helow 
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Analysis of Results 
Standard Monosaccharides 
Separation of standards (20 p I) at a concent ration Ofo I I)f 110 1/ 111 sho%% SCI III I') II POSI I It ýI Is ol, 
each nionosaccharide. 
Extract from mycoplasma 
An aliquot of5pl of the re-dissolved acid hydrolysate was sepatated. A total off'oul peaks 
were detwed. Peak 4 is the major peak and corresponds in clution position to galactose Peak 
3 corresponds to the elution position of N-acetyl galactosamine (converted to galacto., 11,1111C 
during the acid hydrolysis) . 
Two further minor peaks were detected Peak 2 appeals to 
correspond to the ClUtion of Ibcose but the Identity ofpeak I IS Unknown, 
Calculation of amount of monosaccharide in sample 
The mean area for each peak of the sample was ineastired front (hiplit-ate peak jilt-its 1' 
monosaccharides were also measured from duplicate standard runs Front these Nalues i, 11(i tile 
known concentrations of the standards, the concentration ofeach nionosacchande in the sample 
was calculated, after adjusting the areas of the stan(kird and the sample I'm diffei ent injection 
volumes. The monosaccharide concentrations in (fie sample %ýcie as 101loN%s 
P. Iýýc I of", 
Monosaccharide Concentratioit 
Samp)e Fucose- Gal - NA .c-- -- GIcNAc- (.;, I (, I(, - 
Mycoplasma 0,045 0.095 0.0 0.70 0.0 0.0 
extract 
The sample injected was from a total volume of 250pl 1 hi SI epresent. " 4000 oft lie total 
sample i. e. 300pi from 760pl solution Therefore, the total amount ofeach monosaccliaride in 
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Conclusions 
I, The mycoplasma culture extract contains approximately 9.7% carbohydrate vvilich is 
present mainly as fucose, N-acetyl-galactosaninie and galnetose 
2. Galactose is the most abundant of these monosace lia rides, representing abotit 8",, of di ie(I 
material that was supplied. 
3. Fucose and N-acetyl-galactosamine arc present in much smaller amount,,, file Illolar ratio 
Fuc: Ga]NAc: Gal being approximately 1: 2: 15. 
4. Another minor component is present but this would require fbithet %%ork to be identified 
5. Sialic acids may also be present. This would not be detectable under the chioniatography 
conditions used for neutral nionosaccharides. A suitable aliquot t*oi sialic acid 
determination was removed prior to the main liý, drolN, sis and this could be used in a tutule 
analysis. 
Reported dated December 4'" , 1998 
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Compositional Analysis Report on samples from 
Veterinary Laboratories Agency 
Three samples were supplied by the customer in dried form foranalysis ot'neutral 
monosaccharides. One sample was supplied previously and a neutral monosýaccha ride 
analysis performed. It has now been analysed for sialic acid. 
Details as supplied by customer 
BioMed Details 
ref 
VLOI Sample I is an extract from media from mycoplasina culture 
VI-02 Sample 2 is an extract from the harvested cells 
VL03 Sample 3 was purified from medium and prepared for analysis by re- 
precipitation from water, sodium azidc was added 
VL04 Sample 4 was previously analysed for neutral nionosaccha rides 
Upon receipt at BioMed labs all samples were storeciat -20' before analYsis. 
Hydrolysis of samples 
Samples 1-3 were dissolved in 2 MTFA and an appropriatevolume renimcd foracid 
hydrolysis as described for analysis VLAOI-98. Conir)ositioii; iliii. iiN. %i. %I't)riietitr; iI 
monosaccharides was then performed on the Dionex carIx)h , 
ydrateanalysis sN'steni (DX 300) 
against reference monosaccharide standards usinga PA I colt, 11111 Thc rcinaining solution 
was stored frozen at -20'. For sialic acid determination on samplc 4 hN drol) sis %ýas 
performed in 0.1 M TFA at I OO'C for two hours. 
Results of Analysis 
Dionex moitosaccharide standards used 
Monosaccharide Source 
- ---- -- 
Reference 
Number 
----------- ----- - 
Concentration 
(1111101 /ILI) 
L Fucose - -------- D1011ex 0090-41-1) 01 
(x-D Galactosamine Dionex 1772-03-8 01 
ct-D Glucosamine Dionex 66-94-2 0,1 
ct-D Galactose Dionex 59-23A 01 
ct-D Glucose Dionex 192-62-0 01 
oc-D Mannose Dionex -1-158-28--l 
01 
P; Ipc " ()I I 
vla99-01 271 is/o. i/9, ) 
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The chromatograms obtained from the standard monosaccharides and the sampics are shown 
below. 







-Figure 2 Analysis of sialic acids 
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Analysis of Results 
Standard Monosaccharides 
Separation of standards (10 0 injection) at a concentration of 0.1 nmol/ ld Figure I shows 
elution positions of each monosaccharide. This is used to standardise thc [vak arcasalld 
response for each monosaccharide 
Samples 
1. Medium extract 
2. Cell extract 
3. Preparation 
4. Preparation for sialic acid analysis 
Sialic Acid Analysis 
Figure 2 shows a chromatogram of a standard preparation ol'N-; icctN I neuraininic acid (ýOpl 
injection 20 ng/ýd and a corresponding chromatograin ofsarnple 4 
From the chromatogram shown in the peak I in the sampleappcars to be N-aceIN I 
neuraminic acid. The second peak could not be identified. Addition ofslandard N-ack, (N I 
ncuram-inic acid to the sample showed the peak %vas very close but did not co- CI tile Po%IIINc 
identification cannot therefore be made. 
Calculation of the concentration in peak I by comparison of the area in oftlic suid; -ird peak 
gives estimated amount in the sample would of 76.75 nmol 
Neutral Monosaccharide Analysis 
Identification of peaks 
From the retention time of the peaks in chromatogranisshown in Fil', 11re 2 and comparison 
with that of the standard monosaccharides the I-ollomng [vak idcnlification %%as made 
Ileak Identification 
VIA II Fuc 
VL-02 Fuc 
VI-03 Fuc 
Ileak 2 Ileak 3 Peak 4 Peak 5 Peak 6 
GaINAc 
1-(-ilcN-Ac I 
Oal (; Ic Man 
Gal I GIC 
GaINAc I GlcNAc I Gal 
(1c Man 
Parc " of I 
vla99-01 2 74 1 x/(yj/q, ) 
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Calculation of amount of monosaccliaride in samples 
The inean area for each pcak ol'the cample %us mewmcd 1'rom duplicalc rum Pcak arcas- of 
(lic standard monosaccharitIcs %Ncrc also nicasurcd 1'rom triplicalc Mandard nins From thesc 
valtics and Ilic knomi concciarations oi'thc manclards, Ilic amount of cadi ivionmacdimidc in 
the samplc was calculated 
The control samplc ofmcdmin supplied sho%%cd trace amotint% of and kicow %%hiL h 
%N, crc insignificant and probablv duc to conlaininallOn 
Dilution Monosaccharide Qiianiltallon ninol 
Factor 
Sample Sample Fllcose GANAc (. IcN, kc al GIC 
dillitioll 
VIA) 1 20/820 18.1 302 597 2S7 1 8-10 
VL-02 20/540 26 03 17o I 
VL-03 300/600 8 21 08 .1 
NI oil os. kcc 11.1 ride 
Sample Fucose (, aINAc (. IcN.. %c Cal Clc Mall 
V IA) I 1 10.1 1ý1 
VL-02 43 07 17 o 9 
VL-03 1-3 1.9 45 12 
Conclusions 
Iý The coniflosition of"the mcclia extract (sariiplc I) I% %mular to that ol'. wium yJNcoprolcills 
\N all N and () linked y. IN-co%. \ lalioll The total Illollo-'acclial life (. 0111clit 1% 443. m jig 
The comfvsition ol'the cell cmract (.,;; iiiil)lc 2) %lio%%s clc\; itcd 1ýalak-iow III pioiximon to 
the other nionosaccliarides and is %millar to that ol'the C\11.10 %tildicd In It-poll 9X4H 
VLA The total mono. "ccha ride contcni is 43 jig of'%% luch 31.7 ýig is 1,. alaL tow 
The collifX)sition of' mullple I also , 
Iio%% sa galactose concentlatioll and tile rallos of' 
the other monos-iccliaricics is similar to the extract Mudicd III the pivN ious wix)it 1, Inlikc 
tile previous sample some N-; kcctN lgluco%anune %%; I% dclected Thc tolal monosack-hataik 
content is 22.1 jig of Much 12.5 jig I% galaoow 
4 The IIINcoplastil; J C. \Ir; kct sinipic anakwd In tcl-Kitt 
9K 01 Lontaiw, malic ak id III tile 
loint 
of N-acetvl ricuranunic acid and another uni(Icnitlik-d lval, I fic aniount of N ak cl\ I 
licuraminic acid is 76.8 nmol 
V11199 01 -, 1" 1xoI, ), ) 
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APPENDIX 4 
RESULTS FROM CBPP AFFECTED FARMS IN POItTUGAL 
TABLE A4.1. COMPARISON OF ACTUAL RESULTS OF SAMPLES FROM 
CATTLE FROM CBPP AFFECTED FARMS IN PORTUGAL: FARM I 
SAMPLE NO. LESIONS LAT EFF E. I. ISA HIT 
I None 0.24 + 
2 Positive + 1: 160 0.62 + 
3 Positive 1: 40 0.74 + 
4 Positive + 1: 10 0.78 + 
5 None + 1: 10 1.04 + 
6 Positive + 1: 20 0.73 + 
7 None + 1: 10 0.43 + 
8 Positive + 1: 10 0.50 + 
9 Positive + 1: 40 OAS + 
10 Positive + 1: 20 0.80 + 
11 None + 1: 10 0.53 + 
12 None 0.31 + 
13 Positive 1: 20 0.62 + 
14 None + 0.58 + 
15 None 0.27 
16 Positive 1: 20 0.61 + 
17 None + 1: 80 0.72 + 
18 Positive + 1: 40 0.83 + 
19 Positive 1: 40 0.90 + 
20 nd + 1: 40 0.62 + 
21 Positive + 1: 20 0.69 + 
22 None 0.30 + 
23 Positive + 1: 80 1.20 + 
24 Positive + 1: 20 0.76 + 
25 Positive 1-10 0.48 + 
26 None + 1: 320 1.22 + 
27 Positive + 1: 40 0.44 + 
28 None + 1: 10 0.44 + 
29 None + 1: 10 0.54 
30 None + 1: 20 0.56 + 
31 Positive 1: 20 0.87 + 
32 Positive + 1: 80 0.98 + 
33 Positive + 1: 80 0.87 + 
34 Positive + 1: 10 UH) + 
35 None + 1.10 0.65 + 
36 Positive + 1: 20 0.92 
37 Positive 1: 10 0.56 + 
38 None 0.13 
39 Positive + 1: 40 0.65 + 
40 None + 0.44 + 
41 nd 1: 20 0.64 + 
42 nd + 1: 10 0.36 + 
43 nd 1: 10 0.41 + 
44 None + 0.29 
45 Positive + 0.42 
46 Positive + 1: 160 LIS + 
47 Positive + 1: 10 0.39 + 
48 None + 1: 40 0.41 + 
49 Positive + 1: 160 11.10 + 
so Positive + 1-1280 1.31 + 
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TABLE A4.1. (continued) FARM 2 
SAMPLE NO. LESIONS LAT cFr EIIASA fill, 
51 Positive 1: 10 0.23 
52 Positive + 1: 40 0.60 + 
53 None 1: 10 0.37 
54 nd + 1: 40 1.12 + 
55 nd 0.39 + 
56 Positive + 1: 1280 1.25 + 
57 None + 1: 1280 1.25 + 
58 None 0.16 
59 None 0.16 
60 None 0.17 
61 None 0.31 
62 None + 0.20 
63 None 0.16 
64 None 0.16 
65 None 0.16 
66 None 0.18 
67 None 0.15 
69 None 0.13 
70 None 0.18 
71 None 0.18 
72 Positive + 1: 2560 1.10 + 
73 Positive + 1: 2560 1.46 + 
74 Positive + 1: 640 1.13 + 
75 Positive 1: 320 1.14 + 
76 None 0.20 
77 Positive + 1: 2560 1.28 + 
78 Positive + 1: 10 1.11 + 
79 None 0.27 + 
80 Positive + 1: 160 0.62 + 
81 Positive + 1: 320 0.75 + 
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TABLE A4.1. (continued) FARM 3 
SAMPLE NO. LESIONS LAT cFr ELISA 11111, 
82 None 0.33 + 
83 None 0.30 
84 Positive + 1: 160 US + 
85 Positive + 1: 20 0.90 + 
86 Positive + 1: 640 1.20 + 
87 Positive + 1: 40 0.67 + 
88 None - 0.27 + 
89 Positive + 1: 320 1.04 + 
90 Positive + 1: 80 1.31 + 
91 None 0.30 + 
92 None 0.39 + 
93 None + 1: 10 OSS + 
94 None + 1: 20 0.80 + 
95 Positive 1: 40 0.96 + 
96 None + 1: 20 0.53 + 
97 Positive + 1: 160 1.36 + 
98 Positive + 1: 160 US + 
99 None + 1: 10 0.85 + 
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TABLE A4.1. (continued) FARM 4 
SAMPLE NO. LESIONS LAT cFr ELISA 111,11 
100 None 1: 80 0.83 + 
101 None 0.20 
102 None 0.15 + 
103 None 1: 20 0.19 + 
104 None - 0.19 
105 None - 0.18 
106 nd - 0.21 
107 nd - 0.06 
108 nd 1: 40 0.87 
109 None 0.29 
110 None 0.34 
ill None 0.30 
112 None 0.72 
113 Positive + 1: 320 0.90 + 
114 None + 1: 80 1.00 + 
115 None 0.31 
116 None 0.30 
117 None 0.29 
118 Positive 1: 80 0.87 + 
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TABLE A4.1. (continued) FARM 5 
SAMPLE NO. LESIONS LAT CV1, ELISA HIT 
134 nd 1: 80 1.20 + 
135 Positive 1: 40 0.81 + 
136 Positive 1: 10 0.41 
137 Positive + 1: 40 0.72 + 
138 Positive + 1: 10 0.67 + 
139 Positive 1: 20 1.28 + 
140 Positive + 1: 10 1.09 + 
141 Positive 1: 40 0.76 + 
142 Positive 1: 20 0.79 + 
143 Positive 0.57 + 
144 Positive + 1: 10 0.71 + 
145 Positive 1: 40 1.25 + 
146 Positive + 1: 20 0.97 + 
147 Positive + 1: 160 1.37 + 
148 Positive + - 0.42 + 
149 Positive + 1: 40 0.71 + 
ISO Positive + 0.55 
151 Positive 0.33 + 
152 Positive 1: 10 0.57 + 
153 Positive 0.61 + 
154 Positive + 1: 20 0.41 + 
155 Positive + 1: 20 0.46 + 
156 Positive 1: 10 0.61 + 
157 Positive + 1: 320 1.28 + 
158 Positive + 1: 40 0.76 + 
159 Positive + 1: 40 0.60 + 
160 Positive + 1: 640 1.14 + 
161 Positive 1: 40 0.90 + 
162 Positive 1: 10 0.83 + 
163 Positive + 1: 20 0.61 + 
164 Positive - 0.36 + 
165 Positive + 1: 10 0.55 + 
166 Positive 0.34 + 
167 Positive 1: 10 0.33 + 
168 Positive 0.20 + 
169 Positive 0.25 + 
170 None 1: 10 nd + 
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TABLE A4.1. (continued) FARM 6 
SAMPLE NO. LESIONS LAT cll-r ELISA HIT 
119 Positive 0.38 + 120 Positive 0.38 + 
121 Positive 0.28 
122 Positive 0.25 
123 Positive 0.20 
124 Positive 0.16 
125 Positive 0.33 
126 Positive 0.22 
127 Positive 0.15 
128 Positive 0.25 
129 Positive 0.20 
130 Positive 0.17 
131 Positive 0.14 
132 Positive 0.16 
133 Positive 0.21 
Results highlighted in bold are positive. 
For the CFr a positive result in this study was considcred to be >1: 20. 
nd = not determined. 
For the ELISA the threshold value was considered to be 0.3; values of 0.25-0.29 
were then scored as negative, though these tests might be considered as 
inconclusive. From the 6 farms only 9 samples fell in this range. IF-or 3 samples all 
other tests were negative; 3 had lesions, one of which was also positive by IBT; 2 
were only positive by IBT; and one was positive only by LAT. 
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